<allTrials totalCount="74" xmlns="http://www.67bricks.com/isrctn"><fullTrial>
  <trial lastUpdated="2007-11-06T00:00:00.000Z" version="20">
    <isrctn dateAssigned="2007-11-06T00:00:00.000Z">94348100</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>The influence of surgical interventions with and without cardiopulmonary bypass on Ca2+ signalling in alveolar macrophages</title>
      <scientificTitle/>
      <acronym>Cacao</acronym>
      <studyHypothesis>A direct G-protein-stimulated ratiometric calcium ion (Ca2+) signal in alveolar macrophages decreases after surgical interventions with cardiopulmonary bypass.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Calcium signal intensity, measured immediately preoperatively and after the surgical procedure.</primaryOutcome>
      <secondaryOutcome>Postoperative pulmonary infection, measured on day of discharge.</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Ethics approval received from the Charite - Universitaetsmedizin Berlin ethikkommission on the 8th March 2003 (ref: EA1/146/06).</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN94348100</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>VO 741/6-1</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Prospective cohort trial with two control groups.</studyDesign>
      <primaryStudyDesign>Observational</primaryStudyDesign>
      <secondaryStudyDesign>Cohort study</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2007-06-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2010-05-31T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Germany</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="73ba5a82-5919-40a1-8d7d-91a9dcad47cc">
	  <name>Klinik fur Anaesthesiologie und Operative Intensivmedizin</name>
	  <address/>
	  <city>Berlin</city>
	  <state/>
	  <country>Germany</country>
	  <zip>10117</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Elective coronary bypass graft surgery
2. Elective panendoscopy
3. Elective thoracic surgery</inclusion>
      <ageRange>Adult</ageRange>
      <gender>Both</gender>
      <targetEnrolment>60</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>60</totalTarget>
      <exclusion>1. Aged less than 18 years
2. Relevant pulmonary diseases with oxygenation deficit
3. Liver disease stage greater than Child B
4. Human Immunodeficiency Virus (HIV)-infection
5. Corticosteroid therapy
6. Organ transplantation
7. Perioperative infection
8. Chronic inflammatory disease
9. Pregnancy</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2007-06-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2010-05-31T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Pulmonary dysfunction after surgery</description>
	<diseaseClass1>Respiratory</diseaseClass1>
	<diseaseClass2>Postprocedural respiratory disorders</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Bronchoscopy with Broncho-Alveolar Lavage (BAL) and blood samples before and after surgery. Routine bronchoscopy is used as recommended in a guideline. Duration of treatment is defined by the length of hospital stay. Duration of the diagnostic procedure is approximately 10 minutes. Total duration of follow up also is defined by the length of the hospital stay.</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
        
      </outputs>
    <parties>
      <funderId>Funder16964-0</funderId>
      <contactId>Contact54925_16964</contactId>
      <sponsorId>Sponsor53490</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact54925_16964">
    <title>Prof</title>
    <forename>Thomas</forename>
    <surname>Volk</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Klinik fur Anaesthesiologie und Operative Intensivmedizin
Charite Campus Mitte und Campus Virchow Klinikum
Chariteplatz 1</address>
      <city>Berlin</city>
      <country>Germany</country>
      <zip>10117</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
  </contact>
  <sponsor id="Sponsor53490">
    <organisation>Charite - University Medicine Berlin (Charite - Universitaetsmedizin Berlin) (Germany) </organisation>
    <website>http://www.charite.de</website>
    <sponsorType>University/education</sponsorType>
    <contactDetails>
      <address>Chariteplatz 1</address>
      <city>Berlin</city>
      <country>Germany</country>
      <zip>10117</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.6363.0</gridId>
    <rorId>https://ror.org/001w7jn25</rorId>
  </sponsor>
  <funder id="Funder16964-0">
    <name>Humboldt University of Berlin (Germany)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-11-06T00:00:00.000Z" version="20">
    <isrctn dateAssigned="2007-11-06T00:00:00.000Z">22416062</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>An open-label, prospective, non-comparative clinical trial to evaluate the efficacy and safety of rosuvastatin in high risk Indian population with diabetes and dyslipidemia</title>
      <scientificTitle/>
      <acronym>RESIDD</acronym>
      <studyHypothesis>Rosuvastatin is effective in treating high risk Indian population of diabetic patients who have abnormal lipid levels.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>1. Mean change in total cholesterol
2. Mean change in LDL cholesterol
3. Mean change in High Density Lipoprotein (HDL) cholesterol
4. Mean change in triglycerides
5. Number of patients achieving ATP III target LDL of less than 100 mg/dl

Primary and secondary time points will be measured by evaluating the blood parameters on week 6 and week 12 against the baseline collected at the time of enrolment.</primaryOutcome>
      <secondaryOutcome>1. Mean change in the level of hs-CRP
2. Mean change in level of apoprotein B
3. Mean change in apoB/apoA1 ratio
4. Mean change in apoprotein A1
5. Mean change in lipoprotein a
6. Change in glycosylated haemoglobin at the end of study period
7. Incidence of hepatic dysfunction defined by liver enzyme elevation more than three times in the absence of other systemic cause
8. Compliance and side effects
9. Mean change in the level of creatinine kinase

Primary and secondary time points will be measured by evaluating the blood parameters on week 6 and week 12 against the baseline collected at the time of enrolment.</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Ethics approval received from the Dhanvantry Independent Ethics Committee on the 11th June 2007 (ref: RANB11/06/2007).</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN22416062</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>CT/RNBX &#150; CV-LIFE/07</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Open label, prospective, non-comparative clinical trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Non randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2007-09-15T00:00:00.000Z</overallStartDate>
      <overallEndDate>2008-01-01T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>India</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="f130b798-6dec-4cc2-8d53-6976e1e04790">
	  <name>Ranbaxy Laboratories Ltd</name>
	  <address/>
	  <city>Gurgaon</city>
	  <state/>
	  <country>India</country>
	  <zip>122001</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Diabetes type II defined by American Diabetes Association criteria of fasting venous plasma glucose of greater than or equal to 126 mg/dl, two-hour post prandial plasma glucose of greater than or equal to 200 mg/dl or already on treatment of diabetes
2. Dyslipidemia defined by Low Density Lipoprotein (LDL) cholesterol more than 100 mg/dl or on prior statin therapy
3. Age of greater than or equal to 30 and less than or equal to 70 years
4. Informed consent by the patient</inclusion>
      <ageRange>Adult</ageRange>
      <gender>Both</gender>
      <targetEnrolment>360</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>360</totalTarget>
      <exclusion>1. Failure to give informed consent 
2. A history of hypersensitivity to statins
3. Evidence of fundoscopy grade 2 hypertensive or diabetic retinopathy
4. Serum creatinine greater than 1.5 mg/dl  
5. Overt proteinuria 
6. Pregnant or lactating mothers 
7. Evidence/history of heart failure
8. Systolic blood pressure above 180 mmHg and diastolic blood pressure above 110 mmHg 
9. Recent history of cerebrovascular disease, myocardial infarction, unstable angina, new onset Left Bundle Branch Block (LBBB) in the past 4 weeks
10. Documented case of homozygous familial hypercholesterolemia
11. Type I Diabetes Mellitus (DM)
12. Use of concomitant medications (cyclosporin, systemic itraconazole or ketoconazole, erythromycin, or clarithromycin, glucocorticoids or verapamil) known to affect the lipid profile or with potency safety concern
13. Recent ongoing inter-current infection/high sensitivity C-Reactive Protein (hsCRP) greater than 10 mg/L
14. Active liver disease or hepatic dysfunction (defined as Alanine aminotransferase [ALT], aspartate aminotransferase [AST], Gamma-Glutamyl Transferase [GGT], alkaline phosphate or bilirubin levels greater than or equal to 1.5 the upper limit of normal)
15. Diagnosed to have any other endocrinal or metabolic disease other than Type II DM that is known to influence serum lipids and lipoproteins
16. Patients having history suggestive of myalgia/myositis/arthralgia
17. Serious or unstable medical or psychological condition that could compromise the patient&#146;s safety or successful trial participation
18. History of alcohol consumption greater than 2 drinks/day (30 ml) or 10 drinks per week</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2007-09-15T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2008-01-01T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Diabetes patients with dyslipidemia</description>
	<diseaseClass1>Nutritional, Metabolic, Endocrine</diseaseClass1>
	<diseaseClass2>Dyslipidemia</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Once the enrolment of the patient is through he will be kept on:
1. Tab. rosuvastatin 10 mg once a day if his LDL level ranges between 100 mg/dL to 130 mg/dL for first 6 weeks, or
2. Tab. rosuvastatin 20 mg once a day if his LDL level is above 130 mg/dL for first 6 weeks

Week 6 (first follow-up):
The patients lipid profile will be evaluated and if the patient&#146;s LDL does not come under 100 mg/dL as per the guidelines of National Cholesterol Education Program (NCEP)-Adult Treatment Panel (ATP) III then the dose will be doubled, i.e., patients on rosuvastatin 10 mg will receive rosuvastatin 20 mg and patients getting rosuvastatin 20 mg will be given rosuvastatin 40 mg. It will remain once a day therapy.

Week 12 (second and last follow-up - end of study):
Patient&#146;s blood will be evaluated for the endpoints and the continuation of therapy will be on the treating clinician.</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>Rosuvastatin</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
        
      </outputs>
    <parties>
      <funderId>Funder16894-0</funderId>
      <contactId>Contact54853_16894</contactId>
      <sponsorId>Sponsor53411</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact54853_16894">
    <title>Dr</title>
    <forename>Santosh</forename>
    <surname>Jha</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Ranbaxy Laboratories Ltd
Plot-90
Sector-32</address>
      <city>Gurgaon</city>
      <country>India</country>
      <zip>122001</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+91 (0)991 003 4380 </telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">dr.santoshjha@ranbaxy.com</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor53411">
    <organisation>Ranbaxy Laboratories Ltd (India)</organisation>
    <website>http://www.ranbaxy.com</website>
    <sponsorType>Industry</sponsorType>
    <contactDetails>
      <address>c/o Dr Santosh Jha
Plot-90
Sector-32</address>
      <city>Gurgaon</city>
      <country>India</country>
      <zip>122001</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+91 (0)991 003 4380 </telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">dr.santoshjha@ranbaxy.com</email>
    </contactDetails>
    <privacy>Public</privacy>
    <gridId>grid.418931.6</gridId>
    <rorId>https://ror.org/030yyf771</rorId>
  </sponsor>
  <funder id="Funder16894-0">
    <name>Ranbaxy Laboratories Ltd (India)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-11-05T00:00:00.000Z" version="20">
    <isrctn dateAssigned="2007-11-05T00:00:00.000Z">27834915</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Evaluation of the sustained effect of Viniyoga in the rehabilitation of hypertensive patients</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>We hypothesise that patients who receive training in Viniyoga will continue practising the method 15% more often than those who receive training in Progressive Relaxation.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>To assess whether more participants in the intervention group will maintain the method taught compared to those in the control group, assessed at three weeks (i.e. at the moment of discharge from our hospital) and six months after the discharge from the hospital.</primaryOutcome>
      <secondaryOutcome>The following will be measured at six months: 
1. Hospital Anxiety and Depression Scale [HADS] 
2. 36-item Short Form health survey (SF-36)
3. Heart rate variability 
4. Blood pressure
5. Use of antihypertensive medication</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Ethics approval received from the Ethics Committee of Arztekammer Nordrhein in May 2007 (ref: 2007113).</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN27834915</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>1</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial.</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Quality of life</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2007-05-07T00:00:00.000Z</overallStartDate>
      <overallEndDate>2009-05-06T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Germany</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="4e2a5114-26e8-4988-af08-b62d9c275ec0">
	  <name>Klinik Roderbirken</name>
	  <address/>
	  <city>Leichlingen</city>
	  <state/>
	  <country>Germany</country>
	  <zip>D-42799</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>Arterial Hypertension.</inclusion>
      <ageRange>Adult</ageRange>
      <gender>Both</gender>
      <targetEnrolment>300</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>300</totalTarget>
      <exclusion>1. Congestive heart failure (New York Heart Association [NYHA] II or more)
2. Relevant rhythm disorders
3. Relevant pulmonary disease
4. Dialyses
5. Surgery within the last four weeks
6. ST-elevation myocardial infarction within the last four weeks</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2007-05-07T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2009-05-06T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Arterial hypertension</description>
	<diseaseClass1>Circulatory System</diseaseClass1>
	<diseaseClass2>Arterial hypertension</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Viniyoga or Progressive Relaxation group training (maximum 10 people per group), 45 minutes per session, five days a week for three weeks.</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      
    </outputs>
    <parties>
      <funderId>Funder16602-0</funderId>
      <contactId>Contact54560_16602</contactId>
      <sponsorId>Sponsor53115</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact54560_16602">
    <title>Mrs</title>
    <forename>Claudia</forename>
    <surname>Fusshoeller</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Klinik Roderbirken</address>
      <city>Leichlingen</city>
      <country>Germany</country>
      <zip>D-42799</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+49 (0)2175 824310</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">Claudia.Fusshoeller@klinik-roderbirken.de</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor53115">
    <organisation>Refonet (Germany)</organisation>
    <website>http://refonet.de</website>
    <sponsorType>Research organisation</sponsorType>
    <contactDetails>
      <address>Burgweg 3</address>
      <city>Bad Neuenahr-Ahrweiler</city>
      <country>Germany</country>
      <zip>D-53474</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">Claudia.Fusshoeller@klinik-roderbirken.de</email>
    </contactDetails>
    <privacy>Public</privacy>
    <gridId>grid.487444.f</gridId>
    <rorId>https://ror.org/04yeh2x21</rorId>
  </sponsor>
  <funder id="Funder16602-0">
    <name>Refonet (Germany)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-10-31T00:00:00.000Z" version="20">
    <isrctn dateAssigned="2007-10-31T00:00:00.000Z">44961472</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Pycnogenol® to reduce use of commercial anti-hypertensive medications: a randomised, double-blind, placebo-controlled, prospective, 15-week study</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>Pycnogenol®, a natural product, a  "complementary or alternative medicine", will reduce the use of antihypertensive medicines (Angiotensin Converting Enzyme [ACE] inhibitors) and Cardiovascular Disease (CVD) risk factors in subjects with both hypertension and type 2 diabetes.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Measured at 12th week of treatment:
1. Blood pressure, measured on the left arm after 10 minutes rest (Korotkoff sounds I and V were taken as the systolic and diastolic blood pressures)
2. Serum endothelin-1
3. Fasting Low Density Lipoprotein (LDL)-cholesterol
4. Glycosylated haemoglobin (HbA1c)
5. Fasting plasma glucose
6. Urinary albumin concentration</primaryOutcome>
      <secondaryOutcome>Measured at 4th and 8th week of treatment:
1. Blood pressure, measured on the left arm after 10 minutes rest (Korotkoff sounds I and V were taken as the systolic and diastolic blood pressures)
2. Serum endothelin-1
3. Fasting Low Density Lipoprotein (LDL)-cholesterol
4. Glycosylated haemoglobin (HbA1c)
5. Fasting plasma glucose
6. Urinary albumin concentration</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Ethics approval received from the Human Subjects Protection Program at University of Arizona on the 16th August 2003 (ref: 03-129).</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN44961472</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Single-centre, interventional, randomised double-blind placebo-controlled study</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2003-08-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2007-08-01T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>United States of America</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="2fa26299-0db8-4134-b100-0a56346418d8">
	  <name>Mel and Enid Zuckerman College of Public Health</name>
	  <address/>
	  <city>Tucson</city>
	  <state/>
	  <country>United States of America</country>
	  <zip>85724-5155</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Men and women, 40 - 75 years of age
2. Non-insulin dependent type 2 diabetes
3. Receiving pharmaceutical treatment (ACE-inhibitors) for hypertension 
4. Pre-trial systolic blood pressure of 130 - 150 mmHg</inclusion>
      <ageRange>Adult</ageRange>
      <gender>Both</gender>
      <targetEnrolment>80</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>80</totalTarget>
      <exclusion>1. Type 1 diabetes
2. Use of insulin
3. Any supplements other than single daily multivitamin
4. Having any major illness such as cancer, asthma, or heart failure
5. Any previous cardiac events
6. Pregnancy, or being nursing mother</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2003-08-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2007-08-01T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Cardiovascular risk factors in diabetes</description>
	<diseaseClass1>Circulatory System</diseaseClass1>
	<diseaseClass2>Cardiovascular risk factors</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Oral administration of Pycnogenol® pills (25 mg, 5 times a day) or matched inactive placebo for 12 weeks. Total duration of follow-up is 15 weeks.</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>Pycnogenol®</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
        
      </outputs>
    <parties>
      <funderId>Funder17202-0</funderId>
      <contactId>Contact55163_17202</contactId>
      <sponsorId>Sponsor53729</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact55163_17202">
    <title>Prof</title>
    <forename>Ronald</forename>
    <surname>Watson</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Mel and Enid Zuckerman College of Public Health
University of Arizona, Health Science Center
1295 N. Martin
P. O. Box 245155 [FedEx building 202 room 252]</address>
      <city>Tucson</city>
      <country>United States of America</country>
      <zip>85724-5155</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
  </contact>
  <sponsor id="Sponsor53729">
    <organisation>Horphag Research Ltd (Switzerland) </organisation>
    <website>http://www.horphag.com</website>
    <sponsorType>Industry</sponsorType>
    <contactDetails>
      <address>P.O. Box 80
Avenue Louis-Casai 71
Cointrin</address>
      <city>Geneva</city>
      <country>Switzerland</country>
      <zip>CH-1216</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.487164.8</gridId>
    <rorId>https://ror.org/003n34405</rorId>
  </sponsor>
  <funder id="Funder17202-0">
    <name>Horphag Research Ltd (Switzerland)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-10-30T00:00:00.000Z" version="21">
    <isrctn dateAssigned="2007-10-30T00:00:00.000Z">03887874</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Imaging-based Thrombolysis trial in Acute Ischemic Stroke -III</title>
      <scientificTitle/>
      <acronym>ITAIS- III</acronym>
      <studyHypothesis>Whether the patients without occlusion or significant stenosis of the large vessels should receive thrombolysis had been focused on and questioned for a long time. However, there is still no large Randomised Controlled Trial (RCT) to prove if these patients can benefit from thrombolysis. The objective of this trail is to investigate: 
1. For the selected acute ischemic stroke patients without large vessels occlusion or significant stenosis, whether the IntraVenous (IV) thrombolysis can improve the clinical outcome if the mismatch exists on CTP/Computed Tomography Angiography-Source Images (CTA-SI) scan in 3-9 hr time-window
2. For the selected acute ischemic stroke patients without large vessels occlusion or significant stenosis, whether the IV thrombolysis can improve the blood perfusion of brain if the mismatch exists on CT perfusion (CTP)/CTA-SI scan in 3-9 hr time-window
3. For the selected acute ischemic stroke patients without large vessels occlusion or significant stenosis, but the mismatch exists on CTP/CTA-SI scan in 3-9 hr time-window, whether the safety of IV thrombolysis is better than the NINDS trial which was in 3 hr window or implemented on the patients with large vessels occlusion or significant stenosis in 3-9 hr time-window.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Proportion of participants who achieve the following: 
1. Reperfusion improvement, assessed 24 to 48 hours post-treatment and defined as either greater than or equal to 30% reduction of Mean Transit Time (MTT) volume of abnormality
2. Good clinical outcome at 90 days defined as a modified Rankin score (mRS) of 0-1
3. Intracerebral haemorrhage within 24-36 h after thrombolysis</primaryOutcome>
      <secondaryOutcome>Proportion of participants who achieve the following: 
1. mRS 0 to 2 at 90 days 
2. Barthel Index (BI) score 75 to 100 at 90 days 
3. NIHSS 4 points improvement or 0-1 at 2 hours after treatment 
4. NIHSS 4 points improvement or 0-1 at 24 to 48 hours 
5. NIHSS 4 points improvement or 0-1 at day 7</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Approval gained from the Beijing Tiantan Hospital Capital Medical University Ethics Board on October 10, 2006.</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN03887874</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>5</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>A prospective, multi-center, assessor-blind controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Non randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2007-10-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2010-06-01T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>China</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="b9a281d3-ee60-428f-b959-e23ff373ca0e">
	  <name>Neurology Department</name>
	  <address/>
	  <city>Beijing</city>
	  <state/>
	  <country>China</country>
	  <zip>100050</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Female or male inpatients 
2. Age 18-80 years 
3. Clinical diagnosis of ischaemic stroke 
4. Onset of symptoms within 3-9 hours prior to initiation of thrombolysis treatment 
5. Stroke symptoms present for at least 30 minutes and has not significantly improved before treatment 
6. The National Institutes of Health Stroke Scale (NIHSS) score greater than or equal to 4 
7. m-CT screening to be started within 8.5 hrs after stroke onset 
8. Perfusion abnormality of CT scan &gt;2cm in diameter involving hemisphere 
9. CT Perfusion/CTA source image mismatch greater than or equal to 20% 
10. CTA shows occlusion or significant stenosis of large vessels (Thrombolysis In Cerebral Ischemia [TICI] grade is 0 or 1) 
11. Patients are willing to receive thrombolysis treatment and to give informed consent 
12. Patients are willing and able to comply with the study protocol</inclusion>
      <ageRange>Adult</ageRange>
      <lowerAgeLimit unit="Years" value="18.0"/>
      <upperAgeLimit unit="Years" value="80.0"/>
      <gender>Both</gender>
      <targetEnrolment>200</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>200</totalTarget>
      <exclusion>1. Evidence of IntraCranial Haemorrhage (ICH), brain tumors, vascular malformation, aneurysm, SubArachnoid Hemorrhage (SAH) 
2. Major infarct involving greater than 1/3 of Middle Cerebral Artery (MCA) territory on the CTA-SI 
3. Presenting obvious neurologic deficits because of past stroke (mRS &gt;2) 
4. Severe stroke as assessed clinically (e.g. The National Institute of Health Stroke Scale [NIHSS] &gt;25) and/or by appropriate magnetic imaging techniques. 
5. Seizure at onset of stroke 
6. Prior stroke within the last 3 months 
7. Patients with any history of prior stroke and concomitant diabetes 
8. Administration of heparin within the previous 48 hours and a thromboplastin time exceeding the upper limit of normal for laboratory 
9. Platelet count of below 100,000/mm3
10. Uncompensated hypertension at study entry or hypertension requiring aggressive treatment to reduce blood pressure to nonhypertensive limits. Uncompensated hypertension is defined as systolic blood pressure &gt;185 mm Hg or diastolic blood pressure &gt;=110 mm Hg on 3 repeated measures at least 10 minutes apart 
11. Blood glucose &lt;50 or &gt;400 mg/dl 
12. Known haemorrhagic diathesis within the last 6 months 
13. Patients receiving oral anticoagulants e.g. warfarin sodium, and coagulant response time (INR) &gt;1.5 
14. Known history of or suspected intracranial haemorrhage including subarachnoid haemorrhage 
15. Pregnancy or lactation 
16. Any history of severe central nervous system damage (i.e. neoplasm, aneurysm, intracranial or spinal surgery) 
17. Haemorrhagic retinopathy,e.g. in diabetes (vision disturbances may indicate haemorrhagic retinopathy) 
18. Bacterial endocarditis, pericarditis
19. Prolonged traumatic external heart massage, or recent (less than 10 days) obstetrical delivery or recent puncture of a non-compressible blood-vessel (e.g. subclavian or jugular vein puncture) 
20. Acute pancreatitis 
21. Documented ulcerative gastrointestinal disease during the last 3 months, 
22. Oesophageal varices, arterial aneurysm, arterial/venous malformation 
23. Neoplasm with increased bleeding risk 
24. Severe liver disease including hepatic failure, cirrhosis, portal hypertension, oesophageal varices and active hepatitis 
25. Major surgery or significant trauma in past 10 days 
26. Known serious sensitivity to alteplase</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2007-10-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2010-06-01T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Acute ischemic stroke</description>
	<diseaseClass1>Circulatory System</diseaseClass1>
	<diseaseClass2>Acute ischemic stroke</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Patients included were divided into recombinant tissue Plasminogen Activator (rt-PA) (0.9 mg/kg) intravenous thrombolysis group and regular treatment group according to the intention of doctors and patients.</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>Recombinant tissue Plasminogen Activator (rt-PA)</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
        
      </outputs>
    <parties>
      <funderId>Funder17196-0</funderId>
      <contactId>Contact55157_17196</contactId>
      <sponsorId>Sponsor53722</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact55157_17196">
    <title>Prof</title>
    <forename>Yongjun </forename>
    <surname>Wang</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Neurology Department
Beijing Tiantan Hospital 
Tiantan Xili 6 
Chongwen District </address>
      <city>Beijing</city>
      <country>China</country>
      <zip>100050</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">yongjunwang111@yahoo.com.cn</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor53722">
    <organisation>Beijing Tiantan Hospital (China) </organisation>
    <website>http://www.bjtth.com/</website>
    <sponsorType>Hospital/treatment centre</sponsorType>
    <contactDetails>
      <address>Beijing Tiantan Hospital 
Tiantan Xili 6 
Chongwen District</address>
      <city>Beijing</city>
      <country>China</country>
      <zip>100050</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">yongjunwang111@yahoo.com.cn</email>
    </contactDetails>
    <privacy>Public</privacy>
    <gridId>grid.411617.4</gridId>
    <rorId>https://ror.org/003regz62</rorId>
  </sponsor>
  <funder id="Funder17196-0">
    <name>The Ministry of Science and Technology and the Ministry of Health of the People's Republic of China - the key scientific research program of the 11th National Five-Year Planning of China</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-10-30T00:00:00.000Z" version="21">
    <isrctn dateAssigned="2007-10-30T00:00:00.000Z">05620936</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Development of a simple protocol to enhance compliance in home management of malaria</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>Malaria is a disease caused by the protozoan plasmodium falciparum. It is still rampant in sub-Saharan Africa and endemic in Nigeria with perennial transmission. It causes febrile illness which could be severe in children accounting for 25% of infant mortality and 8-12% of death under age of five years. Malaria is responsible for 40-60% of out patient consultation. It presents in two clinical types - uncomplicated and severe malaria. 

Study Domain: Parasitic infection; child care and health education/behaviour change

Study hypotheses:  
1. There will be no significant difference in the outcome of malaria in children whose mothers or caregivers used treatment protocol to treat malaria at home and those whose mothers did not use the protocol. 
2. There will be no significant difference in the correctness of use of chloroquine by mothers who used the treatment protocol and those who did not use the protocol. 
3. There will be no significant difference in the correctness of use of chloroquine by trained mothers and mothers who were not trained.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>The mothers/caregivers were asked about the treatment given to the child during visits by the research assistants. The mothers/caregivers were asked to record these details in their diary, which was checked on Day 7 from recruitment at the time of collecting Day 7 blood sample for microscopy examination. These data were used to assess the following: 

1. Correct use of chloroquine, measured in terms of dose, frequency and duration 
2. Timeliness of commencing treatment (commencing treatment within 24 hours of noticing fever in child) 
3. Treatment outcome, measured by mean parasite clearance time, fever clearance time, and progression of illness as reported by mothers/caregivers 
4. Use of the protocol. Proportion of mothers who referred to the treatment protocol in the treatment of last episode of malaria in children</primaryOutcome>
      <secondaryOutcome>1. Attack rate of malaria over a period of one year 
2. Sensitivity and specificity of presumptive diagnosis of malaria by mothers/caregivers</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>The joint University of Ibadan/University College Hospital Institutional Ethical Review Board. Date of Approval: 29th June 2000</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN05620936</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Single-centre, single-blind, randomised controlled field study.</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2004-06-16T00:00:00.000Z</overallStartDate>
      <overallEndDate>2005-06-30T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Nigeria</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="773fd67e-3d02-42e4-aba1-c87a70aaee4e">
	  <name>Department of Epidemiology</name>
	  <address/>
	  <city>Ibadan</city>
	  <state/>
	  <country>Nigeria</country>
	  <zip>PMB 5116</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Mothers with children 10 years or less who have febrile illness presumed to be malaria 
2. Willingness of mothers to allow their child remain in study for a period of 14 days 
3. Mothers who consent to their child having finger prick to collect blood for blood smears</inclusion>
      <ageRange>Child</ageRange>
      <upperAgeLimit unit="Years" value="10.0"/>
      <gender>Both</gender>
      <targetEnrolment>152</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>152 children (76 in each arm)</totalTarget>
      <exclusion>1. Child with severe illness or requiring parenteral medication 
2. Child with other diseases, co-morbid with febrile illness 

Withdrawal Criteria: 
1. Parents of children choosing not to continue with the study 
2. Progression of illness in child</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2004-06-16T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2005-06-30T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Malaria</description>
	<diseaseClass1>Infections and Infestations</diseaseClass1>
	<diseaseClass2>Malaria</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Randomisation of the communities to the intervention and control groups was done by ballots. 

Interventions carried out at the intervention site: 
1. Training of 'mother trainers' and community members about cause, symptoms and signs of the clinical types, treatment and prevention of malaria including referral. 

2. Development of a treatment protocol using participatory approach and distribution of the protocol to households. The development of the protocol was done in phases using modified focus group sessions with several community checks at different stages of development. The participants were the 'mother trainers', selected community members, research team and a graphic artist. The treatment protocol consists of treatment guidelines for each of the clinical types of malaria compiled together on a cardboard. The protocol illustrated the presentation of clinical types of malaria, the appropriate steps to take for each type and the correct dose and schedule of treatment of uncomplicated malaria using chloroquine according to the age of the child. The protocol was in cartoon format and the local language was used. 

Mothers/caregivers in both arms of the study were requested to purchase the chloroquine used for treatment from their regular source which in most instances are the drug hawkers and patent medicine sellers. 

Control arm of the study: 
They were passive controls. The communities in the control arm of the study were left to continue their usual treatment practice for malaria in their children. No training or guideline was provided.

Duration of intervention: One year</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
        
      </outputs>
    <parties>
      <funderId>Funder17213-0</funderId>
      <contactId>Contact55174_17213</contactId>
      <sponsorId>Sponsor53740</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact55174_17213">
    <title>Dr</title>
    <forename>Ikeoluwapo </forename>
    <surname>Ajayi</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Department of Epidemiology
Medical Statistics and Environmental Health
College of Medicine
University of Ibadan </address>
      <city>Ibadan </city>
      <country>Nigeria</country>
      <zip>PMB 5116</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">ikeajayi2003@yahoo.com</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor53740">
    <organisation>University of Ibadan (Nigeria)</organisation>
    <website>http://www.ui.edu.ng/</website>
    <sponsorType>University/education</sponsorType>
    <contactDetails>
      <address>c/o Dr Ikeoluwapo Oyeneye Ajayi
Department of Epidemiology
Medical Statistics and Environmental Health
College of Medicine
University of Ibadan</address>
      <city>Ibadan </city>
      <country>Nigeria</country>
      <zip>PMB 5116</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+234 8 023 268431</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">ikeajayi2003@yahoo.com</email>
    </contactDetails>
    <privacy>Public</privacy>
    <gridId>grid.9582.6</gridId>
    <rorId>https://ror.org/03wx2rr30</rorId>
  </sponsor>
  <funder id="Funder17213-0">
    <name>Investigator funded (Nigeria)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-10-10T00:00:00.000Z" version="21">
    <isrctn dateAssigned="2007-10-10T00:00:00.000Z">79667806</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>The differential effects of visceral fat reduction compared with subcutaneous fat reduction on parameters of the metabolic indices and adipocytokines</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>The weight reduction with the change of fat distribution influence on the adipokines and metabolic indices.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>The changes of body fat distribution and adipocytokines, determined by computed tomography scan and measured both before and 16 weeks after the weight reduction program.</primaryOutcome>
      <secondaryOutcome>The relationship of body fat distribution and adipocytokines, determined by computed tomography scan and measured both before and 16 weeks after the weight reduction program.</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Ethics approval received from the Institutional Review Board of Yondong Severance Hospital, Yonsei University College of Medicine (South Korea) on the 6th September 2006 (ref: 3-2006-0044).</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN79667806</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>1</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>A prospective intervention study</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Quality of life</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2006-09-06T00:00:00.000Z</overallStartDate>
      <overallEndDate>2007-05-31T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Korea, South</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="8c6ddf10-9d3c-41c5-a239-5d99a0200273">
	  <name>Department of Family Medicine</name>
	  <address/>
	  <city>Seoul</city>
	  <state/>
	  <country>Korea, South</country>
	  <zip>135-270</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Apparently healthy, either sex, aged 18 - 60 years
2. Non-smokers 
3. Low alcohol consumers
4. Overweight or obese with an average Body Mass Index (BMI) of 23 kg/m^2 or greater</inclusion>
      <ageRange>Adult</ageRange>
      <lowerAgeLimit unit="Years" value="18.0"/>
      <upperAgeLimit unit="Years" value="60.0"/>
      <gender>Both</gender>
      <targetEnrolment>52</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>52</totalTarget>
      <exclusion>1. A past history of cardiovascular disease
2. Diabetes
3. Moderate to severe hypertension (resting blood pressure greater than 170/100 mmHg)
4. Renal impairment (serum creatinine greater than 120 µmol/L) or overt proteinuria
5. Obesity caused by an endocrine disorder
6. Psychiatric disorders
7. Current pregnancy or breast-feeding
8. A body weight fluctuation of more than 5 kg in the previous six months
9. Taking any kind of medication</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2006-09-06T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2007-05-31T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Obesity</description>
	<diseaseClass1>Nutritional, Metabolic, Endocrine</diseaseClass1>
	<diseaseClass2>Obesity</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>All patients received all three interventions for 16 weeks:
1. The subjects visited an obesity clinic twice per month and restricted their caloric intake to less than their usual intake by 600 kcal/day
2. All patients were encouraged to achieve the goal of five hours of aerobic exercise (physical activity of moderate intensity, such as brisk walking, light jogging or stationary ergometer usage) per week
3. They were also administered 10 - 15 mg of sibutramine (in the morning)</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>Sibutramine</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
        
      </outputs>
    <parties>
      <funderId>Funder16940-0</funderId>
      <contactId>Contact54901_16940</contactId>
      <sponsorId>Sponsor53466</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact54901_16940">
    <title>Dr</title>
    <forename>Ji-Won</forename>
    <surname>Lee</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Department of Family Medicine
Yonsei University College of Medicine
Yongdong Severance Hospital
Kangnam 
P.O. Box 1217</address>
      <city>Seoul</city>
      <country>Korea, South</country>
      <zip>135-270</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
  </contact>
  <sponsor id="Sponsor53466">
    <organisation>Yonsei University College of Medicine (South Korea) </organisation>
    <website>http://medicine.yonsei.ac.kr/en/index.asp</website>
    <sponsorType>University/education</sponsorType>
    <contactDetails>
      <address>250 Sungsan-Ro 
Seodaemoon-gu</address>
      <city>Seoul </city>
      <country>Korea, South</country>
      <zip>120-752 </zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.15444.30</gridId>
    <rorId>https://ror.org/01wjejq96</rorId>
  </sponsor>
  <funder id="Funder16940-0">
    <name>Yonsei University College of Medicine (South Korea) - faculty research grant (2006)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-10-10T00:00:00.000Z" version="21">
    <isrctn dateAssigned="2007-10-09T00:00:00.000Z">68305337</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>The efficacy of chiropractic spinal adjustments as a treatment protocol in the management of infantile colic: a randomised controlled trial</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>Chiropractic manipulation is more effective than placebo for the treatment of infantile colic.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Parental questionnaire at baseline, each subsequent treatment session and follow-up consultation. The questionnaire asked the following quetisons: 
1. Measured from the parents' perception, how long does the baby cry with each attack of colic?  
2. How often does the colic occur in 24 hours?  
3. Does the colic attack occur at any particular time of day or night?  
4. Does anything seem to precipitate an attack?  
5. For how long does the baby sleep between colic attacks?  
6. Does the baby still require medicine to relieve the colic?  
7. How would you rate the baby's response to treatment (1-5)?  
8. Has the baby had any other illnesses?</primaryOutcome>
      <secondaryOutcome>Increased joint motion assessed at baseline, each subsequent treatment session and follow-up consultation.</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Responsible Committee on Human Experimentation, and the Research Ethics Committee of Technikon Natal, Durban, South Africa. Approved in 1998.</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN68305337</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>1998-01-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>1998-12-01T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Australia</country>
	<country>South Africa</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="0ef1a2e0-2797-44f9-950b-f1da42f66641">
	  <name>Murdoch University</name>
	  <address/>
	  <city>Murdoch</city>
	  <state/>
	  <country>Australia</country>
	  <zip>6150</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. The infant was to undergo a thorough examination by the consulting paediatrician to determine the health of the infant and to exclude any underlying organic problem, thereby ensuring a strict diagnosis of infantile colic
2. The infant was to be 0 to 8 weeks of age at the commencement of treatment to exclude the possibility of spontaneous cessation of the colic at 3 months
3. Apart from the colic, the infant was to suffer from no other condition/disease
4. If any medication had been administered to the infant to relieve the symptomatology of colic prior to the commencement of treatment (whether prescribed or over-the-counter drugs) the infant was required to remain on the same medication for the duration of the study, if the medication was required
5. Written informed consent was to be obtained from a parent before participation in the study</inclusion>
      <ageRange>Neonate</ageRange>
      <gender>Both</gender>
      <targetEnrolment>30</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>30</totalTarget>
      <exclusion>Any participant that did not meet the inclusion criteria.</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>1998-01-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>1998-12-01T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Infantile colic</description>
	<diseaseClass1>Neonatal Diseases</diseaseClass1>
	<diseaseClass2>Infantile colic</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Chiropractic manipulation/mobilization for spinal adjustments vs placebo treatment. One hour per session, 6 sessions over a 2-week period with a follow-up consultation after 1 month.</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
        
      </outputs>
    <parties>
      <funderId>Funder16103-0</funderId>
      <contactId>Contact54049_16103</contactId>
      <sponsorId>Sponsor52603</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact54049_16103">
    <title>Dr</title>
    <forename>Brian</forename>
    <surname>Nook</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Murdoch University
School of Chiropractic
Room ECL 1.009
South Street</address>
      <city>Murdoch</city>
      <country>Australia</country>
      <zip>6150</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+61 08 9360 7690</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">b.nook@murdoch.edu.au</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor52603">
    <organisation>Technikon Natal School of Chiropractic (South Africa)</organisation>
    <website>http://www.dut.ac.za/front%20page.aspx</website>
    <sponsorType>University/education</sponsorType>
    <contactDetails>
      <address>Durban University Of Technology - Durban Central Offices
41/43 Centenary Road</address>
      <city>Durban</city>
      <country>South Africa</country>
      <zip>4001</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+27 (0)31 308 5111</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">CharmaK@dut.ac.za</email>
    </contactDetails>
    <privacy>Public</privacy>
    <gridId>grid.412114.3</gridId>
    <rorId>https://ror.org/0303y7a51</rorId>
  </sponsor>
  <funder id="Funder16103-0">
    <name>Technikon Natal School of Chiropractic (South Africa)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-10-03T00:00:00.000Z" version="17">
    <isrctn dateAssigned="2007-10-03T00:00:00.000Z">25515380</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Occupational orientation in medical neurorehabilitation (Berufliche Orientierung in der Medizinischen Neurorehabilitation [BOMeN])</title>
      <scientificTitle/>
      <acronym>BOMeN</acronym>
      <studyHypothesis>The trial studies survivors of stroke or brain injury with a special occupational difficulty concerning the reintegration to work. For these patients return-to-work is accompanied by explicit strains because of the coincidence of physical and cognitive impairments. Furthermore patients with acquired brain injury often focus only on the physical deficits and do not show adequate awareness for cognitive constraints. 

Hypotheses: 
1. Until 15 months after rehabilitation the ratio of (re-)employed persons in the intervention group is significantly higher than the ratio of (re-)employed persons in the control group
2. Until 15 months after rehabilitation the ratio of (re-)employable persons in the intervention group is significantly higher than the ratio of (re-)employable persons in the control group
3. Patients of the intervention group can be re-integrated significantly quicker than patients of the control group
4. Re-integrated patients who participated in the intervention group show significantly less days of incapacity for work than re-integrated patients who participated in the control group
5. Patients who participated in the intervention group show a significantly higher satisfaction with life and health than patients who participated in the control group
6. Patients who participated in the intervention group show a significantly higher motivation for rehabilitation than patients who participated in the control group
7. The intervention treatment will gain a higher valuation than the control treatment by the parties involved  (patients and rehabilitation workers)</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>The following variables are measured by standardized or self-developed questionnaires: 
1. Re-employment (patients) 15 months after rehabilitation
2. (Re-)employability (patients) 15 months after rehabilitation
3. Days of incapacity to work (patients), measured using the Indicators of the Status of Rehabilitation questionnaire (Indikatoren des Reha-Status [IRES]) 15 months after rehabilitation
4. Expectations concerning the rehabilitation (patients), measured using the Questionnaire on Expectations and Motivation Concerning Rehabilitation (Fragebogen zu Reha-Erwartungen und Reha-Motivation [FREM]) at the start and end of rehabilitation
5. Motivation for rehabilitation (patients), measured using the Diagnostic Investigation of Motivation Concerning Work questionnaire (Diagnostik von Arbeitsmotivation [DIAMO]) at the start and end of rehabilitation, 6, 12 and 15 months after rehabilitation
6. Satisfaction with life and health (patients) (the 36-item Short Form health survey [SF-36]/the World Health Organization Quality of Life Questionnaire [WHO-QoL-BREF]) at the start and end of rehabilitation, 6, 12 and 15 months after rehabilitation
7. Satisfaction with rehabilitation procedure and contents (patients and rehabilitation workers). Timepoints for patients: at the start and end of rehabilitation, 6, 12 and 15 months after rehabilitation. Timepoints for workers: once in Summer 2008.</primaryOutcome>
      <secondaryOutcome>1. Cognitive functional status at the start and end of rehabilitation, 6, 12 and 15 months after rehabilitation
2. Motivation for work at the start and end of rehabilitation, 6, 12 and 15 months after rehabilitation</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Ethics Committee of the Arztekammer Westfalen-Lippe and the Medical Faculty of the Westfalischen Wilhelms Unitersigy of Munster. Approved on 24th May 2007 (ref: 2007-235-f-S)</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN25515380</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>GfR 06/006</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial.</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2007-07-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2010-06-30T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Germany</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="750eeeaf-3705-4a02-b7ce-7b0eea1010ac">
	  <name>Johanniterstrasse 7</name>
	  <address/>
	  <city>Bad Oeynhausen</city>
	  <state/>
	  <country>Germany</country>
	  <zip>32545</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>All participants must meet all of the following conditions: 
1. Positive prognostic estimation of occupational ability 
2. Stroke or craniocerebral trauma 
3. Estimated Functional Independence Measure (FIM) greater than or equal to 90 
 
Also, all participants must meet at least one of the following conditions: 
1. Advice for medical rehabilitation based on paragraph 51.1 of the Social Security Statutes, Book No. 5 (SGB V)
2. Inability to work for 3 months during the last 12 months 
3. Ability to work is less than 6 hours 
4. Not in paid work before start of rehabilitation 
5. Necessary occupational reorientation 
6. Application for a pension 
7. Risk of early retirement</inclusion>
      <ageRange>Adult</ageRange>
      <gender>Both</gender>
      <targetEnrolment>306</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>306</totalTarget>
      <exclusion>1. Older than 60 years 
2. Acute psychiatric disorder 
3. Acute addiction 
4. Restrictive aphasic disorder
5. Insufficient knowledge of German language 
6. Estimated FIM &lt;90 
7. Neurological diseases other than stroke or craniocerebral trauma</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2007-07-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2010-06-30T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Neurorehabilitation for survivors of stroke and brain injury</description>
	<diseaseClass1>Nervous System Diseases</diseaseClass1>
	<diseaseClass2>Neurorehabilitation for survivors of stroke and brain injury</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Intervention group: Patients of the intervention group take part in a newly developed rehabilitation concept called Occupational Orientation in Medical Neurorehabilitation (BOMeN) which consists of nine sessions of 3 hours during a 4-week rehabilitation. In this therapy the patients get to know relevant information about stress, perspectives, motivation and the relevance of attention, memory, planning functions and motor skills for everyday working life. The contents are mediated by patient education, experiments of perception and ergotherapeutic exercises. Furthermore the neuropsychological, socialmedical and ergotherapeutical assessments are more related to work and therapy is integrated in a fixed schedule. Finally different disciplines show a higher degree of interworking. 

Control group: Medical Neurorehabilitation (MeN) patients of the control group take part in the conventional rehabilitation concept (MeN) which contains shorter units of assessment and therapy without an explicit relation to work. The average duration of treatment in both groups is controlled.</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
        
      </outputs>
    <parties>
      <funderId>Funder16876-0</funderId>
      <funderId>Funder16876-1</funderId>
      <contactId>Contact54835_16876</contactId>
      <sponsorId>Sponsor53393</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact54835_16876">
    <title>Dr</title>
    <forename>Anke</forename>
    <surname>Menzel-Begemann</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Johanniterstrasse 7</address>
      <city>Bad Oeynhausen</city>
      <country>Germany</country>
      <zip>32545</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+49 5731 151 773</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">anke.menzel-begemann@ahb-klinik.de</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor53393">
    <organisation>Association for Rehabilitation Sciences Nordrhein-Westfalen e.V. (Germany)</organisation>
    <website>http://www.rehaforschung-nrw.de</website>
    <sponsorType>Not defined</sponsorType>
    <contactDetails>
      <address>Königsallee 71</address>
      <city>Düsseldorf</city>
      <country>Germany</country>
      <zip>40215 </zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
  </sponsor>
  <funder id="Funder16876-0">
    <name>Association for Rehabilitation Sciences Nordrhein-Westfalen e.V. (Gesellschaft für Rehabilitationswissenschaften Nordrhein-Westfalen e.V.) (ref: GfR 06006 / 623-06)</name>
    <fundRef/>
  </funder>
  <funder id="Funder16876-1">
    <name>Houses of Holy Order of Johanniter Rehabilitation Centre (Johanniter-Ordenshäuser Bad Oeynhausen gemGmbH) (ref: BOMeN 98410)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-10-03T00:00:00.000Z" version="20">
    <isrctn dateAssigned="2007-10-03T00:00:00.000Z">46330948</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>A randomised controlled trial comparing group to individual prenatal care</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>It was hypothesised that group prenatal care would improve maternal mental health (depression and anxiety), psychosocial health (social support, stress, parenting morale, parenting self-efficacy) and infant birth outcomes (low birth weight, small for gestational age and preterm birth rates) compared to individual prenatal care among a community sample of women in Calgary, Alberta.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>1. Maternal mental health: depression and anxiety - measured at study intake (prior to 20 weeks gestation), third trimester (32 - 36 weeks gestation) and 4 months postpartum 
2. Maternal psycho-social health:
2.1. Social support and stress - measured at study intake (prior to 20 weeks gestation) and 4 months postpartum 
2.2. Parenting morale and parenting self efficacy - measured at 4 months postpartum</primaryOutcome>
      <secondaryOutcome>1. Rates of infant birth outcomes (low birth weight, small for gestational age, preterm birth) - measured at birth 
2. Rates of breast feeding, uptake of parenting classes/supports, attendance at well child visits, immunisation rates - measured at 4 months postpartum</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Ethics approval received from the Conjoint Health Research Ethics Board, University of Calgary and Calgary Health Region on the 7th June 2007 (ref: E-20821).</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN46330948</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Quality of life</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2007-11-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2011-07-31T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Canada</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="8ab309bc-ee9f-4272-a795-3d8feb2be694">
	  <name>Alberta Children's Hospital (ACH)</name>
	  <address/>
	  <city>Calgary</city>
	  <state/>
	  <country>Canada</country>
	  <zip>T3B 6A8</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Pregnant woman living in Northeast Calgary
2. Less than 20 weeks gestation at study intake
3. Able to communicate in English, Punjabi, Mandarin, Hindi, Arabic, Urdu or Spanish</inclusion>
      <ageRange>Not Specified</ageRange>
      <gender>Female</gender>
      <targetEnrolment>1200</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>1200</totalTarget>
      <exclusion>1. Pregnant woman living outside Northeast Calgary
2. Greater than 20 weeks gestation at study intake
3. Unable to communicate in English, Punjabi, Mandarin, Hindi, Arabic, Urdu or Spanish</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2007-11-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2011-07-31T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Maternal mental health</description>
	<diseaseClass1>Mental and Behavioural Disorders</diseaseClass1>
	<diseaseClass2>Post-natal mental disorders</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Pregnant women are randomised to: 
1. Standard individual prenatal care
2. Group prenatal care

Control: Standard Prenatal Care 
Women randomly assigned to individual prenatal care will receive a standard schedule of one-on-one prenatal visits with a physician. The timing and frequency of visits will be decided by each womens' physician, although it is anticipated that they will follow the clinical practice guidelines, Healthy Beginnings: Guidelines for Care during Pregnancy and Childbirth provided by the Society for Obstetrics and Gynaecologists of Canada (SOGC). Women with high medical risk pregnancies will be referred for obstetrical care. 

Intervention: Group Prenatal Care 
Women randomly assigned to group prenatal care will receive an initial individual prenatal visit with a physician to confirm their pregnancy and subsequently will be grouped with 8 - 12 other women who are at a similar stage in pregnancy. Each group will meet with a health care provider for nine group sessions including one-on-one time with the provider for a prenatal check-up, time to conduct self measurements of their weight and blood pressure and a group discussion covering a topic appropriate to their stage of pregnancy. The group discussion will be co-facilitated by the physician and a perinatal educator who will encourage group members to participate in discussing topics of interest related to pregnancy, childbirth, parenting, and personal growth. These group sessions will take place at approximately 16, 20, 24, 28, 32, 34, 36, 38 weeks gestation and 2 weeks postpartum. Women will also receive individual prenatal visits at 37 and 39 weeks gestation. Women with high medical risk pregnancies will be referred for obstetrical care.</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
        
      </outputs>
    <parties>
      <funderId>Funder16761-0</funderId>
      <funderId>Funder16761-1</funderId>
      <contactId>Contact54719_16761</contactId>
      <sponsorId>Sponsor53275</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact54719_16761">
    <title>Dr</title>
    <forename>Suzanne</forename>
    <surname>Tough</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Alberta Children's Hospital (ACH)
c/o Decision Support Research Team, Room C4-301
2888 Shaganappi Trail NW</address>
      <city>Calgary</city>
      <country>Canada</country>
      <zip>T3B 6A8</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
  </contact>
  <sponsor id="Sponsor53275">
    <organisation>Calgary Health Region (Canada) - Three Cheers for the Early Years </organisation>
    <website>http://www.calgaryhealthregion.ca/3cheers/home.htm</website>
    <sponsorType>Research organisation</sponsorType>
    <contactDetails>
      <address>5th Floor
1509 Centre Street South</address>
      <city>Calgary</city>
      <country>Canada</country>
      <zip>T2G 2E6</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.413574.0</gridId>
    <rorId>https://ror.org/02nt5es71</rorId>
  </sponsor>
  <funder id="Funder16761-0">
    <name>Calgary Health Region (Canada) - Three Cheers for the Early Years</name>
    <fundRef/>
  </funder>
  <funder id="Funder16761-1">
    <name>Alberta Heritage Foundation for Medical Research (Canada)</name>
    <fundRef>http://dx.doi.org/10.13039/501100003179</fundRef>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-11-07T00:00:00.000Z" version="22">
    <isrctn dateAssigned="2007-09-13T00:00:00.000Z">21996121</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Impact of In-exsufflator Treatment on hospitalisation for Respiratory Exacerbation in Neuromuscular Disease</title>
      <scientificTitle/>
      <acronym>In-ex TREND study</acronym>
      <studyHypothesis>We will be looking specifically at a heterogeneous group of neuromuscular disorders which, either as a secondary consequence of degeneration of the spinal nerves (spinal muscular atrophy, amyotrophic lateral sclerosis) or as a primary muscle defect (muscular dystrophies, myopathies) result in progressive loss of muscle strength. Respiratory complications are the primary cause of morbidity and mortality associated with these diseases, as involvement of the respiratory muscles leads to either progressive hypoventilation or recurrent atelectasis and pneumonia secondary to decreased cough efficacy.

For this study we will look at those children with neuromuscular disorders who are admitted to hospital with a respiratory deterioration (hypoxemia and/or the presence of new onset radiologically proven atelectasis or consolidation).

Hypotheses:
We expect that the addition of the Emerson in-exsufflator to a standard treatment regimen for acute respiratory deterioration:
1. Will result in a decreased duration of hospitalisation in a population of children with neuromuscular disease
2. Resulting in hospitalisation will decrease the time requiring supplemental oxygen in a population of children with neuromuscular disease
3. Resulting in hospitalisation will result in a more rapid improvement in chest X-ray changes in a population of children with neuromuscular disease
4. Resulting in hospitalisation will decrease the length of stay in intensive care unit or days invasively ventilated in a population of children with neuromuscular disease</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Time to discharge: an estimate of the primary end-point, time to discharge with standard care, was based on the clinical experience of the principal investigators and is currently being verified with a three-year retrospective chart review at Childrens Hospital of Eastern Ontario (CHEO). The mean length of stay in these patients is estimated to be 10 days. Discussions with several paediatric respirologists have taken place, focusing on what magnitude of difference in time to discharge would be clinically important between treatment and control groups. The consensus was a Minimally Clinically Important Difference (MCID) of three days' reduction from the average current length of stay in the study population. These numbers translate to a hazard ratio of 1.4. A two-sided time-to-event test at a = 0.05 will be used to detect a significant difference in time to discharge between the two arms.</primaryOutcome>
      <secondaryOutcome>1. Time (in days) to improvement in oxygenation (no longer requiring supplemental oxygen for 24 hours)
2. X-ray changes: improvement or progression (increasing atelectasis, consolidation)
3. Development of acute hypercapnic respiratory failure requiring intubation and mechanical ventilation
4. Days in intensive care unit</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Each site will submit to their local hospital ethics boards. Ethics approval received from the Children's Hospital of Eastern Ontario Research Ethics Board (REB) on the 2nd October 2007 (ref: 07/24E).</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN21996121</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Multi-centre randomised unblinded controlled trial of the mechanical inexsufflator. Randomisation sequence will be stratified by centre with a block-size randomisation protocol.</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2007-10-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2009-04-01T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Canada</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="f835c857-2436-4192-ab3d-fb30544e6fe5">
	  <name>Children's Hospital of Eastern Ontario</name>
	  <address/>
	  <city>Ottawa</city>
	  <state/>
	  <country>Canada</country>
	  <zip>K1H 8L1</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Patients aged 3 to 17 years
2. Patients have a known neuromotor disorder affecting respiratory muscles  
3. Admitted to hospital with a respiratory deterioration (hypoxemia in the presence of new onset radiologically proven atelectasis or consolidation)</inclusion>
      <ageRange>Child</ageRange>
      <lowerAgeLimit unit="Years" value="3.0"/>
      <upperAgeLimit unit="Years" value="17.0"/>
      <gender>Both</gender>
      <targetEnrolment>128</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>128</totalTarget>
      <exclusion>1. Refusal to participate
2. Already using the Emerson in-exsufflator at home on a regular basis
3. Development of new uncompensated hypercapnic respiratory failure requiring intubation and mechanical ventilation
4. History of bullous emphysema, known susceptibility to pneumothorax or pneumomediastinum, or known to have had any recent barotraumas</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2007-10-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2009-04-01T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Children with neuromuscular disorders who are admitted to hospital with a respiratory deterioration (hypoxemia and/or the presence of new onset radiologically proven atelectasis or consolidation).</description>
	<diseaseClass1>Nervous System Diseases</diseaseClass1>
	<diseaseClass2>Neuromuscular disorders</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>1. Conventional treatments, as deemed appropriate by the treating physician:
1.1. Physiotherapy 
1.2. Nutritional support
1.3. Antibiotics (fever, elevated White Blood Cells [WBC])
1.4. Non-invasive positive pressure ventilation
2. Conventional treatments and Emerson in-exsufflator

Using Friedman's formula for survival analysis study design, 62 patients per arm would achieve 80% power to detect a hazard ratio of 1.4.  To account for potential withdrawals and withdrawal of consent, estimated at about 2.5%, four additional participants will be recruited for a grand total of 128 participants.</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      
    </outputs>
    <parties>
      <funderId>Funder16646-0</funderId>
      <contactId>Contact54604_16646</contactId>
      <sponsorId>Sponsor53159</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact54604_16646">
    <title>Dr</title>
    <forename>Sherri</forename>
    <surname>Katz</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Children's Hospital of Eastern Ontario
401 Smyth Road
w1406</address>
      <city>Ottawa</city>
      <country>Canada</country>
      <zip>K1H 8L1</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+1 613 737 7600 ext. 2868</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">skatz@cheo.on.ca</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor53159">
    <organisation>Children's Hospital of Eastern Ontario (Canada)</organisation>
    <website>http://www.cheo.on.ca/english/hub.shtml</website>
    <sponsorType>Hospital/treatment centre</sponsorType>
    <contactDetails>
      <address>c/o Sherri Katz, MD
401 Smyth Road
W1406</address>
      <city>Ottawa</city>
      <country>Canada</country>
      <zip>K1H 8L1</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+1 613 737 7600 ext. 2868</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">skatz@cheo.on.ca</email>
    </contactDetails>
    <privacy>Public</privacy>
    <gridId>grid.414148.c</gridId>
    <rorId>https://ror.org/05nsbhw27</rorId>
  </sponsor>
  <funder id="Funder16646-0">
    <name>Fight Spinal Muscular Atrophy (FightSMA) (USA)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-10-01T00:00:00.000Z" version="20">
    <isrctn dateAssigned="2007-08-23T00:00:00.000Z">73594603</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Neurocognitive functioning and brain plasticity in high-grade glioma patients: a magnetoencephalography pilot</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>We hypothesise that a relationship is present between functional connectivity, network features and neurocognitive performance in Glioblastoma Multiforme (GBM) patients. We also expect treatment and recurrence of the tumour to lead to remodelling of the neuronosynaptic maps and network features (i.e. plasticity), and hypothesise that these dynamic changes correlate with improvements of cognition.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Main study parameters are neurocognitive functioning and Magnetoencephalogram (MEG)-measures (synchronisation likelihood and small-world features).</primaryOutcome>
      <secondaryOutcome>No secondary outcome measures</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Ethics approval received from ethics boards of two centres participating in the study:
1. Academic Medical Centre (AMC) Medisch Ethische Commissie, received on the 16th July 2007 (ref: MEC 07/134) 
2. VU University Medical Center Medical Ethical Board, received on the 12th June 2007 (ref: 2007/108)</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN73594603</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>NWOpilot01</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Multicentre, observational, case-control study</studyDesign>
      <primaryStudyDesign>Observational</primaryStudyDesign>
      <secondaryStudyDesign>Case-control study</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Screening</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2007-09-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2008-06-01T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Netherlands</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="e55e6895-8e36-4e25-bfe3-16a4843cdfcd">
	  <name>Department of Medical Psychology, D343</name>
	  <address/>
	  <city>Amsterdam</city>
	  <state/>
	  <country>Netherlands</country>
	  <zip>1081 BT</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>For newly diagnosed patients: 
1. Adult (greater than 18 years)
2. Radiologically suspected GBM prior to surgery
3. Histologically confirmed GBM after surgery
4. Treatment consisting of surgery followed by combined radiotherapy and chemotherapy
5. Written informed consent

For patients with GBM recurrence: 
1. Adult (greater than 18 years)
2. Histologically confirmed GBM
3. Treatment consisting of surgery followed by chemotherapy
4. Written informed consent

For matched healthy controls: 
1. Adult (greater than 18 years)
2. Written informed consent</inclusion>
      <ageRange>Adult</ageRange>
      <lowerAgeLimit unit="Years" value="18.0"/>
      <gender>Not Specified</gender>
      <targetEnrolment>40</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>40</totalTarget>
      <exclusion>For patient groups: 
1. Use of centrally acting drugs, including corticosteroids, other than antiepileptic drugs
2. Psychiatric disease or symptoms
3. Insufficient mastery of the Dutch language
4. Inability to communicate adequately

For controls: 
1. Use of centrally acting drugs (including analgesics)
2. Psychiatric disease or symptoms
3. Disorders of the central nervous system
4. Insufficient mastery of the Dutch language</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2007-09-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2008-06-01T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Glioblastoma multiforme, high grade Glioma</description>
	<diseaseClass1>Cancer</diseaseClass1>
	<diseaseClass2>Glioma</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Using prospective cognitive data and MEG recordings of ten newly diagnosed glioblastoma multiforme patients and ten glioblastoma multiforme patients with tumour recurrence we will investigate:
1. The impact of tumour- and treatment-related factors on functional connectivity and neural network features, and
2. The correlation between changes in these measures and cognitive function

If such treatment- and/or tumour-related cerebral plasticity and its correlation with cognition can be established in this pilot, future prospective studies will focus in more detail on:
1. The effects of different treatment modalities (e.g. less or more extensive surgery, radiotherapy), and 
2. The contribution of tumour-related symptoms (e.g. epilepsy) and their treatment (e.g. anti-epileptic drugs) on neural network function and cognition

This knowledge will eventually assist in the guidance of clinical decision-making in these patients.</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
        
      </outputs>
    <parties>
      <funderId>Funder16852-0</funderId>
      <contactId>Contact54810_16852</contactId>
      <sponsorId>Sponsor53367</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact54810_16852">
    <title>Dr</title>
    <forename>M.</forename>
    <surname>Klein</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Department of Medical Psychology, D343
Vrije University Medical Centre</address>
      <city>Amsterdam</city>
      <country>Netherlands</country>
      <zip>1081 BT</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+31 (0)20 444 8432</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">m.klein@vumc.nl</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor53367">
    <organisation>Vrije University Medical Centre (VUMC) (The Netherlands)</organisation>
    <website>http://www.vumc.nl/english/</website>
    <sponsorType>Hospital/treatment centre</sponsorType>
    <contactDetails>
      <address>Department of Medical Psychology</address>
      <city>Amsterdam</city>
      <country>Netherlands</country>
      <zip>1081 BT</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.16872.3a</gridId>
    <rorId>https://ror.org/00q6h8f30</rorId>
  </sponsor>
  <funder id="Funder16852-0">
    <name>Vrije University Medical Centre (VUMC) (The Netherlands)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-10-02T00:00:00.000Z" version="24">
    <isrctn dateAssigned="2007-07-30T00:00:00.000Z">35782567</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Applications of body surface mapping in cardiac resynchronisation therapy and ventricular tachycardia</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>1. Electrocardiographic Imaging (ECGI) using potentials derived from the body surface can be used to identify electrical dyssynchrony within the Left Ventricle (LV), along with activation patterns and regions of slow conduction. It could therefore be used to predict response to cardiac resynchronisation therapy, and ultimately to guide placement of the LV pacing lead to the optimal site.
2. ECGI using body surface potentials acquired noninvasively is of comparable accuracy to endocardial data acquired invasively in determining sites of pacing of the LV endocardium and patterns of activation.
3. ECGI is comparable to endocardial data acquired invasively in locating the origin of Ventricular Tachycardia (VT) substrates and may provide useful information over and above endocardial data to aid radiofrequency ablation of this tachyarrhythmia.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>CRT study: 
Response to CRT (assessed clinically using echo, 6 minute walk distance, cardiopulmonary stress testing, and functionally using quality of life questionnaire and NYHA symptom class). This can be assessed in conjunction with pacing site localisation using ECGI in relation to regions of slow conduction/scar tissue. 

ECGI validation and VT studies: These are qualitative studies whereby ECGI data and data acquired invasively are compared directly. Therefore there is no discrete end-point.</primaryOutcome>
      <secondaryOutcome>No secondary outcome measures</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>The Office for Research Ethics Committees in Northern Ireland (ORECNI), approved on 16/09/2005 (ref: 05/NIR01/139)</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN35782567</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>RGHT000233</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Non randomised controlled trial.</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Non randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Diagnostic</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2005-10-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2007-07-31T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Northern Ireland</country>
	<country>United Kingdom</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="55431f13-2a0b-419e-a74b-acee2a2b0231">
	  <name>Regional Medical Cardiology Centre</name>
	  <address/>
	  <city>Belfast</city>
	  <state/>
	  <country>United Kingdom</country>
	  <zip>BT12 6BA</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>Cardiac Resynchronization Therapy (CRT) study: 
1. Poor LV function with ejection fraction on echocardiogram (ECHO) &lt;35%
2. Symptomatic with New York Heart Association (NYHA) class 2-4
3. Dilated LV (&gt;55 mm)
4. Any QRS duration (representing the duration of ventricular depolarisation)
LV dysfunction can be of any aetiology. All patients must be able and willing to give writted informed consent. 

ECGI validation study: 
Patients must require EPS/ablation of tachyarrhythmias requiring LV access e.g. VT ablation/EPS, Brugada EPS, left sided pathways. All must be willing and able to give written informed consent. 

VT study: 
All patients must require EPS for induction of LV tachyarrhythmias or ablation of VT. Again all must give written informed consent.</inclusion>
      <ageRange>Adult</ageRange>
      <gender>Not Specified</gender>
      <targetEnrolment>70</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>70 (CRT study, 50; ECGI validation study, 10; VT study, 10)</totalTarget>
      <exclusion>CRT study:
1. Ejection fraction on ECHO &gt;35%
2. Unable or unwilling to come back for 6 month follow-up
3. Unable or unwilling to give written informed consent

ECGI validation and VT studies:
1. Procedures not requiring access to the LV
2. Bleeding conditions
3. Clotting disorders
4. Unwilling to give written informed consent
5. Age &lt;18 years</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2005-10-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2007-07-31T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Left ventricular dysfunction</description>
	<diseaseClass1>Circulatory System</diseaseClass1>
	<diseaseClass2>Left ventricular dysfunction</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>1. CRT study 
This is a pilot study during which 50 consecutive patients undergoing CRT implantation will be identified and worked up appropriately (there is no control group in this study and all participants will be given the same intervenions). All participants will undergo baseline assessment to include echocardiography, 6 minute walk testing, cardiopulmonary stress testing, quality of life assessment (questionnaire) and N-terminal Pro-BNP measurement. Body Surface Mapping (BSM) will be performed at baseline and the day following device implantation during different pacing modalities. They will then be followed up with a single visit at 6 months, at which time all of these tests will be repeated. 

2. ECGI validation study: 
A qualitative study comparing ECGI with data acquired invasively using noncontact endocardial mapping as gold standard. 10 patients undergoing invasive ElectroPhysiological Studies (EPS) requiring access to the left ventricle will be recruited. All patients will have an ECHO at baseline and undergo simultaneous body surface mapping and invasive endocardial mapping during muti-site pacing of the LV endocardium. BSM utilises a plastic 80-electrode mapping harness applied to the anterior and posterior torso. Noncontact endocardial mapping uses the previously validated EnSite 3000 system. This study will enable a qualitative comparison of both imaging modalities for localisation of pacing sites as well as activation sequences. There will be no follow-up for the patients in this sub-study.

3. VT study: 
10 patients requiring VT ablation or simply EPS for induction of ventricular arrhythmias will be studied using both invasive and noninvasive modalities. This is a purely qualitative study.</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2007 Results article in https://pubmed.ncbi.nlm.nih.gov/17993307 results</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="1134c235-a071-4c2c-b0be-73b3f73c68e6" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2007-11-01T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="https://pubmed.ncbi.nlm.nih.gov/17993307"/>
	<description>results</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder16486-0</funderId>
      <contactId>Contact54444_16486</contactId>
      <sponsorId>Sponsor52999</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact54444_16486">
    <title>Prof</title>
    <forename>Jennifer</forename>
    <surname>Adgey</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Regional Medical Cardiology Centre
1st Floor West Wing
Royal Victoria Hospital</address>
      <city>Belfast</city>
      <country>United Kingdom</country>
      <zip>BT12 6BA</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
  </contact>
  <sponsor id="Sponsor52999">
    <organisation>Royal Victoria Hospital (UK)</organisation>
    <website/>
    <sponsorType>Hospital/treatment centre</sponsorType>
    <contactDetails>
      <address>c/o Professor Ian Young
Royal Research Office
Royal Victoria Hospital
Grosvenor Road</address>
      <city>Belfast</city>
      <state xmlns:isrctn="http://www.67bricks.com/isrctn">Northern Ireland</state>
      <country>United Kingdom</country>
      <zip>BT12 6BA</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.416232.0</gridId>
    <rorId>https://ror.org/03rq50d77</rorId>
  </sponsor>
  <funder id="Funder16486-0">
    <name>Frances and Augustus Newman Foundation (UK)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-11-09T00:00:00.000Z" version="19">
    <isrctn dateAssigned="2007-07-12T00:00:00.000Z">96658320</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Inhaled fluticasone in acute severe asthma</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>High dose inhaled fluticasone is superior to standard treatment with intravenous hydrocortisone in patients with acute severe asthma.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>FEV1 and PEF at 90 minutes and 180 minutes from the time of administering the drug.</primaryOutcome>
      <secondaryOutcome>1. Symptom assessment, at 90 minutes and180 minutes from the time of administering the drug
2. Adverse effect of fluticasone at 90 minutes and180 minutes from the time of administering the drug</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>The study was approved by Christian Medical College Ethics committee on the 18th October 2005 (ref: IRB(EC)23/10/05).</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN96658320</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>RES/10/2005</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised, double blind, double dummy, single centre, parallel group design.</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2006-11-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2008-05-30T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>India</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="c11cad31-f27a-4f7b-9887-bf4d7cc61328">
	  <name>Department of Pharmacology</name>
	  <address/>
	  <city>Vellore</city>
	  <state/>
	  <country>India</country>
	  <zip>632002</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Age between 18 to 55
2. Asthma patients with Peak Expiratory Flow (PEF) and Forced Expiratory Volume in one second (FEV1) less than 50% of the predicted
3. Asthmatic for six months or more</inclusion>
      <ageRange>Not Specified</ageRange>
      <gender>Not Specified</gender>
      <targetEnrolment>110</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>110</totalTarget>
      <exclusion>1. Underlying chronic lung disease
2. Fever more than 100.4°F
3. Smoker greater than five pack years
4. Patients with no legal representative or legal representative not willing to give consent
5. Life threatening asthma</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2006-11-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2008-05-30T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Acute severe asthma, acute exacerbation of asthma</description>
	<diseaseClass1>Respiratory</diseaseClass1>
	<diseaseClass2>Asthma</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Baseline Measurements: 
Subjects, those who are randomised will be asked to perform baseline Peak Expiratory Flow (PEF) and Forced Expiratory Volume at one second (FEV1). Blood samples will be drawn for blood Theophylline level, pre-treatment serum potassium, Haemoglobin (Hb), Total Leucocyte Count (TLC), Differential Leucocyte Count (DLC) and Glucometer Random Blood Sugar (GRBS).  Bedside Electrocardiogram (ECG) will be done before initiation of the treatment.

Drug dose, route and time of administration:
One group will receive two doses of Fluticasone 2 mg via nebulizer half an hour apart and single dose of intravenous (IV) placebo. The other group will receive single dose of Hydrocortisone 200 mg IV and two doses of placebo via nebulizer half an hour apart. In addition, all patients will receive salbutamol 2.5 mg and ipratropium bromide 0.5 mg via nebulizer alternating every 15 minutes for three hours.

Monitoring:
PEF and FEV1 to be measured at 0, 30, 60, 90, 120, 150 and 180 minutes from the time of administering the drug, for close monitoring of the patient although the primary outcome measurement is at 90th and 180th minute.  If there is no improvement at 90th minute, the subject will be withdrawn from the trial and standard care will be given. If there is sign of worsening of the subject's condition from the baseline, at any point of time after the start of the trial, the subject will be immediately admitted into intensive care unit. 

During the period of drug administration the patient will be continuously monitored for adverse effect. At the end of three hours serum potassium level and GRBS level will be assessed. At the end of three hours, those who fulfilled the discharge criteria will be discharged and the rest will be admitted in the ward for further management. 

Follow up: 
At the time of discharge, all subjects will be advised to take Tab. Prednisolone 30 mg Once Daily (OD) and Tab. Ranitidine 150 mg twice daily for seven days along with Metered Dose Inhaler (MDI) Salbutamol 100 mcg two puffs when necessary (PRN) and MDI Fluticasone 250 mcg two puffs twice daily (BD) for one month. All of them will be advised follow up in Pulmonary Medicine Out-Patients Department (OPD) or Pulmonary Function laboratory at one month from the date of admission, to repeat PEF and FEV1.   

If there is any aggravation of symptoms prior to the day of follow up, all patients are advised to report to the Emergency Department immediately.</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>Fluticasone</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
        
      </outputs>
    <parties>
      <funderId>Funder16678-0</funderId>
      <contactId>Contact54636_16678</contactId>
      <sponsorId>Sponsor53191</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact54636_16678">
    <title>Dr</title>
    <forename>K.R.</forename>
    <surname>Dhanasekar</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Department of Pharmacology 
Christian Medical College
Thorapadi Post
Bagayam, Tamil Nadu</address>
      <city>Vellore</city>
      <country>India</country>
      <zip>632002</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
  </contact>
  <sponsor id="Sponsor53191">
    <organisation>Christian Medical College (India)</organisation>
    <website>http://www.cmch-vellore.edu/</website>
    <sponsorType>Government</sponsorType>
    <contactDetails>
      <address>Bagayam
Thorapadi Post
Tamil Nadu</address>
      <city>Vellore</city>
      <country>India</country>
      <zip>632002</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.11586.3b</gridId>
    <rorId>https://ror.org/00c7kvd80</rorId>
  </sponsor>
  <funder id="Funder16678-0">
    <name>Christian Medical College (India) - FLUID research grant (ref: R.C. Min No: 5735, RES/10/2005).</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-10-25T00:00:00.000Z" version="24">
    <isrctn dateAssigned="2007-03-01T00:00:00.000Z">72748991</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>A televised, web-based randomised trial of an herbal remedy (valerian) for insomnia</title>
      <scientificTitle/>
      <acronym>SøvnStudien</acronym>
      <studyHypothesis>The primary objective is to evaluate whether valerian root (valerian) improves the self-assessed quality of sleep compared with placebo for people with primary insomnia</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Proportion of participants in each group with an improvement in self-assessed quality of sleep of &gt; or = 0.5 units between the average score for the 2 weeks before and 2 weeks during treatment</primaryOutcome>
      <secondaryOutcome>1. Proportion of participants in each group with an improvement of &gt; or = 0.5 units between the average score for the 2 weeks before and 2 weeks during treatment for each of the four variables: 
1.1 Sleep latency
1.2 Number of awakenings
1.3 Total sleep time
1.4 Energy level during the day

2. Mean changes in the five outcomes listed above

3. Global self-assessment

If a difference is not found between the treatment groups for the primary and secondary variables, the following explorative variables will be analysed:
1. Proportion of participants in each group with any improvement in mean difference (i.e. all score changes &gt; 0) between the average score for the 2 weeks before and 2 weeks during treatment for each of the five variables: 
1.1 Quality of sleep
1.2 Sleep latency
1.3 Number of awakenings
1.4 Total sleep time
1.5 Energy level during the day

2. Difference in the profile of the five endpoints during the intervention period taking into account the baseline period, including a potential time effect</secondaryOutcome>
      <trialWebsite>http://sovnstudien.forskningspuls.no/</trialWebsite>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Regional Committee for Medical Research Ethics for Southern Norway (Regional komité for medisinsk forskningsetikk, Sør- Norge) 5 January 2006, Ref: S-05280</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN72748991</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>2005001TVT</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised, double-blind, parallel group, placebo controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2007-01-29T00:00:00.000Z</overallStartDate>
      <overallEndDate>2007-03-30T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Norway</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="4cd12084-91df-42fd-a3c6-13a0e1b4e932">
	  <name>Norwegian Knowledge Centre for the Health Services</name>
	  <address/>
	  <city>Oslo</city>
	  <state/>
	  <country>Norway</country>
	  <zip>N-0130</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Aged 18 &#150;75 years, both inclusive
2. Insomnia lasting more than one month
3. Pittsburgh Sleep Quality Index (PSQI) score of &gt; 5
4. Provide name of primary physician
5. Access to internet and own email address
6. At least 10 days of the sleep diary completed prior to randomisation</inclusion>
      <ageRange>Adult</ageRange>
      <lowerAgeLimit unit="Years" value="18.0"/>
      <gender>Not Specified</gender>
      <targetEnrolment>550</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>500 to 550</totalTarget>
      <exclusion>1. Secondary insomnia
2. Use of hypnotics by prescription
3. Depression
4. Alcohol or drug abuse 
5. Psychotherapy within the past six months
6. Sleep apnoea, periodic limb movements disorder or restless legs syndrome
7. Pregnant or lactating women or women of childbearing potential who do not use an approved method of contraception (oral contraceptives orIntrauterine device [IUD])
8. Shift workers
9. History of hypersensitivity to valerian or its constituents
10. Participant rating of &#145;usually&#146; or &#145;always&#146; to the following questions in the Global Sleep Assessment Questionnaire:
During the past four weeks, how often:
a. Did you hold your breath, have breathing pauses, or stop breathing in your sleep?
b. Did you have restless or "crawling" feelings in your legs at night that went away if you moved your legs?
c. Did you have repeated rhythmic leg jerks or leg twitches during your sleep?
d. Did you have nightmares, or did you scream, walk, punch, or kick in your sleep?
e. Did any of the following disturb you in your sleep: 
f. Pain? 
g. Other physical symptoms?
h. Medications? 
i. Did you snore loudly?
11. Current participation in another trial using an investigational compound</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2007-01-29T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2007-03-30T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Primary insomnia</description>
	<diseaseClass1>Signs and Symptoms</diseaseClass1>
	<diseaseClass2>Insomnia</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Coated Valerian Forte tablets 200 mg extract per tablet, corresponding to 1200 mg Valeriana officinalis. 3 tablets to be taken every night for 14 days

Information about the study will be televised nationally on a weekly health program. Viewers interested in participation will be invited to visit the web pages of the study to enrol. Participant registration and data collection will be by use of Internet.</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2007 Results article in http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17940604 Results</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="8cc482e2-f5b6-4155-9ed5-54daca75364f" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2007-10-17T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17940604"/>
	<description>Results</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder16073-0</funderId>
      <contactId>Contact54019_16073</contactId>
      <sponsorId>Sponsor52571</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact54019_16073">
    <title>Dr</title>
    <forename>Andrew David</forename>
    <surname>Oxman</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Norwegian Knowledge Centre for the Health Services 
P.O. Box 7004
St. Olavs plass</address>
      <city>Oslo</city>
      <country>Norway</country>
      <zip>N-0130</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">oxman@online.no</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor52571">
    <organisation>Norwegian Knowledge Centre for the Health Services (Norway)</organisation>
    <website>http://www.kunnskapssenteret.no</website>
    <sponsorType>Government</sponsorType>
    <contactDetails>
      <address>P.O. Box 7004
St. Olavs plass</address>
      <city>Oslo</city>
      <country>Norway</country>
      <zip>N-0130</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">post@kunnskapssenteret.no</email>
    </contactDetails>
    <privacy>Public</privacy>
    <gridId>grid.425407.0</gridId>
    <rorId>https://ror.org/01thff661</rorId>
  </sponsor>
  <funder id="Funder16073-0">
    <name>Norwegian Knowledge Centre for the Health Services (Norway)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-10-03T00:00:00.000Z" version="21">
    <isrctn dateAssigned="2007-02-28T00:00:00.000Z">14949974</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Methods for evaluating the extent to which different ways of presenting evidence of the effects of health care help people make decisions that are consistent with their own values: a randomised trial</title>
      <scientificTitle/>
      <acronym>HIPPO pilot</acronym>
      <studyHypothesis>Pilot study - development of methodology to: 
1. Analyse which of several presentations of evidence of treatment effects best help people to make treatment decisions congruent with their own values
2. Compare visual analogue scales and category rating scales as value elicitation instruments</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>1. Acceptance or rejection of statin treatment
2. Estimated probability to accept or reject statin treatment in relation to value score</primaryOutcome>
      <secondaryOutcome>1. To investigate the feasibility of conducting Internet-based randomised trials comparing different risk reduction presentations
2. To compare two methods of eliciting values
3. Four ways of weighting the elicited values to calculate a total value
4. To generate hypotheses and calculate sample size for a confirmatory study comparing six summary statistics for communicating evidence of reduced risk of Coronary Heart Disease (CHD) with statin therapy for treatment of high cholesterol</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>This study was approved by the ethics review board at the University at Buffalo on the 15 May 2002 with several renewals.</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN14949974</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>HIPPO 1</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2002-10-31T00:00:00.000Z</overallStartDate>
      <overallEndDate>2002-12-04T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Norway</country>
	<country>United States of America</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="0891a4c2-6486-4c45-a201-171abb237fc7">
	  <name>Norwegian Knowledge Centre for the Health Services</name>
	  <address/>
	  <city>Oslo</city>
	  <state/>
	  <country>Norway</country>
	  <zip>0130</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. 18 years old
2. Fluent in English or Norwegian
3. Must give informed consent</inclusion>
      <ageRange>Adult</ageRange>
      <lowerAgeLimit unit="Years" value="18.0"/>
      <gender>Both</gender>
      <targetEnrolment>770</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>770</totalTarget>
      <exclusion>Not meeting inclusion requirements</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2002-10-31T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2002-12-04T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>N/A</description>
	<diseaseClass1 xmlns:isrctn="http://www.67bricks.com/isrctn">Other</diseaseClass1>
	<diseaseClass2>N/A</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Six different summary statistics presenting ten year risk reduction effect of statins on coronary heart disease in the treatment of hypercholesteremia.

The methodological aspects reported in this study include comparison of two value elicitation instruments (visual analogue scales and category rating scales), four theory-grounded approaches to weighting elicited values, and six summary statistics to evaluate the extent to which they promote decisions consistent with elicited values. In addition, we report hypothesis generation and sample size calculation for a randomised controlled trial comparing the same six summary statistics for communicating evidence of reduced risk of coronary heart disease, as well as on the feasibility of conducting this type of Internet-based randomised trial.</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
        
      </outputs>
    <parties>
      <funderId>Funder16017-0</funderId>
      <contactId>Contact53963_16017</contactId>
      <sponsorId>Sponsor52512</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact53963_16017">
    <title>Dr</title>
    <forename>Andrew</forename>
    <surname>Oxman</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Norwegian Knowledge Centre for the Health Services
P.O. Box 7004 
St Olavs Plass</address>
      <city>Oslo</city>
      <country>Norway</country>
      <zip>0130 </zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
  </contact>
  <sponsor id="Sponsor52512">
    <organisation>Norwegian Research Council (Norway)</organisation>
    <website>http://www.forskningsradet.no</website>
    <sponsorType>Government</sponsorType>
    <contactDetails>
      <address>P.O. Box 2700 
St. Hanshaugen</address>
      <city>Oslo</city>
      <country>Norway</country>
      <zip>0131</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.13985.36</gridId>
    <rorId>https://ror.org/00epmv149</rorId>
  </sponsor>
  <funder id="Funder16017-0">
    <name>Norwegian Research Council (Norway) (project 135210 - A series of randomised trials comparing different ways of presenting health evidence on the Internet)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-10-17T00:00:00.000Z" version="24">
    <isrctn dateAssigned="2007-02-26T00:00:00.000Z">08189331</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Metabolic control with Glucose-Insulin-Potassium infusion in acute myocardial infarction</title>
      <scientificTitle/>
      <acronym>GIPS II</acronym>
      <studyHypothesis>Treatment with Glucose-Insulin-Potassium (GIK) infusion during the acute phase of myocardial infarction has been proposed as therapeutic intervention for protection of the ischaemic myocardium.

Current evidence suggests an effect in patients with acute myocardial infarction without signs of heart failure at admission treated with reperfusion therapy (i.e. primary coronary angioplasty). There is also evidence for the treatment with insulin-glucose infusion in combination with strict metabolic control for at least three months thereafter for patients with type two diabetes mellitus (i.e. a history of diabetes mellitus, previously treated with oral hypoglycaemic agents or blood glucose level at admission greater than or equal to 11.1 mmol/l) and acute myocardial infarction.

Recently, it has been shown that obtaining and maintaining normoglycaemia (i.e. plasma-glucose concentrations of 4.4 and 6.1 mmol/l) in patients admitted to a Surgical Intensive Care Unit will lead to a marked reduction in morbidity and mortality.

This study will address what the effects will be of metabolic intervention with or without the infusion of GIK on 30-day and one-year mortality in patients eligible for reperfusion therapy (i.e. primary coronary angioplasty or thrombolysis).</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>30-day mortality (death from any cause and cardiovascular death).</primaryOutcome>
      <secondaryOutcome>1. One-year mortality
2. Analysis of pre-specified subgroups</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Approval received from the local ethics committee (Medisch Ethische Toetsings Commissie) on the 2nd May 2003 (ref: 02.1280).</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN08189331</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised, active controlled, parallel group, multicentre trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2003-05-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2006-03-01T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Netherlands</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="347a2e6e-a288-4fc2-bdb1-44adeeb4b079">
	  <name>Diagram B.V. Zwolle</name>
	  <address/>
	  <city>Zwolle</city>
	  <state/>
	  <country>Netherlands</country>
	  <zip>8011 NB</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Acute myocardial infarction diagnosed by:
1.1. Chest pain suggestive for acute myocardial infarction
1.2. Symptom-onset less than six hours after hospital admission
1.3. Electrocardiogram (ECG) with ST-T segment elevation more than 1 mV in two or more leads
2. Patients are eligible for either primary coronary angioplasty or thrombolysis
3. Patient who has given his or her informed consent to take part in the study</inclusion>
      <ageRange>Not Specified</ageRange>
      <gender>Both</gender>
      <targetEnrolment>900</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>900</totalTarget>
      <exclusion>1. Unwillingness to participate
2. Presence of heart failure (either one of these symptoms):
2.1. Heart rate more than 90 beats/minute
2.2. Systolic blood pressure less than 100 mmHg with anterior myocardial infarction
2.3. Killip class greater than or equal to II (third heart sound, greater than or equal to hand-wide rales)</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2003-05-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2006-03-01T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Acute myocardial infarction</description>
	<diseaseClass1>Circulatory System</diseaseClass1>
	<diseaseClass2>Myocardial infarction</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>An infusion of 80 mmol potassium chloride in 500 ml 20% glucose with a rate of 2 ml/kilogram body weight/hour over an 12 hour period in a peripheral venous line. The infusion is started as soon as possible after admission to the hospital after determination of blood-glucose level in combination with reperfusion therapy. A continuous infusion of short-acting insulin (50 units Actrapid HM [Novo Nordisk, Copenhagen, Denmark] in 49.5 ml of 0.9 percent sodium chloride) with the use of a perfusor-pump will also be started.
Blood-glucose levels will be measured hourly. Baseline insulin infusion dose and adjustments of insulin dose will be based on a nomogram to obtain and maintain blood-glucose levels of 6.0 to 10.0 mmol/l.

The insulin infusion will be stopped one hour prior to the discontinuation of the glucose-potassium infusion. After the Glucose-Potassium (GK) infusion is stopped insulin may be continued based on glucose measurements according to conventional care or until the infusion rate is less than 1 IU/hour.</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>Glucose-Insulin-Potassium (GIK) infusion</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2006 Results article in https://pubmed.ncbi.nlm.nih.gov/16631017 Results</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="5bb19281-2972-4a52-9a1b-eab75f430b02" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2006-04-18T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="https://pubmed.ncbi.nlm.nih.gov/16631017"/>
	<description>Results</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder16229-0</funderId>
      <funderId>Funder16229-1</funderId>
      <contactId>Contact54184_16229</contactId>
      <sponsorId>Sponsor52738</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact54184_16229">
    <title>Dr</title>
    <forename>J</forename>
    <surname>Klijn</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Diagram B.V. Zwolle 
Van Nahuysplein 6 </address>
      <city>Zwolle</city>
      <country>Netherlands</country>
      <zip>8011 NB </zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+31 (0)38 426 2997</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">j.klijn@diagram-zwolle.nl</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor52738">
    <organisation>Isala Klinieken (The Netherlands)</organisation>
    <website>http://www.isala.nl/Pages/default.aspx</website>
    <sponsorType>Hospital/treatment centre</sponsorType>
    <contactDetails>
      <address>Locatie Weezenlanden
Department of Cardiology
Groot Wezenland 20</address>
      <city>Zwolle</city>
      <country>Netherlands</country>
      <zip>8011 JW</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.452600.5</gridId>
    <rorId>https://ror.org/046a2wj10</rorId>
  </sponsor>
  <funder id="Funder16229-0">
    <name>Netherlands Heart Foundation (The Netherlands)</name>
    <fundRef/>
  </funder>
  <funder id="Funder16229-1">
    <name>Guidant (The Netherlands)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-10-08T00:00:00.000Z" version="24">
    <isrctn dateAssigned="2007-01-05T00:00:00.000Z">27796329</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>A randomised controlled trial to evaluate the effectiveness of community Paramedic Practitioners managing Older People calling 999 with minor conditions</title>
      <scientificTitle/>
      <acronym>PPOPS</acronym>
      <studyHypothesis>Aims:
1. Comparing differences in patient experience and satisfaction of community paramedic practitioners with the existing standard service.
2. Comparing the clinical and cost effectiveness of community paramedic practitioners with the existing standard service.
3. Assessing the effects of community paramedic practitioners on ambulance service and Emergency Department (ED) performance.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>1. Emergency Department attendance or hospital admission between zero and 28 days
2. Interval from time of call to time of discharge
3. Patient satisfaction with the service received</primaryOutcome>
      <secondaryOutcome>1. Investigations and treatments prescribed
2. Subsequent use of health services within 28 days
3. Health status and mortality at 28 days
4. Costs</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>The study was approved by North Sheffield LREC on the 31st March 2003, (ref: NS2002 9 1452).</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN27796329</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>577/1962</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Cluster randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Other</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Other</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2003-09-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2004-09-26T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>England</country>
	<country>United Kingdom</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="1611d966-66ad-4b25-b275-e9f995803909">
	  <name>Health Services Research</name>
	  <address/>
	  <city>Sheffield</city>
	  <state/>
	  <country>United Kingdom</country>
	  <zip>S1 4DA</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>Patients aged 60 years and above were eligible for study inclusion following a call to the ambulance service if the call:
1. Originated from a Sheffield postcode
2. Was received between 08:00 am and 20:00 pm
3. Presenting with a complaint that fell within the scope of practice of the paramedic practitioners</inclusion>
      <ageRange>Senior</ageRange>
      <gender>Not Specified</gender>
      <targetEnrolment>2200</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>2200</totalTarget>
      <exclusion>No exclusion criteria</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2003-09-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2004-09-26T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Minor injuries such as falls, lacerations, epistaxis, minor burns, foreign body - ENT (Ears, Nose and Throat) only</description>
	<diseaseClass1>Injury, Occupational Diseases, Poisoning</diseaseClass1>
	<diseaseClass2>Minor injuries</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Intervention:
A community based paramedic scheme intended to deliver patient centred care to older people calling the emergency services with conditions triaged as not immediately life threatening.

Control group:
Care as usual. In practice, this was an ambulance, followed by conveyance to an ED (unless the patient refused to travel to hospital).</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2007 Results article in https://pubmed.ncbi.nlm.nih.gov/17916813 Results</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="ae64ec4f-12a5-4aac-82b3-5370f6a31010" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2007-11-03T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="https://pubmed.ncbi.nlm.nih.gov/17916813"/>
	<description>Results</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder15822-0</funderId>
      <contactId>Contact53762_15822</contactId>
      <sponsorId>Sponsor52315</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact53762_15822">
    <title>Dr</title>
    <forename>Suzanne</forename>
    <surname>Mason</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Health Services Research 
School of Health and Related Research
University of Sheffield
Regent Street</address>
      <city>Sheffield</city>
      <country>United Kingdom</country>
      <zip>S1 4DA</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
  </contact>
  <sponsor id="Sponsor52315">
    <organisation>The Health Foundation (UK)</organisation>
    <website>http://www.health.org.uk/</website>
    <sponsorType>Charity</sponsorType>
    <contactDetails>
      <address>90 Long Acre</address>
      <city>London</city>
      <country>United Kingdom</country>
      <zip>WC2E 9RA</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.453604.0</gridId>
    <rorId>https://ror.org/02bzj4420</rorId>
  </sponsor>
  <funder id="Funder15822-0">
    <name>The Health Foundation (UK) (ref: 577/1962)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-10-22T00:00:00.000Z" version="24">
    <isrctn dateAssigned="2006-09-28T00:00:00.000Z">37259753</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>The GRONORUN study: is a gradual training program for novice runners effective in preventing running related injuries? A randomised controlled trial</title>
      <scientificTitle/>
      <acronym>GRONORUN</acronym>
      <studyHypothesis>A more gradual training program for novice runners will result in a reduction of running related injuries in novice runners.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>The incidence of running related injuries.</primaryOutcome>
      <secondaryOutcome>1. The severity of running related injuries
2. The compliance with the training programme and drop out</secondaryOutcome>
      <trialWebsite>http://www.gronorun.nl</trialWebsite>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Ethics approval received from the local medical ethics committee</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN37259753</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Prevention</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2005-07-11T00:00:00.000Z</overallStartDate>
      <overallEndDate>2006-07-10T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Netherlands</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="c346205c-2b20-4402-a42c-363c6517be25">
	  <name>P.O. Box 30001</name>
	  <address/>
	  <city>Groningen</city>
	  <state/>
	  <country>Netherlands</country>
	  <zip>9700 RB</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>Novice runners (maximum of 30 minutes a month) between 18 and 65 years of age.</inclusion>
      <ageRange>Adult</ageRange>
      <lowerAgeLimit unit="Years" value="18.0"/>
      <gender>Both</gender>
      <targetEnrolment>532</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>532</totalTarget>
      <exclusion>No injury of lower limb in the past three months before the start of the study.</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2005-07-11T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2006-07-10T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Running related injuries</description>
	<diseaseClass1>Injury, Occupational Diseases, Poisoning</diseaseClass1>
	<diseaseClass2>Running related injuries</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>A gradual training programme lasting 13 weeks is performed by the intervention group according to prepare for a four mile run. The increase of running load is 10% per week (time). 

The control group will train for the four mile run using a classic training program lasting eight weeks.</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2007 Protocol article in http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17331264 Study protocol
2008 Results article in https://pubmed.ncbi.nlm.nih.gov/17940147 Results</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>true</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="d1987121-8850-448a-8b07-9eae378d5e6c" outputType="protocolarticle" artefactType="ExternalLink" dateCreated="2007-03-02T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17331264"/>
	<description>Study protocol</description>
	<productionNotes/>
      </output>
      <output id="230c004d-7728-47c5-8795-b9b35bee3400" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2008-01-01T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="https://pubmed.ncbi.nlm.nih.gov/17940147"/>
	<description>Results</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder15422-0</funderId>
      <contactId>Contact53355_15422</contactId>
      <sponsorId>Sponsor51902</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact53355_15422">
    <title>Dr</title>
    <forename>S W</forename>
    <surname>Bredeweg</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>P.O. Box 30001</address>
      <city>Groningen</city>
      <country>Netherlands</country>
      <zip>9700 RB</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+31 (0)50 3611023</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">s.bredeweg@sport.umcg.nl</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor51902">
    <organisation>University Medical Center Groningen (UMCG), University Center for Sport, Exercise and Health (The Netherlands)</organisation>
    <website/>
    <sponsorType>Hospital/treatment centre</sponsorType>
    <contactDetails>
      <address>P.O. Box 30001</address>
      <city>Groningen</city>
      <country>Netherlands</country>
      <zip>9700 RB</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+31 (0)50 3613366</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">g.j.pepping@sport.umcg.nl</email>
    </contactDetails>
    <privacy>Public</privacy>
    <gridId>grid.4494.d</gridId>
    <rorId>https://ror.org/03cv38k47</rorId>
  </sponsor>
  <funder id="Funder15422-0">
    <name>The Netherlands Organisation for Health Research and Development (Zon-MW) (The Netherlands)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-10-19T00:00:00.000Z" version="23">
    <isrctn dateAssigned="2006-02-08T00:00:00.000Z">63217062</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>The effectiveness of intrauterine insemination (IUI) in subfertile couples with an isolated cervical factor: a randomised controlled trial</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>1. We hypothesised a beneficial effect of IUI in couples with an isolated cervical factor
2. Furthermore we hypothesised that the post-coital test can identify those couples who would benefit from IUI without ovarian hyperstimulation</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>The primary endpoint was ongoing pregnancy within six months. Ongoing pregnancy was defined as the presence of foetal cardiac activity at transvaginal sonography at a gestational age of at least 12 weeks.</primaryOutcome>
      <secondaryOutcome>Secondary endpoints were total number of clinical pregnancies, miscarriages and multiple pregnancies.</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Ethics approval received from the local medical ethics committee</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN63217062</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>2</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Multicentre, randomised, active controlled, parallel group trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2002-06-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2005-07-01T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Netherlands</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="84bdb550-270a-48fb-af67-705fc644fdfa">
	  <name>Academic Medical Center</name>
	  <address/>
	  <city>Amsterdam</city>
	  <state/>
	  <country>Netherlands</country>
	  <zip>1100 DD</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>Couples with a cervical factor and otherwise no factors that reduced their fertility i.e. a prognosis for a treatment independent ongoing pregnancy in the next year higher than 30%. A cervical factor was diagnosed by a well-timed, non-progressive post-coital test (PCT) with normal semen parameters.</inclusion>
      <ageRange>Adult</ageRange>
      <gender>Female</gender>
      <targetEnrolment>100</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>100</totalTarget>
      <exclusion>All other subfertile couples</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2002-06-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2005-07-01T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Subfertility</description>
	<diseaseClass1>Pregnancy and Childbirth</diseaseClass1>
	<diseaseClass2>Subfertility</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Couples were randomly allocated to IUI for six months or expectant management for six months. In the first three IUI cycles no controlled ovarian hyperstimulation (COH) was given. If these attempts failed subsequent IUI cycles were performed with COH.

Couples allocated to expectant management were followed until an ongoing pregnancy occurred within six months. If no pregnancy occurred, follow-up ended after this period. If a pregnancy miscarried, follow-up continued until the next pregnancy or the end of the six months period.</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2007 Results article in https://pubmed.ncbi.nlm.nih.gov/17482611 Results</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="eea86a69-b58e-4776-861e-8e3455edcc8b" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2007-12-01T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="https://pubmed.ncbi.nlm.nih.gov/17482611"/>
	<description>Results</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder14749-0</funderId>
      <contactId>Contact52518_14749</contactId>
      <sponsorId>Sponsor51038</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact52518_14749">
    <title>Mrs</title>
    <forename>P</forename>
    <surname>Steures</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Academic Medical Center
Center of Reproductive Medicine
OFO-project
H4-213
P.O. Box 22660</address>
      <city>Amsterdam</city>
      <country>Netherlands</country>
      <zip>1100 DD</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+31 (0)20 5663857</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">ofoproject@amc.uva.nl</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor51038">
    <organisation>Academic Medical Center Amsterdam (The Netherlands)</organisation>
    <website/>
    <sponsorType>University/education</sponsorType>
    <contactDetails>
      <address>Meibergdreef 9</address>
      <city>Amsterdam</city>
      <country>Netherlands</country>
      <zip>1105 AZ</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.5650.0</gridId>
  </sponsor>
  <funder id="Funder14749-0">
    <name>The Netherlands Organisation for Health Research and Development (ZonMw) (The Netherlands)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-10-02T00:00:00.000Z" version="21">
    <isrctn dateAssigned="2006-02-01T00:00:00.000Z">85737357</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Intermittent malaria treatment and iron supplementation for the control of malaria and anaemia in infants in the Forest Belt of rural Ghana: a double-blind randomised controlled trial</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>To establish whether preventive treatment or iron supplementation given at EPI prevented either severe anaemia or malaria.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>1. To assess the effectiveness of intermittent malaria treatment (1.25 mg pyrimethamine plus 25 mg sulfadoxine/kg) given at  10 weeks, 14 weeks and 9 months through the EPI programme in the control of malaria and severe anaemia in infancy
2. To determine the effect of intermittent malaria treatment in infancy on the risk of malaria and anaemia in childhood after completion of trial
3. To evaluate the effect of daily iron supplementation (2 mg/kg) given from 10 weeks to 12 months through the EPI programme on the control of malaria and severe anaemia
4. To assess the socio-cultural factors influencing acceptability of treatment modalities 
5. To evaluate the cost effectiveness of interventions</primaryOutcome>
      <secondaryOutcome>No secondary outcome measures</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Ethics approval received on the 17th June 1999.</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN85737357</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>980643</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>1999-06-17T00:00:00.000Z</overallStartDate>
      <overallEndDate>2001-06-17T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Ghana</country>
	<country>Switzerland</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="8263f984-cc13-47d9-8801-a317d17b67e1">
	  <name>20, Avenue Appia</name>
	  <address/>
	  <city>Geneva-27</city>
	  <state/>
	  <country>Switzerland</country>
	  <zip>CH 1211</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>All infants aged at least 10 weeks attending a Mother and Child Health (MCH) Clinic or Child Welfare Clinic (CWC) in the Afigya-Sekyere District, Ashanti Region and are permanent residents in the district. Their mothers or main carers should have given informed consent to participate in the trial.</inclusion>
      <ageRange>Not Specified</ageRange>
      <gender>Not Specified</gender>
      <targetEnrolment>1800</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>450 infants/arm - 1800 infants in total randomised</totalTarget>
      <exclusion>Infants who are not permanent residents of Afigya-Sekyere District, Ashanti Region.</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>1999-06-17T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2001-06-17T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Malaria</description>
	<diseaseClass1>Infections and Infestations</diseaseClass1>
	<diseaseClass2>Malaria</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Double blind placebo controlled trial. One of the following treatments given to children at the time of DPT2, DPT3 and measles vaccination:
1. Iron supplementation and placebo
2. Placebo and sulphadoxine pyrimethamine
3. Iron supplementation and sulphadoxine pyrimethamine</description>
	<interventionType>Supplement</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>Iron supplementation, sulphadoxine pyrimethamine</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
        
      </outputs>
    <parties>
      <funderId>Funder14724-0</funderId>
      <contactId>Contact52486_14724</contactId>
      <sponsorId>Sponsor51001</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact52486_14724">
    <title>Dr</title>
    <forename>Melba</forename>
    <surname>Gomes</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>20, Avenue Appia</address>
      <city>Geneva-27</city>
      <country>Switzerland</country>
      <zip>CH 1211</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+41 (0)22 791 3813</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">gomesm@who.int</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor51001">
    <organisation>UNICEF/UNDP/World Bank/WHO Special Programme for Research and Training in Tropical Diseases (TDR) </organisation>
    <website>http://www.who.int/</website>
    <sponsorType>Research organisation</sponsorType>
    <contactDetails>
      <address>20, Avenue Appia</address>
      <city>Geneva-27</city>
      <country>Switzerland</country>
      <zip>CH 1211</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.3575.4</gridId>
    <rorId>https://ror.org/01f80g185</rorId>
  </sponsor>
  <funder id="Funder14724-0">
    <name>United Nations Children's Fund (UNICEF)/United Nations Development Programme (UNDP)/World Bank/World Health Organization (WHO) - Special Programme for Research and Training in Tropical Diseases (TDR)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-11-09T00:00:00.000Z" version="24">
    <isrctn dateAssigned="2005-12-20T00:00:00.000Z">17616323</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Oral vitamin B12 supplementation and cognitive performance in elderly people</title>
      <scientificTitle/>
      <acronym>Brain12 study</acronym>
      <studyHypothesis>Counteract the process of cognitive impairment in elderly people with mild vitamin B12 deficiency through oral supplementation with vitamin B12 or a combination of vitamin B12 with folic acid</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Cognitive performance.</primaryOutcome>
      <secondaryOutcome>Blood biochemistry.</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Ethics approval received from the local medical ethics committee</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN17616323</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised, double blinded, placebo controlled, parallel group trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2003-05-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2004-10-31T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Netherlands</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="1a4defcb-ece4-4701-bd32-b3af17793199">
	  <name>Wageningen University,</name>
	  <address/>
	  <city>Wageningen</city>
	  <state/>
	  <country>Netherlands</country>
	  <zip>6700 EV</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Men and women aged 70 years or older
2. Mild vitamin B12 deficiency defined as vitamin B12 concentration between 100 and 300 picomol/L and MMA concentration greater than 0.32 micromol/L and creatinine concentration less than 120 micromol/L</inclusion>
      <ageRange>Senior</ageRange>
      <gender>Both</gender>
      <targetEnrolment>195</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>195</totalTarget>
      <exclusion>1. Severe cognitive impairment
2. Anemia
3. Gastrointestinal surgery
4. Use of vitamin B12 injections or supplements containing &gt; 50 micrograms vitamin B12 and/or 25 micrograms folic acid
5. Less than 90% compliance during a 2 week placebo run in period
6. No written informed consent
7. Participation in other studies</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2003-05-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2004-10-31T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Vitamin B12 deficiency</description>
	<diseaseClass1>Nutritional, Metabolic, Endocrine</diseaseClass1>
	<diseaseClass2>Vitamin B12 deficiency</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>1. 1,000 microgram vitamin B12/day
2. 1,000 microgram vitamin B12 and 400 microgram folic acid/day
3. Placebo</description>
	<interventionType>Supplement</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>Vitamin B12, folic acid</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2006 Results article in https://pubmed.ncbi.nlm.nih.gov/16895884 Results</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="51d2c940-f376-4a4f-9b39-cc183be83d1b" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2006-08-01T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="https://pubmed.ncbi.nlm.nih.gov/16895884"/>
	<description>Results</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder14512-0</funderId>
      <funderId>Funder14512-1</funderId>
      <funderId>Funder14512-2</funderId>
      <contactId>Contact52235_14512</contactId>
      <sponsorId>Sponsor50733</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact52235_14512">
    <title>Dr</title>
    <forename>Simone</forename>
    <surname>Eussen</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Wageningen University,
Division of Human Nutrition
P.O. Box 8129</address>
      <city>Wageningen</city>
      <country>Netherlands</country>
      <zip>6700 EV</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+31 (0)317 485395</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">simone.eussen@wur.nl</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor50733">
    <organisation>The Netherlands Organisation for Health Research and Development (ZonMw) (Netherlands)</organisation>
    <website>http://www.zonmw.nl</website>
    <sponsorType>Research organisation</sponsorType>
    <contactDetails>
      <address>P.O. Box 93245</address>
      <city>Den Haag</city>
      <state/>
      <country>Netherlands</country>
      <zip>2509 AE</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+31 (0)70 349 5111</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">info@zonmw.nl</email>
    </contactDetails>
    <privacy>Public</privacy>
    <gridId>grid.438427.e</gridId>
    <rorId>https://ror.org/01yaj9a77</rorId>
  </sponsor>
  <funder id="Funder14512-0">
    <name>Nutricia Research Foundation (The Netherlands)</name>
    <fundRef>http://dx.doi.org/10.13039/501100001720</fundRef>
  </funder>
  <funder id="Funder14512-1">
    <name>European Union BIOMED (Europe)</name>
    <fundRef/>
  </funder>
  <funder id="Funder14512-2">
    <name>Kelloggs' Benelux (Belgium)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-11-07T00:00:00.000Z" version="22">
    <isrctn dateAssigned="2005-12-20T00:00:00.000Z">77274716</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>The effects of a functional fitness training in children with cerebral palsy</title>
      <scientificTitle/>
      <acronym>FITPRO-CP</acronym>
      <studyHypothesis>Children with cerebral palsy will benefit from functional fitness training.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Aerobic capacity.</primaryOutcome>
      <secondaryOutcome>1. Activities of daily life
2. Participation
3. Competence
4. Quality of life</secondaryOutcome>
      <trialWebsite>http://www.netchild.nl</trialWebsite>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Ethics approval received from the local medical ethics committee</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN77274716</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>05-092</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Multicentre, randomised, single blinded, active controlled, parallel group trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2005-10-15T00:00:00.000Z</overallStartDate>
      <overallEndDate>2006-06-15T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Netherlands</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="9e626677-cf0b-4b84-bd7e-7c2f428e1f3e">
	  <name>Revalidatiecentrum De Hoogstraat</name>
	  <address/>
	  <city>Utrecht</city>
	  <state/>
	  <country>Netherlands</country>
	  <zip>3583 TM</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Cerebral palsy
2. Gross Motor Function Classification System (GMFCS) I or II
3. Age 7 - 20 years
4. Informed consent</inclusion>
      <ageRange>Not Specified</ageRange>
      <gender>Not Specified</gender>
      <targetEnrolment>100</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>100</totalTarget>
      <exclusion>1. Cardiac or respiratory conditions that may be affected by exercise
2. Surgical or orthopaedic procedures during or up to three months prior to the study</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2005-10-15T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2006-06-15T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Cerebral parese (cerebral palsy)</description>
	<diseaseClass1>Nervous System Diseases</diseaseClass1>
	<diseaseClass2>Cerebral palsy</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Fitness programme that consists of functional exercises. 45 minutes fitness training twice a week for 8 months.</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2007 Results article in https://pubmed.ncbi.nlm.nih.gov/17984410 Results</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="8a21e65c-59a9-4668-a23d-cc54e08428f9" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2007-11-01T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="https://pubmed.ncbi.nlm.nih.gov/17984410"/>
	<description>Results</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder14343-0</funderId>
      <contactId>Contact52214_14343</contactId>
      <sponsorId>Sponsor50571</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact52214_14343">
    <title>Dr</title>
    <forename>Olaf</forename>
    <surname>Verschuren</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Revalidatiecentrum De Hoogstraat
Rembrandtkade 10</address>
      <city>Utrecht</city>
      <country>Netherlands</country>
      <zip>3583 TM</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+31 (0)30 2561211</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">o.verschuren@dehoogstraat.nl</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor50571">
    <organisation>University Medical Center Utrecht (The Netherlands)</organisation>
    <website>http://www.umcutrecht.nl/zorg/</website>
    <sponsorType>Hospital/treatment centre</sponsorType>
    <contactDetails>
      <address>WKZ, Department of Pediatric Physiotherapy
Lundlaan 6</address>
      <city>Amsterdam</city>
      <country>Netherlands</country>
      <zip>3584 EA</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+31 (0)30 2504030</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">p.j.m.helders@umcutrecht.nl</email>
    </contactDetails>
    <privacy>Public</privacy>
    <gridId>grid.7692.a</gridId>
    <rorId>https://ror.org/0575yy874</rorId>
  </sponsor>
  <funder id="Funder14343-0">
    <name>Dr WM Phelps-Stichting Voor Spastici (The Netherlands)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-10-19T00:00:00.000Z" version="20">
    <isrctn dateAssigned="2005-12-20T00:00:00.000Z">43635237</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>N-acetylcysteine as a Preventive Measure for Contrast Induced Nephropathy in Intensive Care Patients with Renal Insufficiency</title>
      <scientificTitle/>
      <acronym>NACCINIC-trial</acronym>
      <studyHypothesis>On the assumption that N-acetylcysteine might prevent acute contrast induced nephropathy in critically ill patients, we study the effects of prophylactic intravenous administration of N-acetylcysteine in critically ill patients with renal insufficiency.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>1. Rise in plasma creatinine greater than 25% within 48 hours after contrast administration
2. Need for Continuous Venous-Venous Haemofiltration (CVVH) therapy at any moment during stay in ICU
3. Duration of CVVH therapy, if initiated
4. Renal insufficiency (for which ongoing renal replacement therapy) at ICU-discharge</primaryOutcome>
      <secondaryOutcome>No secondary outcome measures</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Ethics approval received from the local medical ethics committee</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN43635237</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Multicentre, randomised, double blind, placebo controlled, parallel group trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2006-01-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2008-01-01T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Netherlands</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="6a7c8ebc-91a9-40d8-8e44-9d100f1c27c1">
	  <name>Department of Intensive Care</name>
	  <address/>
	  <city>Amsterdam</city>
	  <state/>
	  <country>Netherlands</country>
	  <zip>1105 AZ</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. (Chronic or acute) renal insufficiency (not presently on renal replacement therapy) defined as a plasma creatinine greater than 180 µmol/L
2. Planned diagnostic imaging procedure requiring the use of intravenous radiographic contrast agents
3. Admitted to one of the participating intensive care units</inclusion>
      <ageRange>Not Specified</ageRange>
      <gender>Not Specified</gender>
      <targetEnrolment>246</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>246</totalTarget>
      <exclusion>1. Pregnancy
2. No informed consent</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2006-01-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2008-01-01T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Renal insufficiency</description>
	<diseaseClass1>Urological and Genital Diseases</diseaseClass1>
	<diseaseClass2>Renal insufficiency</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Patients are randomly assigned to receive either N-acetylcysteine before and after administration of the contrast agent (acetylcysteine group) or placebo at the same time points (control group).

N-acetylcysteine or placebo is given intravenously in a double blinded fashion. N-acetylcysteine is given at a dose of 5000 mg on the day before and on the day of administration of the contrast agent, for a total of two days.</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>N-acetylcysteine</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
        
      </outputs>
    <parties>
      <funderId>Funder14371-0</funderId>
      <contactId>Contact52196_14371</contactId>
      <sponsorId>Sponsor50646</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact52196_14371">
    <title>Dr</title>
    <forename>M J</forename>
    <surname>Schultz</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Department of Intensive Care
Academic Medical Centre
University of Amsterdam
Meibergdreef 9</address>
      <city>Amsterdam</city>
      <country>Netherlands</country>
      <zip>1105 AZ</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">m.j.schultz@amc.uva.nl</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor50646">
    <organisation>Academic Medical Centre (AMC) (Netherlands)</organisation>
    <website>http://www.amc.uva.nl/</website>
    <sponsorType>Hospital/treatment centre</sponsorType>
    <contactDetails>
      <address>Department of Obstetrics and Gynaecology
Meibergdreef 9</address>
      <city>Amsterdam</city>
      <country>Netherlands</country>
      <zip>1105 AZ</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.5650.6</gridId>
    <rorId>https://ror.org/03t4gr691</rorId>
  </sponsor>
  <funder id="Funder14371-0">
    <name>Academic Medical Center (AMC) (The Netherlands) - Department of Intensive Care</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-11-09T00:00:00.000Z" version="25">
    <isrctn dateAssigned="2005-12-20T00:00:00.000Z">26340837</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Effect of recombinant Granulocyte Colony-Stimulating Factor (G-CSF) on the results of chemotherapy (CHOP) in elderly patients with intermediate-/high-grade Non-Hodgkin's Lymphoma: a prospective phase III study</title>
      <scientificTitle/>
      <acronym>HOVON 25 NHL</acronym>
      <studyHypothesis>The hypothesis to be tested is that the outcome in arm B is better than in arm A.

Objectives:
1. Evaluation of the effect of G-CSF on response and survival of Non-Hodgkin's Lymphoma (NHL) to therapy
2. Evaluation of the effect of prophylactic G-CSF on treatment-related morbidity and mortality
3. Evaluation of possible beneficial effect of G-CSF on patient adherence to Relative Dose Intensity of the standard therapy.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Complete Remission (CR) rate.</primaryOutcome>
      <secondaryOutcome>1. Relapse rate
2. Event-free survival
3. Overall survival
4. Treatment-related morbidity
5. Therapy-related hospital admissions
6. Mortality</secondaryOutcome>
      <trialWebsite>http://www.hovon.nl</trialWebsite>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Ethics approval received from the local medical ethics committee</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN26340837</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>HO25</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Multicentre, randomised, active controlled, parallel group trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>1994-08-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2000-09-05T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Netherlands</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="37d439f3-1609-4968-b984-b4a94d2fa7e0">
	  <name>Erasmus University Medical Centre</name>
	  <address/>
	  <city>Rotterdam</city>
	  <state/>
	  <country>Netherlands</country>
	  <zip>3000 CA</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Previously untreated Non-Hodgkin&#146;s Lymphoma
2. Ann Arbor stage II, III or IV
3. Intermediate- or high grade malignancy (Working Formulation), confirmed by histology
4. Aged greater than or equal to 65 years
5. Informed consent</inclusion>
      <ageRange>Senior</ageRange>
      <gender>Both</gender>
      <targetEnrolment>410</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>410</totalTarget>
      <exclusion>1. Treatment for NHL with chemotherapy or radiotherapy (local irradiation to life-threatening tumor infiltration is allowed)
2. Lymphoblastic lymphoma
3. Other malignant diseases, except localized squamous skin carcinoma
4. Severe heart failure requiring symptomatic treatment or a cardiac ejection fraction of less than 45%
5. Inadequate liver or renal function, ie serum creatinine or serum bilirubin &gt; 15x the upper normal value, except when related to lymphoma organ infiltration
6. HIV positivity</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>1994-08-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2000-09-05T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Non Hogdkin's Lymphoma (NHL)</description>
	<diseaseClass1>Cancer</diseaseClass1>
	<diseaseClass2>Non Hogdkin's Lymphoma</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Patients will be randomised at entry between:
Arm A: CHOP every 3 weeks, 6 or 8 courses
Arm B: CHOP every 3 weeks, 6 or 8 courses and 300 mcg subcutaneous (s.c.) daily G-CSF

CHOP consists of cyclophosphamide, doxorubicin, vincristine and prednisone.</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Phase III</phase>
	<drugNames>Granulocyte Colony-Stimulating Factor (G-CSF), cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP)</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2003 Results article in https://pubmed.ncbi.nlm.nih.gov/12915593 Results</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="afa2d729-16fe-4647-996a-08823c00a2ee" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2003-08-15T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="https://pubmed.ncbi.nlm.nih.gov/12915593"/>
	<description>Results</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder14519-0</funderId>
      <funderId>Funder14519-1</funderId>
      <funderId>Funder14519-2</funderId>
      <funderId>Funder14519-3</funderId>
      <funderId>Funder14519-4</funderId>
      <funderId>Funder14519-5</funderId>
      <contactId>Contact52269_14519</contactId>
      <sponsorId>Sponsor50732</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact52269_14519">
    <title>Prof</title>
    <forename>P</forename>
    <surname>Sonneveld</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Erasmus University Medical Centre
Department of Haematology
P.O. Box 2040</address>
      <city>Rotterdam</city>
      <country>Netherlands</country>
      <zip>3000 CA</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+31 (0)10 463 3589</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">p.sonneveld@erasmusmc.nl</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor50732">
    <organisation>Dutch Haemato-Oncology Association (Stichting Hemato-Oncologie Volwassenen Nederland) (HOVON) (Netherlands)</organisation>
    <website>http://www.hovon.nl/</website>
    <sponsorType>Research organisation</sponsorType>
    <contactDetails>
      <address>Vrije University Medical Centre (VUMC)
PO Box 7057</address>
      <city>Amsterdam</city>
      <country>Netherlands</country>
      <zip>1007 MB</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+31 (0)20 444 2693</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">hdc@hovon.nl</email>
    </contactDetails>
    <privacy>Public</privacy>
    <gridId>grid.476265.4</gridId>
    <rorId>https://ror.org/056kpdx27</rorId>
  </sponsor>
  <funder id="Funder14519-0">
    <name>Johnson &amp; Johnson (The Netherlands)</name>
    <fundRef>http://dx.doi.org/10.13039/100004331</fundRef>
  </funder>
  <funder id="Funder14519-1">
    <name>Commission for Medical Applied Research (Commissie voor Klinisch Toegepast Onderzoek [CKTO]) (The Netherlands)</name>
    <fundRef/>
  </funder>
  <funder id="Funder14519-2">
    <name>Stichting Hemato-Oncologie voor Volwassenen Nederland (HOVON) (The Netherlands)</name>
    <fundRef/>
  </funder>
  <funder id="Funder14519-3">
    <name>Roche Nederland B.V. (The Netherlands)</name>
    <fundRef/>
  </funder>
  <funder id="Funder14519-4">
    <name>Amgen (The Netherlands)</name>
    <fundRef>http://dx.doi.org/10.13039/100002429</fundRef>
  </funder>
  <funder id="Funder14519-5">
    <name>Novartis Pharma B.V. (The Netherlands)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-11-09T00:00:00.000Z" version="25">
    <isrctn dateAssigned="2005-12-20T00:00:00.000Z">82155239</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Myelo-ablative chemo/radiotherapy and autologous stem cell transplantation as compared to only chemotherapy in patients with multiple myeloma</title>
      <scientificTitle/>
      <acronym>HOVON 24 MM</acronym>
      <studyHypothesis>The hypothesis to be tested is that the outcome in arm II (and Allogeneic Bone Marrow Transplant [ABMT]) is better than in arm I.

Objectives:
1. Evaluation of the effect of myeloablative chemo-/radiotherapy and autologous stem cell transplantation in comparison with chemotherapy alone with respect to the mentioned endpoints
2. Assessment of the value of risk factors at diagnosis with dose intensity of treatment</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Remission rate.</primaryOutcome>
      <secondaryOutcome>1. Event-free survival
2. Overall survival
3. Quality of life
4. Cost-benefit</secondaryOutcome>
      <trialWebsite>http://www.hovon.nl</trialWebsite>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Ethics approval received from the local medical ethics committee</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN82155239</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>Ho24</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Multicentre, randomised, active controlled, parallel group trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>1995-11-07T00:00:00.000Z</overallStartDate>
      <overallEndDate>2000-04-01T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Netherlands</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="7bfa1bb6-3c78-47da-9fe0-8f40eacf2c2d">
	  <name>University Medical Center Utrecht,</name>
	  <address/>
	  <city>Utrecht</city>
	  <state/>
	  <country>Netherlands</country>
	  <zip>3508 GA</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>At entry:
1. Previously untreated multiple myeloma, stage 2 or 3 according to Salmon and Durie
2. Aged less than 66 years
3. World Health Organization (WHO) performance status 0 - 3
4. Informed consent

For Interferon (IFN) maintenance and Peripheral Blood Stem Cell Transplant (PBSCT) or Allogeneic Bone Marrow Transplant (ABMT):
1. At least Partial Remission (PR) after induction therapy
2. WHO performance status 0 - 2
3. Suitable peripheral stem or bone marrow graft
4. No active infections
5. Absence of severe cardiac, pulmonary, neurologic, psychiatric disease
6. Serum creatinine, bilirubin and transaminases of less than 2.5 x upper limit of normal values
7. Platelet count greater than 50 x 10^9/l
8. Absolute neutrophil count greater than 1 x 10^9/l
9. Informed consent</inclusion>
      <ageRange>Adult</ageRange>
      <gender>Both</gender>
      <targetEnrolment>452</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>452</totalTarget>
      <exclusion>At entry:
1. Received more than 2 courses of melphalan, prednisone or vincristine, melphalan (M), cyclophosphamide, prednisone (VMCP)
2. Severe cardiac disease (= severe heart failure requiring symptomatic treatment or a cardiac ejection fraction of less than 45% with presence of normal hemoglobin), severe pulmonary, neurologic or metabolic disease- Inadequate liver function, i.e., bilirubin greater than or equal to 25 x upper normal value
3. Prior malignancies except non-melanoma skin tumors or stage 0 (in situ) cervical carcinoma
4. Prior extensive radiotherapy involving the myelum (precluding total body irradiation)</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>1995-11-07T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2000-04-01T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Multiple Myeloma</description>
	<diseaseClass1>Cancer</diseaseClass1>
	<diseaseClass2>Multiple Myeloma</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Patients will be treated with 3 x VAD (vincristine, doxorubicine, dexamethasone). Patients less than or equal to 55 years with a Human Leukocyte Antigen (HLA) identical sibling will proceed to Allo BMT. All other eligible patients will be randomised between:
1. Arm I: PBSC pheresis after cyclophosphamide priming (cyclophosphamide, mesnum, G-CSF), IDM (melphalan, G-CSF) every 8 weeks 2 courses. In case of PR/CR maintenance therapy with IFN-alpha-2a until relapse. PBSCT may be performed after reinduction or relapse
2. Arm II: PBSC pheresis after cyclophosphamide priming (cyclophosphamide, mesnum, G-CSF), IDM (melphalan, G-CSF) q 8 weeks 2 courses. In case of PR/CR intensive treatment with cyclophosphamide/TBI and autologous transplantation, maintenance with IFN-alpha-2a until relapse</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Phase III</phase>
	<drugNames>Vincristine, doxorubicine, dexamethasone (VAD), cyclophosphamide, mesnum, Granulocyte Colony Stimulating Factor (G-CSF), melphalan</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2003 Other publications in https://pubmed.ncbi.nlm.nih.gov/12456509
2003 Results article in https://pubmed.ncbi.nlm.nih.gov/12721248/
2004 Other publications in https://pubmed.ncbi.nlm.nih.gov/15110879</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="b251b5f2-7450-4e71-a158-b7067a71a28e" outputType="otherpublications" artefactType="ExternalLink" dateCreated="2003-03-15T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="https://pubmed.ncbi.nlm.nih.gov/12456509"/>
	<description/>
	<productionNotes/>
      </output>
      <output id="e850d249-44cd-489d-9280-f2cdf1a32a8d" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2003-05-01T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="https://pubmed.ncbi.nlm.nih.gov/12721248/"/>
	<description/>
	<productionNotes/>
      </output>
      <output id="d42462f6-390b-450a-8d6f-951c25d4452d" outputType="otherpublications" artefactType="ExternalLink" dateCreated="2004-05-01T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="https://pubmed.ncbi.nlm.nih.gov/15110879"/>
	<description/>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder14520-0</funderId>
      <funderId>Funder14520-1</funderId>
      <funderId>Funder14520-2</funderId>
      <funderId>Funder14520-3</funderId>
      <funderId>Funder14520-4</funderId>
      <funderId>Funder14520-5</funderId>
      <contactId>Contact52143_14520</contactId>
      <sponsorId>Sponsor50732</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact52143_14520">
    <title>Dr</title>
    <forename>H.M.</forename>
    <surname>Lokhorst</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>University Medical Center Utrecht,
Department of Hematology,
P.O. Box 85500</address>
      <city>Utrecht</city>
      <country>Netherlands</country>
      <zip>3508 GA</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+31 (0)30 2507230</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">h.lokhorst@digd.azu.nl</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor50732">
    <organisation>Dutch Haemato-Oncology Association (Stichting Hemato-Oncologie Volwassenen Nederland) (HOVON) (Netherlands)</organisation>
    <website>http://www.hovon.nl/</website>
    <sponsorType>Research organisation</sponsorType>
    <contactDetails>
      <address>Vrije University Medical Centre (VUMC)
PO Box 7057</address>
      <city>Amsterdam</city>
      <country>Netherlands</country>
      <zip>1007 MB</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+31 (0)20 444 2693</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">hdc@hovon.nl</email>
    </contactDetails>
    <privacy>Public</privacy>
    <gridId>grid.476265.4</gridId>
    <rorId>https://ror.org/056kpdx27</rorId>
  </sponsor>
  <funder id="Funder14520-0">
    <name>Roche Nederland B.V. (The Netherlands)</name>
    <fundRef/>
  </funder>
  <funder id="Funder14520-1">
    <name>Amgen (The Netherlands)</name>
    <fundRef>http://dx.doi.org/10.13039/100002429</fundRef>
  </funder>
  <funder id="Funder14520-2">
    <name>Johnson &amp; Johnson (The Netherlands)</name>
    <fundRef>http://dx.doi.org/10.13039/100004331</fundRef>
  </funder>
  <funder id="Funder14520-3">
    <name>Commission for Medical Applied Research (Commissie voor Klinisch Toegepast Onderzoek [CKTO]) (The Netherlands)</name>
    <fundRef/>
  </funder>
  <funder id="Funder14520-4">
    <name>Novartis Pharma B.V. (The Netherlands)</name>
    <fundRef/>
  </funder>
  <funder id="Funder14520-5">
    <name>Stichting Hemato-Oncologie voor Volwassenen Nederland (HOVON) (The Netherlands)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-10-19T00:00:00.000Z" version="23">
    <isrctn dateAssigned="2005-12-20T00:00:00.000Z">72675518</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Effectiveness of intrauterine insemination with ovarian hyperstimulation in couples with an unexplained moderately reduced fertility</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>There is no additional benefit of Intrauterine Insemination (IUI) with Controlled Ovarian Hyperstimulation (COH) over expectant management for 6 months in couples with unexplained subfertility and a chance of a spontaneous pregnancy between 30% and 40%. Categorisation of unexplained subfertile couples by their prognosis can identify those couples who benefit from IUI with COH and those who do not.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>The primary endpoint was ongoing pregnancy within six months. Ongoing pregnancy was defined as the presence of foetal cardiac activity at transvaginal sonography at a gestational age of at least 12 weeks.</primaryOutcome>
      <secondaryOutcome>Secondary endpoints were total number of clinical pregnancies, miscarriages and multiple pregnancies.</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Ethics approval received from the local medical ethics committee</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN72675518</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>1</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Multicentre, randomised, active controlled, parallel group trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2002-06-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2005-07-01T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Netherlands</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="b5cdeed0-ec89-4f2b-a556-6877a5431dcc">
	  <name>Academic Medical Center</name>
	  <address/>
	  <city>Amsterdam</city>
	  <state/>
	  <country>Netherlands</country>
	  <zip>1100 DD</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>All subfertile couples in whom no reason is found during the basic fertility work-up for their subfertility and in whom their spontaneous pregnancy chance in the next year, calculated by the results of the basic fertility work-up, is between 30% and 40%.</inclusion>
      <ageRange>Adult</ageRange>
      <gender>Female</gender>
      <targetEnrolment>250</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>250</totalTarget>
      <exclusion>All couples in whom a reason is found for their subfertility or who are having another prognosis calculated</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2002-06-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2005-07-01T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Unexplained Subfertility</description>
	<diseaseClass1>Pregnancy and Childbirth</diseaseClass1>
	<diseaseClass2>Subfertility</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>After informed consent had been given, couples were randomly allocated between IUI with COH and expectant management for six months. 

Couples allocated to IUI with COH started treatment in the next cycle. Controlled ovarian hyper stimulation as well as semen preparation and insemination regimens were performed according to hospital-specific protocols. 

Couples allocated to expectant management were followed until an ongoing pregnancy occurred within six months, these pregnancies were finally followed until birth. If no pregnancy occurred, follow-up ended after this period. If a pregnancy miscarried, follow-up continued until the next pregnancy or the end of the six months period.</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2006 Results article in http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&amp;cmd=Retrieve&amp;dopt=Abstract&amp;list_uids=16844491 Results</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="9a1635ce-3dfc-4f6d-8b38-e6f021c07e47" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2006-07-15T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&amp;cmd=Retrieve&amp;dopt=Abstract&amp;list_uids=16844491"/>
	<description>Results</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder14407-0</funderId>
      <contactId>Contact52212_14407</contactId>
      <sponsorId>Sponsor50699</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact52212_14407">
    <title>Mrs</title>
    <forename>P</forename>
    <surname>Steures</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Academic Medical Center
Center of Reproductive Medicine
OFO-project, H4-213
P.O. Box 22660</address>
      <city>Amsterdam</city>
      <country>Netherlands</country>
      <zip>1100 DD</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+31 (0)20 566 3857</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">ofoproject@amc.uva.nl</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor50699">
    <organisation>Academic Medical Centre (AMC) (Netherlands)</organisation>
    <website>http://www.amc.uva.nl/</website>
    <sponsorType>University/education</sponsorType>
    <contactDetails>
      <address>Meibergdreef 9</address>
      <city>Amsterdam</city>
      <state/>
      <country>Netherlands</country>
      <zip>1105 AZ</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.5650.6</gridId>
    <rorId>https://ror.org/03t4gr691</rorId>
  </sponsor>
  <funder id="Funder14407-0">
    <name>The Netherlands Organisation for Health Research and Development (ZonMw) (The Netherlands)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-10-23T00:00:00.000Z" version="22">
    <isrctn dateAssigned="2005-12-20T00:00:00.000Z">45666086</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Leiden-Alloimmunisation-Likelihood (LAL) trial: alloimmunisation after pre-storage filtered, post-storage filtered and buffy-coat-depleted blood transfusion in cardiac surgery patients</title>
      <scientificTitle/>
      <acronym>LAL trial</acronym>
      <studyHypothesis>The use of by filtration-leukocyte reduced blood transfusions in patients undergoing cardiac surgery, will result in lower alloimmunisation frequencies compared to using buffy-coat depleted blood transfusions. This has previously been shown in frequently transfused patients that received transfusions over a longer period of time, and is now investigated in patients receiving several units of blood around a single event, cardiac surgery. Also being investigated in this study is whether post-storage filtration is as effective as pre-storage filtration.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Anti-Human Leukocyte Antigen (HLA) antibody formation (tested by LCT) and anti-erythrocyte antibody formation (tested in 3 cell panel, with PEG). Samples for analyses are collected before surgery, on day 7 post-surgery, 3 - 10 weeks post-surgery and 20 - 30 weeks post-surgery.</primaryOutcome>
      <secondaryOutcome>1. Post-operative infections
2. Hospital stay
3. Intensive Care Unit (ICU)-stay
4. Mortality
5. Costs-effect-analyses
6. In combination with other Randomised Controlled Trials (RCTs), that have randomised between these same two blood products: long term effects on the incidence of  autoimmune diseases and malignancies</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Ethics approval received from the local medical ethics committee</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN45666086</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>n/a</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised, double blinded, active controlled, parallel group trial.</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>1992-03-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>1994-08-15T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Netherlands</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="bade7ee3-f043-4c46-8e30-6239c4df7423">
	  <name>Sanquin Blood Bank</name>
	  <address/>
	  <city>Leiden</city>
	  <state/>
	  <country>Netherlands</country>
	  <zip>2333 BZ</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>Patients planned for open heart surgery: Coronary Artery Bypass Graft (CABG), heart valve surgery or the combination of both.</inclusion>
      <ageRange>Adult</ageRange>
      <gender>Both</gender>
      <targetEnrolment>944</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>944</totalTarget>
      <exclusion>1. Aged less than 18 years
2. Transfusions within last 6 months
3. Pre-existing medical indication for filtered blood products</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>1992-03-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>1994-08-15T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Blood transfusions in cardiac surgery</description>
	<diseaseClass1>Surgery</diseaseClass1>
	<diseaseClass2>Blood transfusions</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Use of by filtration leukocyte reduced blood transfusions versus use of buffy-coat depleted blood transfusions (=1990's standard in NL).</description>
	<interventionType>Procedure/Surgery</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>1990 Other publications in https://pubmed.ncbi.nlm.nih.gov/2378025
1998 Other publications in https://pubmed.ncbi.nlm.nih.gov/9494026
2003 Other publications in https://pubmed.ncbi.nlm.nih.gov/12542735</publicationDetails>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="73e03fd0-ee81-4b92-ba13-6c57d75d8b60" outputType="otherpublications" artefactType="ExternalLink" dateCreated="1990-07-01T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="https://pubmed.ncbi.nlm.nih.gov/2378025"/>
	<description/>
	<productionNotes/>
      </output>
      <output id="63ab26b4-c11a-4d92-8d91-c4cd25dce28c" outputType="otherpublications" artefactType="ExternalLink" dateCreated="1998-02-17T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="https://pubmed.ncbi.nlm.nih.gov/9494026"/>
	<description/>
	<productionNotes/>
      </output>
      <output id="c68100f1-6dbd-4a7a-ba1b-3b109d9450d3" outputType="otherpublications" artefactType="ExternalLink" dateCreated="2003-01-01T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="https://pubmed.ncbi.nlm.nih.gov/12542735"/>
	<description/>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder14473-0</funderId>
      <funderId>Funder14473-1</funderId>
      <contactId>Contact52180_14473</contactId>
      <sponsorId>Sponsor50754</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact52180_14473">
    <title>Dr</title>
    <forename>L.M.G.</forename>
    <surname>van de Watering</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Sanquin Blood Bank
Southwest region
Plesmanlaan 1a</address>
      <city>Leiden</city>
      <country>Netherlands</country>
      <zip>2333 BZ</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
  </contact>
  <sponsor id="Sponsor50754">
    <organisation>Leiden University Medical Centre (LUMC) (Netherlands)</organisation>
    <website>http://www.lumc.nl/</website>
    <sponsorType>University/education</sponsorType>
    <contactDetails>
      <address>Albinusdreef 2
P.O. Box 9600</address>
      <city>Leiden</city>
      <state/>
      <country>Netherlands</country>
      <zip>2300 RC</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.5132.5</gridId>
    <rorId>https://ror.org/027bh9e22</rorId>
  </sponsor>
  <funder id="Funder14473-0">
    <name>Red Cross Blood Bank Leidsenhage (The Netherlands)</name>
    <fundRef/>
  </funder>
  <funder id="Funder14473-1">
    <name>NPBI International B.V. (The Netherlands)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-10-23T00:00:00.000Z" version="22">
    <isrctn dateAssigned="2005-12-20T00:00:00.000Z">04886579</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Dutch National Study to the palliative effect of irradiation comparing two different treatment schemes in Non-Small-Cell-Lung-Cancer (NSCLC)</title>
      <scientificTitle/>
      <acronym>0G98/009 LUNGTRIAL</acronym>
      <studyHypothesis>The treatment of Non-Small-Cell-Lung-Cancer (NSCLC) is still a challenge for the oncologist. In the last decade combined modality treatment in stage III and chemotherapy in stage IV improved the survival and quality of life (QOL) in NSCLC patients. Unfortunately a vast majority of patients will not be fit enough to undergo these intensive treatments, and those who underwent chemotherapy as palliative treatment may eventually still suffer from loco-regional complaints. 

In general, hemoptysis, chest pain, dysphagia, and dyspnoea can all be effectively palliated with acceptable toxicity with all kinds of different radiation treatment schemes. The effectiveness of these different treatment schemes however varies for each different symptom and is most effective for hemoptysis and chest pain in patients with an Eastern Cooperative Oncology Group (ECOG) grade status of 2 - 3. Which dose should be given is still controversial. 

In the first Medical Research Council (MRC) trial reported in 1991 no differences in palliative effect and in survival were seen between 13 x 3 Gy and 2 x 8.5 Gy. In a second MRC study in 1992 for poor prognostic patients only, no differences in palliation or survival were seen between 10 Gy single dose and 2 x 8.5 Gy. However in a study by Bezjak et al. a difference in survival between 20 Gy in 5 fractions and a 10 Gy single dose was demonstrated in favour of the multi-fractionation treatment. In a group-analysis, however, this survival advantage was not seen in patients with an ECOG score of 2 or more. Later data suggested a survival advantage of 13 x 3 Gy over 2 x 8.5 Gy in patients with good performance status. 

For patients in a bad general condition it still has to be proven whether 2 x 8.5 Gy is equally effective as 10 x 3 Gy. Based on these findings radiation oncologists in the Netherlands could not reach consensus on the appropriate fractionation schedule for palliative irradiation of bad prognosis NSCLC patients. The presented study therefore was focused on patients with bad general condition and/or significant weight loss with stage III NSCLC or stage IV patients, not suitable for chemotherapy, comparing 10 x 3 Gy with 2 x 8 Gy.

Purpose: 
This multicentre randomised National Study compared the efficacy of 2 x 8 Gy versus our standard 10 x 3 Gy in patients with inoperable stage IIIA/B (with ECOG score 2 - 4 and/or substantial weight loss) and stage IV Non-Small-Cell Lung Cancer (NSCLC). 

Hypothesis:
We expected both treatment arms to have an equal outcome for palliation as for prognosis, because of the above-mentioned results of the MRC studies.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Palliation of thoracic symptoms measured over 52 weeks after randomisation. A maximum of 33 questionnaires per patient would be sent in case follow-up could be completed. The first questionnaire was given before randomisation, the last questionnaire in the 52nd week after randomisation. Data about effectiveness of the treatment and QOL were based on the Rotterdam Symptom Checklist. Seven symptoms could be scored each on a four point validated scale from 1 (no complaints) to 4 (severe complaints). The baseline total symptom score had to be 8 indicating that the patient had at least one tumour related complaint. The maximum total symptom score could be 28 indicating the patient had all seven complaints in the worst degree. After response the lowest total symptom score could be 7, having no complaints at all. Palliation was defined as a average total score below the baseline score.</primaryOutcome>
      <secondaryOutcome>1. Toxicity, Quality of Life (QOL), and survival
2. Quality of life was measured using the EuroQol classification system (EQ-5D), consisting of five questions on mobility, self-care, usual activities, pain/discomfort, and anxiety/depression 
3. In addition, information about acute toxicity as nausea, vomiting, and radiation oesophagitis induced dysphagia was collected, based on the of the National Cancer Institute of Canada Expanded Clinical Trials Group (NCIC CTG) Common Toxicity Criteria 
4. Patients were also asked to provide information about costs. Together with quality of life data, these data will be published separately in a cost-utility analysis
5. Follow up after 52 weeks was continued by the data manager, who made 3-monthly inquiries after survival of the patient</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Ethics approval received from the local medical ethics committee</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN04886579</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Multicentre, randomsied, active controlled, parallel group trial.</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>1999-01-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2002-05-31T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Netherlands</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="b6320af7-204c-436a-a848-f0591479091f">
	  <name>Arnhems Radiotherapeutisch Instituut,</name>
	  <address/>
	  <city>Arnhem</city>
	  <state/>
	  <country>Netherlands</country>
	  <zip>6815 AD</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Diagnosis of NSCLC had to be cytologically or histologically confirmed
2. Tumour stage was IIIA or IIIB in combination with performance status 3 &#150; 4 and/or a weight loss of more than 5% in 3 months or greater than 10% in 6 months prior to diagnosis
3. Stage IV NSCLC, not suitable for chemotherapeutic treatment
4. A minimum total symptom score of 8, indicating a score greater than 1 for at least one of the following complaints caused by the tumour itself: 
4.1. Loss of appetite
4.2. Dyspnoea
4.3. Chest pain
4.4. Coughing
4.5. Hemoptysis
4.6. Hoarseness and/or dysphagia
5. Physically and mentally fit enough to participate in the study</inclusion>
      <ageRange>Not Specified</ageRange>
      <gender>Not Specified</gender>
      <targetEnrolment>303</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>303</totalTarget>
      <exclusion>1. Superior Vena Cava Syndrome (SVCS) at presentation
2. Prior radiotherapy to the chest and/or other malignant diseases in the past
3. Concurrent chemotherapy</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>1999-01-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2002-05-31T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Non Small Cell Lung Cancer (NSCLC)</description>
	<diseaseClass1>Cancer</diseaseClass1>
	<diseaseClass2>Lung cancer</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Patients were randomised, without stratification, either to the multiple fractionation scheme of 10 x 3 Gy, 4 - 5 times a week, or the hypo fractionation scheme of 2 x 8 Gy, given at day 1 and day 8. 

Irradiation was given with two opposing anterior-posterior fields with 6 - 18 MV photon beams. The treatment portals encompassed the tumour with a margin of 1.5 - 2 cm including adjacent pathological lymph nodes. No limitations were set for the Target Volume. Dose calculation was not corrected for tissue inhomogeneities. Co-medication, including corticosteroids and analgetics, and extra oxygen supply were allowed and registered.</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2005 Results article in https://pubmed.ncbi.nlm.nih.gov/15860852 Results</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="8f76f40c-98c7-40fc-b39c-cecb06626634" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2005-05-01T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="https://pubmed.ncbi.nlm.nih.gov/15860852"/>
	<description>Results</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder14474-0</funderId>
      <contactId>Contact52134_14474</contactId>
      <sponsorId>Sponsor50686</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact52134_14474">
    <title>Dr</title>
    <forename>G.W.P.M.</forename>
    <surname>Kramer</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Arnhems Radiotherapeutisch Instituut,
Wagnerlaan 47</address>
      <city>Arnhem</city>
      <country>Netherlands</country>
      <zip>6815 AD</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+31 (0)26 371 2493</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">g.kramer@arnhemrti.nl</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor50686">
    <organisation>Arnhems Radiotherapeutic Institute (ARTI) (The Netherlands)</organisation>
    <website/>
    <sponsorType>Research organisation</sponsorType>
    <contactDetails>
      <address>Wagnerlaan 47</address>
      <city>Arnhem</city>
      <country>Netherlands</country>
      <zip>6815 AD</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.491092.7</gridId>
    <rorId>https://ror.org/048338z54</rorId>
  </sponsor>
  <funder id="Funder14474-0">
    <name>The Dutch Health Care Insurance Board (CVZ) (The Netherlands)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-10-23T00:00:00.000Z" version="20">
    <isrctn dateAssigned="2005-12-20T00:00:00.000Z">76815071</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Risk adapted treatment of Acute Myelocytic Leukaemia (AML)</title>
      <scientificTitle/>
      <acronym>HOVON 29 AML/SAKK 30/95</acronym>
      <studyHypothesis>The hypotheses to be tested are that: 
1. The outcome in arm B is better than in arm A 
2. Following Peripheral Blood Stem Cell Transplant (PBSCT) is better than following Cycle III chemotherapy</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>CR rate.</primaryOutcome>
      <secondaryOutcome>1. Disease-free survival
2. Overall survival</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Ethics approval received from the local medical ethics committee</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN76815071</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>HO29</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Multicentre, randomised, active controlled, parallel group trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>1995-03-30T00:00:00.000Z</overallStartDate>
      <overallEndDate>2001-06-06T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Netherlands</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="66c425ca-c0b1-4a3d-a51c-fb890ffbf30e">
	  <name>Erasmus Medical Centre</name>
	  <address/>
	  <city>Rotterdam</city>
	  <state/>
	  <country>Netherlands</country>
	  <zip>3008 AE</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>First randomisation:
1. Patients with newly diagnosed de novo Acute Myelocytic Leukaemia (AML) (including all cytological subtypes M0-M7)
2. Age 15 - 60 years inclusive
3. Patients have given informed consent
4. Leucocytosis (White Blood Cells [WBC] greater than 30 x 10^9/l) is not an exclusion criterion, but it will require postponement of Granulocyte-Colony Stimulating Factor (G-CSF) administration until WBC have declined to 20 x 10^9/l on chemotherapy

Patients after completion of CYCLE II and peripheral blood stem cell collection are eligible for second randomisation if:
1. Complete remission continues (marrow cytology and blood evaluation)
2. Poor risk status according to criteria of Appendix III
3. Not eligible for genotypically Human Leukocyte Antigen (HLA) matched allogeneic Bone Marrow Transplant (BMT)
4. Absence of congestive heart failure or pulmonary disease
5. Serum bilirubin as parameter of liver function abnormalities not elevated above 3 x normal value
6. Number of blood cells collected ('transplant'; PBSCT) being at least 2 x 10^8 nucleated cells/kg or 10 x 10^4 Colony-Forming Units Granulocyte-Macrophage (CFU-GM) per kg or 2 x 10^6 CD34-positive cells per kg. In case of no or insufficient PBSCT, an adequate autologous marrow graft must have been collected
7. Performance status of World Health Organization (WHO) grade 0, 1 or 2 at time of randomisation
8. Informed consent</inclusion>
      <ageRange>Adult</ageRange>
      <gender>Both</gender>
      <targetEnrolment>1105</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>1105</totalTarget>
      <exclusion>First randomisation:
1. Patients with a concurrent active malignancy, except stage I cervix carcinoma and basocellular carcinoma
2. Patients previously treated with chemotherapy
3. Leukaemia following from a documented myelodysplasia with a duration of more than 6 months
4. Blastic crisis of chronic myeloid leukaemia or leukaemia developing from myeloproliferative diseases (e.g. polycythemia vera, myelofibrosis)
5. Renal or liver function abnormalities i.e. creatinine and bilirubin of more than 3 x normal value, except if directly attributable to the leukaemia (high serum lysosymes, hyperuricemia, leukaemic cell infiltration)
6. Human Immunodeficiency Virus (HIV) positive serology
7. Patients with severe cardiac, pulmonary or neurologic disease
8. Pregnancy</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>1995-03-30T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2001-06-06T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Acute Myeloid Leukaemia (AML)</description>
	<diseaseClass1>Cancer</diseaseClass1>
	<diseaseClass2>Acute Myeloid Leukaemia (AML)</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Patients (except AML-M3 or t[15;17]) will be randomised on entry between:

Arm A:
Cycle I: idarubicin + cytarabin
Cycle II: amsacrin + cytarabin

Arm B:
Cycle I: idarubicin + cytarabin + G-CSF
Cycle II: amsacrin + cytarabin + G-CSF

Patients with AML-M3 or t(15;17) will receive arm A treatment. Patients in Complete Remission (CR) with good risk will proceed to cycle III: Mitoxantrone + VP-16. Patients in CR with poor risk and a HLA matched donor will proceed to Allo BMT. Patients in CR with poor risk without a HLA matched donor will be randomised between cycle III chemotherapy and Busulfan/Cyclophosphamide marrow ablative treatment and PBSCT.</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
        
      </outputs>
    <parties>
      <funderId>Funder14495-0</funderId>
      <funderId>Funder14495-1</funderId>
      <funderId>Funder14495-2</funderId>
      <funderId>Funder14495-3</funderId>
      <funderId>Funder14495-4</funderId>
      <funderId>Funder14495-5</funderId>
      <contactId>Contact52252_14495</contactId>
      <sponsorId>Sponsor50732</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact52252_14495">
    <title>Prof</title>
    <forename>B.</forename>
    <surname>Löwenberg</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Erasmus Medical Centre
Daniel den Hoed Cancer Centre
Department of Hematology
P.O. Box 5201</address>
      <city>Rotterdam</city>
      <country>Netherlands</country>
      <zip>3008 AE</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+31 (0)10 439 1598</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">b.lowenberg@erasmusmc.nl</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor50732">
    <organisation>Dutch Haemato-Oncology Association (Stichting Hemato-Oncologie Volwassenen Nederland) (HOVON) (Netherlands)</organisation>
    <website>http://www.hovon.nl/</website>
    <sponsorType>Research organisation</sponsorType>
    <contactDetails>
      <address>Vrije University Medical Centre (VUMC)
PO Box 7057</address>
      <city>Amsterdam</city>
      <country>Netherlands</country>
      <zip>1007 MB</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+31 (0)20 444 2693</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">hdc@hovon.nl</email>
    </contactDetails>
    <privacy>Public</privacy>
    <gridId>grid.476265.4</gridId>
    <rorId>https://ror.org/056kpdx27</rorId>
  </sponsor>
  <funder id="Funder14495-0">
    <name>Amgen (The Netherlands)</name>
    <fundRef>http://dx.doi.org/10.13039/100002429</fundRef>
  </funder>
  <funder id="Funder14495-1">
    <name>Novartis (The Netherlands)</name>
    <fundRef>http://dx.doi.org/10.13039/100004336</fundRef>
  </funder>
  <funder id="Funder14495-2">
    <name>Pharma B.V. (The Netherlands)</name>
    <fundRef/>
  </funder>
  <funder id="Funder14495-3">
    <name>Roche Nederland B.V. (The Netherlands)</name>
    <fundRef/>
  </funder>
  <funder id="Funder14495-4">
    <name>Commission for Medical Applied Research (Commissie voor Klinisch Toegepast Onderzoek [CKTO]) (The Netherlands)</name>
    <fundRef/>
  </funder>
  <funder id="Funder14495-5">
    <name>Johnson &amp; Johnson (The Netherlands)</name>
    <fundRef>http://dx.doi.org/10.13039/100004331</fundRef>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-10-17T00:00:00.000Z" version="23">
    <isrctn dateAssigned="2005-12-20T00:00:00.000Z">21565532</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Neoadjuvant pre-radical prostatectomy gene therapy (HSV-tk gene transduction followed by Ganciclovir) in patients with poor prognostic indicators</title>
      <scientificTitle/>
      <acronym>Genetherapy 1</acronym>
      <studyHypothesis>This phase I dose-escalating study is designed to analyse the safety and effects of adenovirus-mediated thymidine kinase gene transfection into prostate cells, followed by systemic Ganciclovir treatment in patients with poor risk confined prostate carcinoma. Three weeks after gene therapy, radical prostatectomy will be performed, enabling the evaluation of the histological effects.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>To study the safety and toxicity of adenovirus-mediated thymidine kinase gene therapy for the neoadjuvant treatment of prostate cancer. This is established by patient monitoring from day 0 to day 14, during hospitalisation for surgery (day 21 - 28), and subsequently during routine follow-up at weeks 6 and 12, months 6, 9 and 12 and every 6 months thereafter. For this purpose, PSA, blood count, serum hepatic enzumes and creatinine measurements are performed according to routine clinical procedures. A clinical follow-up of one year will be used for safety and toxicity analysis.</primaryOutcome>
      <secondaryOutcome>To study and characterize the biological effects of and the immune response induced by adenovirus-mediated thymidine kinase gene therapy.</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Ethics approval received from the local medical ethics committee</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN21565532</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>A300009</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Phase I, non-randomised, non-controlled, dose-escalating study</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Non randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2001-02-20T00:00:00.000Z</overallStartDate>
      <overallEndDate>2007-09-01T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Netherlands</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="f27fa459-c49c-43d1-acd4-95018d3c89a3">
	  <name>Dept. Urology</name>
	  <address/>
	  <city>Rotterdam</city>
	  <state/>
	  <country>Netherlands</country>
	  <zip>3000 CA</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Men, 35 - 70 years old
2. Histologically proven adenocarcinoma of the prostate which is clinically localised (including bone scan, not Computed Tomography [CT])
3. Prostate Specific Antigen (PSA) greater than 4 ng/ml
4. Medically fit
5. Scheduled to undergo radical prostatectomy
6. Neutrophils = 2 x 10^9/l, platelets = 100 x 10^9/l, bilirubin less than 40 ng/l, Aspartate Aminotransferase (ASAT) less than 4 x normal, Haemoglobin (Hb) = 6.5 mmol/l, Creatinine less than 150 ng/l, Partial Thromboplastin Time (PTT) and Prothrombin Time (PT)
7. Living within one hour travel distance of the hospital
8. Written consent for gene therapy after appropriate information</inclusion>
      <ageRange>Adult</ageRange>
      <gender>Male</gender>
      <targetEnrolment>12</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>12</totalTarget>
      <exclusion>1. Prior androgen ablation hormonal therapy (except treatment with finasteride if discontinued greater than 3 months prior to inclusion)
2. Prior surgery or other invasive treatment for Benign Prostatic Hyperplasia (BPH) (i.e. Transurethral Resection of the Prostate [TURP], hyperthermia, laser prostatectomy etc.)
3. Patients on corticosteroids
4. Concurrent treatment with immunosuppessive drugs (Imuran, cyclophosphamide etc.)
5. Uncontrolled infections (defined as viral, bacterial of fungal infections requiring specific therapy)
6. Human Immunodeficiency Virus (HIV) positive patients
7. Immunocompromised patients</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2001-02-20T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2007-09-01T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Prostate cancer</description>
	<diseaseClass1>Cancer</diseaseClass1>
	<diseaseClass2>Prostate cancer</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Intratumoral gene therapy with adenoviral vector coding for HSV-tk followed by Ganciclovir treatment. Patients are treated with gene therapy three weeks prior to radical prostatectomy.</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Phase I</phase>
	<drugNames>HSV-tk gene transduction, Ganciclovir</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2005 Results article in https://pubmed.ncbi.nlm.nih.gov/15967266 Results</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="03548a94-d9b2-4825-9761-475c8393258f" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2005-07-01T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="https://pubmed.ncbi.nlm.nih.gov/15967266"/>
	<description>Results</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder14350-0</funderId>
      <contactId>Contact52253_14350</contactId>
      <sponsorId>Sponsor50741</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact52253_14350">
    <title>Prof</title>
    <forename>C.H.</forename>
    <surname>Bangma</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Dept. Urology
Erasmus MC
P.O. Box 2040</address>
      <city>Rotterdam</city>
      <country>Netherlands</country>
      <zip>3000 CA</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+31 (0)10 4633607</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">h.j.vanalphen@erasmusmc.nl</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor50741">
    <organisation>Erasmus Medical Centre (Netherlands)</organisation>
    <website>http://www.erasmusmc.nl/</website>
    <sponsorType>University/education</sponsorType>
    <contactDetails>
      <address>Dr Molewaterplein 40/50</address>
      <city>Rotterdam</city>
      <state/>
      <country>Netherlands</country>
      <zip>3000 CA</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.5645.2</gridId>
    <rorId>https://ror.org/018906e22</rorId>
  </sponsor>
  <funder id="Funder14350-0">
    <name>Erasmus Medical Centre (The Netherlands) - Revolving Fund</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-10-17T00:00:00.000Z" version="23">
    <isrctn dateAssigned="2005-12-20T00:00:00.000Z">72821021</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Quality management: improvement of patient care in recently diagnosed rheumatoid arthritis</title>
      <scientificTitle/>
      <acronym>CAMERA</acronym>
      <studyHypothesis>It is possible to increase the efficacy of treatment in early Rheumatoid Arthritis (RA)-patients with Methotrexate (MTX) when treatment is intensified according to a strict and intensive, computer-assisted protocol, i.e. the number of patients in remission will increase.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Number of patients in remission, in which remission is defined as:
1. Number of swollen joints = 0 
2. Plus at least two out of three following criteria:
2.1. Number of swollen joints less than 3
2.2. Erythrocyte Sedimentation Rate (ESR) less than 20 mm/hr 
2.3. Visual Analogue Scale (VAS) general well being less than 20 mm</primaryOutcome>
      <secondaryOutcome>1. Disease activity during 1 year
2. Feasibility of computer assisted program in daily practice</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Not provided at time of registration</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN72821021</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>1999-01-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2003-12-31T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Netherlands</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="23fc6dd0-af59-4691-82cf-5c8486a27a0c">
	  <name>UMC Utrecht</name>
	  <address/>
	  <city>Utrecht</city>
	  <state/>
	  <country>Netherlands</country>
	  <zip>3508 GA</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. RA, defined according to the revised American College of Rheumatology (ACR) criteria for RA
2. A disease duration of less than 1 year, estimated by the rheumatologist
3. Aged greater than 16 years
4. No previous treatment with Disease Modifying Anti-Rheumatic Drugs (DMARDs)
5. Written informed consent by the patient</inclusion>
      <ageRange>Adult</ageRange>
      <gender>Both</gender>
      <targetEnrolment>301</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>301</totalTarget>
      <exclusion>1. Abnormal renal function (Cockroft less than 75 ml/min)
2. Abnormal liver function (Aspartate Aminotransferase [ASAT]/Alanine Aminotransferase [ALAT] greater than 2 x normal), active or recent hepatitis, cirrhosis
3. Major co-morbidities like malignancies, severe diabetic mellitus, severe infections, severe cardio and/or respiratory diseases
4. Leukopenia and/or thrombocytopenia
5. Inadequate birth control conception, pregnancy, and/or breastfeeding
6. Chronic use of oral glucocorticoids
7. Treatment with cytoxic or immunosuppressive drugs within a period of 3 months prior to the study
8. Alcohol intake greater than 2 units per day or drug abuse, presently or in the past
9. Psychiatric or mental disorders which makes adherence to the study protocol impossible
10. Taking part into another clinical trial</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>1999-01-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2003-12-31T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Rheumatoid arthritis</description>
	<diseaseClass1>Musculoskeletal Diseases</diseaseClass1>
	<diseaseClass2>Rheumatoid arthritis</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>In this study the efficacy of two treatment strategies will be compared: intensive treatment versus conventional treatment with MTX. In both treatment strategy groups, patients will be treated with MTX. Starting dose MTX in both groups is 7.5 mg/wk.

In the intensive strategy group, based on predefined scores of disease activity with the help of a computer program, MTX will be increased to 15 mg/wk after 6 weeks. Thereafter, MTX is increased, if necessary, every 4 weeks by 5 mg/wk until a maximum dose of 30 mg/wk or until the maximum tolerable dose.

In the conventional treatment group, patients come to the outpatient clinic once every three months. In case of inefficient results of treatment after 3 months, dose MTX is increased until 15 mg/wk. After three months, dose MTX is increased by 5 mg/wk until a maximum of 30 mg/wk or maximum tolerable dose, if necessary. 

In both groups folinic acid (0.5 mg/day) is prescribed to all patients. 

To patients with gastrointestinal side effects or with insufficient efficacy, MTX is given subcutaneously. Treatment with Non-Steroidal Anti-Inflammatory Drugs (NSAIDS) is allowed next to study medication. Oral glucocorticoids are not allowed during the trial unless unavoidable which has to be approved then by another rheumatologist. Intra-articular injections should be avoided as much as possible, and if necessary this should be mentioned.</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>Methotrexate</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2007 Results article in https://pubmed.ncbi.nlm.nih.gov/17519278 Results</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="89a257d7-86d3-48b3-af08-4a6a520f6659" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2007-11-01T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="https://pubmed.ncbi.nlm.nih.gov/17519278"/>
	<description>Results</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder14376-0</funderId>
      <contactId>Contact52090_14376</contactId>
      <sponsorId>Sponsor50753</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact52090_14376">
    <title>Dr</title>
    <forename>A C A</forename>
    <surname>Marijnissen</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>UMC Utrecht
Rheumatology &amp; Clin. Immunology, F02.127
P.O. Box 85500</address>
      <city>Utrecht</city>
      <country>Netherlands</country>
      <zip>3508 GA</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+31 (0)30 250 9758</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">a.c.a.marijnissen@umcutrecht.nl</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor50753">
    <organisation>University Medical Centre Utrecht (UMCU) (Netherlands)</organisation>
    <website>http://www.umcutrecht.nl/zorg/</website>
    <sponsorType>University/education</sponsorType>
    <contactDetails>
      <address>PO Box 85500</address>
      <city>Utrecht</city>
      <country>Netherlands</country>
      <zip>3508 GA</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.5477.1</gridId>
    <rorId>https://ror.org/04pp8hn57</rorId>
  </sponsor>
  <funder id="Funder14376-0">
    <name>Not provided at time of registration</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-10-01T00:00:00.000Z" version="22">
    <isrctn dateAssigned="2005-10-04T00:00:00.000Z">34513421</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Angioplasty with Stent in Symptomatic Intracranial Stenosis Trial-II</title>
      <scientificTitle/>
      <acronym>ASSIST&#150;II</acronym>
      <studyHypothesis>H0: Adjunctive stenting to optimal medical therapy is not superior to optimal medical therapy alone in reducing ipsilateral stroke risk in patients with symptomatic intracranial atherosclerotic stenoses.
H1: Adjunctive stenting to optimal medical therapy is superior to optimal medical therapy alone in reducing ipsilateral stroke risk in patients with symptomatic intracranial atherosclerotic stenoses.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>1. Ipsilateral stroke, fatal or non-fatal, within 12 months
2. Events of clinically-driven emergency revascularization related to the treated stenosis
3. Modified Rankin score in 12 months</primaryOutcome>
      <secondaryOutcome>1. Stroke and death unrelated to the target stenosis
2. Acute myocardial infarction in 12 months
3. Follow up cerebral angiography or magnetic resonance (MR) angiography, CT and CT-perfusion in 6 months
4. NIHSS in 12 months</secondaryOutcome>
      <trialWebsite>http://www.strokecn.com</trialWebsite>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Not provided at time of registration</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN34513421</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>2004BA714B-7</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2005-09-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2009-09-30T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>China</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="3c4773e0-6aca-42d3-9a50-6b89666f9b51">
	  <name>No. 6 Tiantan Xili</name>
	  <address/>
	  <city>Beijing</city>
	  <state/>
	  <country>China</country>
	  <zip>100050</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. 18-75 years of age
2. ≥1 major atherosclerotic risk factors (arterial hypertension, hyperlipidemia, diabetes mellitus, hyperhomocystinemia and smoking)
3. Recurrent ischemic events (transient ischemic attack [TIA] and/or stroke) attributed to an intracranial stenosis ≥50% at digital subtraction angiography (DSA)
4. Evidence of perfusion deficit at the territory referable to the target stenosis in computed tomography (CT)-perfusion
5. The diameters of the parent arteries were between 2.0 to 4.0 mm, and length of stenoses &lt;12 mm
6. Modified Rankin score ≤2 prior to last ischemic event</inclusion>
      <ageRange>Adult</ageRange>
      <lowerAgeLimit unit="Years" value="18.0"/>
      <upperAgeLimit unit="Years" value="75.0"/>
      <gender>Both</gender>
      <targetEnrolment>399</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>399</totalTarget>
      <exclusion>1. Stenosis of non-atherosclerotic origin (for example, vasculitis, Moya Moya disease and fibromuscular dysplasia)
2. Intracranial hemorrhage and major ischemic stroke (National Institutes of Health-Stroke-Scale [NIHSS] ≥8) in the same hemisphere as the target lesion within 6 weeks
3. A potential source of cardiac embolism
4. Concurrent intracranial tumors, cerebral arteriovenous malformation (AVM) and aneurysms
5. Presence of a neurological illness that can confound the diagnosis of TIA or stroke
6. Known contraindication to aspirin, clopidogrel, probucol, heparin, stainless steel, anesthesia, or X-ray contrast
7. Uncorrectable bleeding diathesis; previous stenting of the target artery
8. A positive pregnancy test
9. Life expectancy &lt;1 year because of other medical conditions
10. Patients were not eligible if they could not cooperate with the study procedures or provide informed consent</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2005-09-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2009-09-30T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Ischemic stroke</description>
	<diseaseClass1>Circulatory System</diseaseClass1>
	<diseaseClass2>Ischemic stroke</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Stent-assisted angioplasty of the offending intracranial stenosis plus optimal medical therapy versus optimal medical therapy alone</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>true</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
        
      </outputs>
    <parties>
      <funderId>Funder13375-0</funderId>
      <contactId>Contact51001_13375</contactId>
      <sponsorId>Sponsor49392</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact51001_13375">
    <title>Dr</title>
    <forename>Wei-Jian</forename>
    <surname>Jiang</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>No. 6 Tiantan Xili</address>
      <city>Beijing</city>
      <country>China</country>
      <zip>100050</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+86 1067050137</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">cjr.jiangweijian@vip.163.com</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor49392">
    <organisation>The Ministry of Health of the People's Republic of China</organisation>
    <website/>
    <sponsorType>Government</sponsorType>
    <contactDetails>
      <address>No.1 The South Road Of Xizhimenwai</address>
      <city>Beijing</city>
      <country>China</country>
      <zip>100044</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">manluzhu@yahoo.com.cn</email>
    </contactDetails>
    <privacy>Public</privacy>
    <gridId>grid.419897.a</gridId>
    <rorId>https://ror.org/01mv9t934</rorId>
  </sponsor>
  <funder id="Funder13375-0">
    <name>The Ministry of Health of The People's Republic of China</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-10-04T00:00:00.000Z" version="24">
    <isrctn dateAssigned="2005-09-13T00:00:00.000Z">18282824</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Does vitamin D stop inpatients falling? A randomised controlled trial</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>Does routine vitamin D and/or calcium supplementation reduce falls in older inpatients?</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>1. Proportion of patients who fall
2. Total number of falls in the intervention and control groups</primaryOutcome>
      <secondaryOutcome>1. Compliance in both groups
2. Changes in functional outcomes
3. Changes in nutritional parameters
4. Vitamin D levels and change over time</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Not provided at time of registration</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN18282824</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>001</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Not Specified</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2004-09-07T00:00:00.000Z</overallStartDate>
      <overallEndDate>2005-12-01T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Scotland</country>
	<country>United Kingdom</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="aa2786ff-99c3-4ac0-8d49-290fd8cd7955">
	  <name>Department of Medicine for the Elderly</name>
	  <address/>
	  <city>Glasgow</city>
	  <state/>
	  <country>United Kingdom</country>
	  <zip>G51 4TF</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>All inpatients &gt;65 years old admitted to a Geriatric rehabilitation unit</inclusion>
      <ageRange>Senior</ageRange>
      <gender>Both</gender>
      <targetEnrolment>216</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>216</totalTarget>
      <exclusion>1. Bedbound or terminally ill
2. Known hypercalcaemia

3. Known urolithiasis
4. Renal failure on dialysis
5. ALready on routine calcium and vitamin D supplementation
6. Those patients who are nil by mouth for medical reasons.</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2004-09-07T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2005-12-01T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Falls, musculo-skeletal, nutrition</description>
	<diseaseClass1>Injury, Occupational Diseases, Poisoning</diseaseClass1>
	<diseaseClass2>Falls</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Treatment group: 800 IU cholecalciferol + 1200 mg calcium 
Control group: 1200 mg calcium only</description>
	<interventionType>Supplement</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>Vitamin D</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2007 Results article in https://pubmed.ncbi.nlm.nih.gov/17656420 Results</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="51167f19-5667-4f2f-afd6-692f8fdd8da1" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2007-09-01T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="https://pubmed.ncbi.nlm.nih.gov/17656420"/>
	<description>Results</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder13417-0</funderId>
      <contactId>Contact51058_13417</contactId>
      <sponsorId>Sponsor49453</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact51058_13417">
    <title>Dr</title>
    <forename>Elizabeth</forename>
    <surname>Burleigh</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Department of Medicine for the Elderly
Southern General Hospital</address>
      <city>Glasgow</city>
      <country>United Kingdom</country>
      <zip>G51 4TF</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+44 (0)141 201 1100</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">liz.burleigh@sgh.scot.nhs.uk</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor49453">
    <organisation>South Glasgow Division of Greater Glasgow Health Board (UK)</organisation>
    <website>http://www.nhsgg.org.uk</website>
    <sponsorType>Research organisation</sponsorType>
    <contactDetails>
      <address>Southern General Hospital
1345 Govan Road</address>
      <city>Glasgow</city>
      <country>United Kingdom</country>
      <zip>G51 4TF</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.413301.4</gridId>
    <rorId>https://ror.org/05kdz4d87</rorId>
  </sponsor>
  <funder id="Funder13417-0">
    <name>South Glasgow Division of Greater Glasgow Health Board (UK)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-11-01T00:00:00.000Z" version="23">
    <isrctn dateAssigned="2005-09-13T00:00:00.000Z">83261243</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>TREC2 - Rapid tranquillisation for agitated patients in emergency psychiatric rooms in Rio de Janeiro. A randomised trial of intramuscular Haloperidol versus intramuscular Haloperidol + Promethazine.</title>
      <scientificTitle/>
      <acronym>TREC - Rapid Tranquillisation Clinical Trial (Tranquilização Rápida-Ensaio Clínico)</acronym>
      <studyHypothesis>The trial was undertaken to test the risks and benefits of adding promethazine to haloperidol for rapid intramuscular tranquillisation.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Tranquil or asleep by 20 minutes after medication is given</primaryOutcome>
      <secondaryOutcome>1. Asleep by 20 minutes
2. Tranquil or asleep by 40, 60 and 120 minutes
3. Physically restrained or given additional medication within 2 hours
4. Severe adverse events during the subsequent 24 hours
5. Another episode of agitation/aggression during the subsequent 24 hours
6. Needing additional visits from the doctor during the subsequent 24 hours
7. Overall antipsychotic load in the first 24 hours
8. Still in hospital after 2 weeks</secondaryOutcome>
      <trialWebsite>http://www.fotolog.net/trec</trialWebsite>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Not provided at time of registration</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN83261243</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2004-01-06T00:00:00.000Z</overallStartDate>
      <overallEndDate>2004-07-01T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Brazil</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="2578e36d-7fbb-4a2c-9abb-704925f44967">
	  <name>INCQS-FIOCRUZ</name>
	  <address/>
	  <city>Rio de Janeiro</city>
	  <state/>
	  <country>Brazil</country>
	  <zip>21045-900</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>People are eligible for trial entry if:
1. It is clear that they need acute intramuscular sedation because of disturbed and dangerous behaviour thought to be due to serious mental illness
2. The clinician is uncertain about the benefits and risks of the comparator 
medications</inclusion>
      <ageRange>Not Specified</ageRange>
      <gender>Not Specified</gender>
      <targetEnrolment>600</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>600</totalTarget>
      <exclusion>People are not eligible for trial entry if the clinician believes that one treatment represents an additional risk for the patient</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2004-01-06T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2004-07-01T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Serious mental illnesses combined with overt aggression or violence</description>
	<diseaseClass1>Mental and Behavioural Disorders</diseaseClass1>
	<diseaseClass2>Aggression or violence</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>1. Haloperidol (up to 10 mg intramuscular [IM])
2. Haloperidol (up to 10 mg IM) with promethazine (up to 50 mg IM)
Doses are not fixed and are at the discretion of the attending doctors.</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>Promethazine, haloperidol</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2007 Results article in https://pubmed.ncbi.nlm.nih.gov/17954515 Results</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="4d5fe09e-5267-4c76-a8a0-e2c4287467d6" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2007-10-27T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="https://pubmed.ncbi.nlm.nih.gov/17954515"/>
	<description>Results</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder13445-0</funderId>
      <funderId>Funder13445-1</funderId>
      <contactId>Contact51091_13445</contactId>
      <sponsorId>Sponsor49489</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact51091_13445">
    <title>Dr</title>
    <forename>Gisele</forename>
    <surname>Huf</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>INCQS-FIOCRUZ
Av. Brasil 4365 Manguinhos
Cx. Postal: 926 </address>
      <city>Rio de Janeiro</city>
      <country>Brazil</country>
      <zip>21045-900</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+55 21 3865 5112</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">gisele@ensp.fiocruz.br</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor49489">
    <organisation>National School of Public Health (ENSP), Oswaldo Cruz Foundation (FIOCRUZ) (Brazil)</organisation>
    <website>http://www.ensp.fiocruz.br</website>
    <sponsorType>Charity</sponsorType>
    <contactDetails>
      <address>Rua Leopoldo Bulhões 4036/816 Manguinhos</address>
      <city>Rio de Janeiro</city>
      <country>Brazil</country>
      <zip>21041-210</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.418068.3</gridId>
    <rorId>https://ror.org/04jhswv08</rorId>
  </sponsor>
  <funder id="Funder13445-0">
    <name>The National Council for Research and Development (Consejo Nacional de Desarrollo Cientifico y Tecnologico [CNPq]) (Brazil)</name>
    <fundRef/>
  </funder>
  <funder id="Funder13445-1">
    <name>Regional Health Authorities (Brazil) - donated drugs</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-10-04T00:00:00.000Z" version="24">
    <isrctn dateAssigned="2005-07-08T00:00:00.000Z">56511757</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Prospective randomised trial of stented versus stentless bioprosthesis for aortic valve replacement (AVR)</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>To find out which prosthetic valves represent the better option for patients requiring AVR.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Post-operative pressure gradient across the prosthetic valve and effective valve orifice area.</primaryOutcome>
      <secondaryOutcome>No secondary outcome measures</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Not provided at time of registration</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN56511757</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>P00715</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2001-03-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2005-07-05T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>England</country>
	<country>United Kingdom</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="7251541a-a6b0-44cf-90e1-8d1569c30331">
	  <name>Surgical Unit</name>
	  <address/>
	  <city>Papworth Everard</city>
	  <state/>
	  <country>United Kingdom</country>
	  <zip>CB3 8RE</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>Inclusion criteria:
1. Patients who require elective AVR with a tissue valve for symptomatic aortic valve stenosis (peak valve gradient equal to or greater than 50 mmHg as measured by echocardiography), with or without concomitant artery bypass grafting
2. Patients = 65 years of age at the time of surgery</inclusion>
      <ageRange>Senior</ageRange>
      <gender>Both</gender>
      <targetEnrolment>240</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>240</totalTarget>
      <exclusion>1. Patients who are already enrolled in another major cardiovascular trial
2. AVR performed primarily for aortic valve regurgitation
3. Active aortic valve infection
4. Active malignant disease
5. Renal failure requiring dialysis
6. Any previous cardiac surgery
7. The need for additional cardiac procedures other than coronary artery bypass grafting
8. Emergency operations
9. Patients unable to give informed consent</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2001-03-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2005-07-05T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Aortic valve replacement</description>
	<diseaseClass1>Circulatory System</diseaseClass1>
	<diseaseClass2>Aortic valve replacement</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Prima Plus (Edwards Lifesciences) stentless bioprosthesis or the Carpentier-Edwards Perimount stented bioprosthesis (Edwards Lifesciences).</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2007 Results article in https://pubmed.ncbi.nlm.nih.gov/17532416/ Results</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="2f7aaa76-cb37-4b0a-81d6-db8bf41619da" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2007-06-01T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="https://pubmed.ncbi.nlm.nih.gov/17532416/"/>
	<description>Results</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder13081-0</funderId>
      <contactId>Contact50617_13081</contactId>
      <sponsorId>Sponsor49000</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact50617_13081">
    <title>Mr</title>
    <forename>Steven</forename>
    <surname>Tsui</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Surgical Unit
Papworth Hospital NHS Trust</address>
      <city>Papworth Everard</city>
      <country>United Kingdom</country>
      <zip>CB3 8RE</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
  </contact>
  <sponsor id="Sponsor49000">
    <organisation>Papworth Hospital NHS Trust (UK)</organisation>
    <website/>
    <sponsorType>Hospital/treatment centre</sponsorType>
    <contactDetails>
      <address>Surgical Unit</address>
      <city>Papworth Everard</city>
      <state>England</state>
      <country>United Kingdom</country>
      <zip>CB3 8RE</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.412939.4</gridId>
    <rorId>https://ror.org/01qbebb31</rorId>
  </sponsor>
  <funder id="Funder13081-0">
    <name>Edwards LifeSciences Ltd (UK) - Industrial grant</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-11-12T00:00:00.000Z" version="23">
    <isrctn dateAssigned="2005-07-05T00:00:00.000Z">94451985</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>The use of perioperative n-acetylcysteine to prevent renal dysfunction in high-risk patients undergoing coronary artery bypass graft surgery with cardiopulmonary bypass</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>To determine whether perioperative intravenous (IV) N-acetylcysteine preserves renal function in high-risk patients undergoing Coronary Artery Bypass Graft (CABG) surgery with Cardiopulmonary Bypass (CPB) compared with placebo.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>The primary outcome was the proportion of patients developing postoperative renal dysfunction, defined by an increase in serum creatinine level greater than 0.5 mg/dL (44 micromol/L) or a 25% increase from baseline within the first 5 postoperative days.</primaryOutcome>
      <secondaryOutcome>Secondary outcomes included postoperative interventions and complications, the requirement for renal replacement therapy (RRT), adverse events, hospital mortality, and ICU and hospital length of stay.</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Not provided at time of registration</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN94451985</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Prevention</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2003-10-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2004-09-01T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Canada</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="be571e97-0ba4-44a0-b1ac-ef71156e39f1">
	  <name>375 South Street</name>
	  <address/>
	  <city>London</city>
	  <state/>
	  <country>Canada</country>
	  <zip>N6A 4G5</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>Elective or urgent coronary artery bypass graft surgery patients with at least one of: pre-esisting renal dysfunction, age greater than or equal to 70, diabetes mellitus, impaired left ventricular function or undergoing concomitant valve or redo surgery.</inclusion>
      <ageRange>Senior</ageRange>
      <gender>Both</gender>
      <targetEnrolment>295</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>295</totalTarget>
      <exclusion>Not provided at time of registration</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2003-10-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2004-09-01T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Coronary artery bypass graft surgery</description>
	<diseaseClass1>Circulatory System</diseaseClass1>
	<diseaseClass2>Coronary artery bypass graft surgery</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>We randomized patients to receive four (two intraoperative and two postoperative) doses of intravenous N-acetylcysteine 600 mg or placebo over a 24-hour period.</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>Intravenous N-acetylcysteine</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2005 Results article in http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16030279&amp;query_hl=7&amp;itool=pubmed_DocSum Results</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="26a786fa-fbe4-4e5e-abc7-4cd867fa973c" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2005-07-20T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16030279&amp;query_hl=7&amp;itool=pubmed_DocSum"/>
	<description>Results</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder13067-0</funderId>
      <funderId>Funder13067-1</funderId>
      <contactId>Contact50600_13067</contactId>
      <sponsorId>Sponsor48983</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact50600_13067">
    <title>Dr</title>
    <forename>Karen</forename>
    <surname>Burns</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>375 South Street</address>
      <city>London</city>
      <country>Canada</country>
      <zip>N6A 4G5</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
  </contact>
  <sponsor id="Sponsor48983">
    <organisation>The Physician Services Incorporated Foundation (Canada)</organisation>
    <website/>
    <sponsorType>Charity</sponsorType>
    <contactDetails>
      <address>5160 Yonge Street, Suite 1006</address>
      <city>Toronto</city>
      <country>Canada</country>
      <zip>M2N 6L9</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.453633.4</gridId>
    <rorId>https://ror.org/0385yzn06</rorId>
  </sponsor>
  <funder id="Funder13067-0">
    <name>The Physician Services Incorporated Foundation (Canada)</name>
    <fundRef/>
  </funder>
  <funder id="Funder13067-1">
    <name>The Lawson Health Research Institute Internal Research Fund (Canada)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-10-22T00:00:00.000Z" version="21">
    <isrctn dateAssigned="2005-06-07T00:00:00.000Z">48295733</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Safety of rectal artesunate in pregnancy - an assessment of pregnancy outcomes in a randomised controlled trial in Bangladesh</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>Evaluation of the risks associated with the use of artesunate in pregnancy in comparison to placebo. 

This study follows up pregnant women exposed to treatment within a larger trial: ISRCTN83979018 - Evaluate impact of rectal artesunate on resolution of severe malaria and mortality (Bangladesh).</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>As this study is a sub-study within a larger trial that has mortality as the main outcome, this should be considered as the same outcome for this trial.</primaryOutcome>
      <secondaryOutcome>1. Proportion of anomalies in live-born, proportion of stillborn and late foetal deaths (artesunate versus placebo)
2. Determination of effect on foetal viability in second and third trimester and inadvertent  exposures in first trimester (artesunate and placebo)
3. Determination of neonatal and maternal mortality (artesunate versus placebo)
4. Assessment of developmental delays (artesunate versus placebo)
5. Determination of proportion of children with low birth weight (artesunate versus placebo) in the subgroup of patients assessed prospectively</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Ethics approval was obtained on 10.11.03 from the Secretariat Committee on Research Involving Human Subjects and (continuing review) on 19.10 2005 from the World Health Organization (WHO) Ethics Committee.</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN48295733</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>A30248</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2003-11-10T00:00:00.000Z</overallStartDate>
      <overallEndDate>2006-01-01T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Bangladesh</country>
	<country>Switzerland</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="8ea07507-7b9d-4a50-ab8d-f2b9339a9e7d">
	  <name>20, Avenue Appia</name>
	  <address/>
	  <city>Geneva -27</city>
	  <state/>
	  <country>Switzerland</country>
	  <zip>CH 1211</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Pregnant women
2. Consent of patient or parent/guardian
3. Participation in survival benefit of early treatment with rectal artesunate</inclusion>
      <ageRange>Adult</ageRange>
      <gender>Female</gender>
      <targetEnrolment>684</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>684</totalTarget>
      <exclusion>1. Males
2. Non pregnant female enrolled into study ISRCTN83979018
3. Absence of informed consent from patient or parent/guardian</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2003-11-10T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2006-01-01T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Artesunate use in pregnancy</description>
	<diseaseClass1>Infections and Infestations</diseaseClass1>
	<diseaseClass2>Malaria</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>A single dose of either 400 mg artesunate suppository or an identical placebo suppository is given.</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>Artesunate</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
        
      </outputs>
    <parties>
      <funderId>Funder12977-0</funderId>
      <funderId>Funder12977-1</funderId>
      <funderId>Funder12977-2</funderId>
      <funderId>Funder12977-3</funderId>
      <funderId>Funder12977-4</funderId>
      <funderId>Funder12977-5</funderId>
      <funderId>Funder12977-6</funderId>
      <funderId>Funder12977-7</funderId>
      <contactId>Contact50500_12977</contactId>
      <sponsorId>Sponsor48878</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact50500_12977">
    <title>Dr</title>
    <forename>Melba</forename>
    <surname>Gomes</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>20, Avenue Appia</address>
      <city>Geneva -27</city>
      <country>Switzerland</country>
      <zip>CH 1211</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">gomesm@who.int</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor48878">
    <organisation>UNICEF/UNDP/World Bank/WHO Special Programme for Research and Training in Tropical Diseases (TDR) </organisation>
    <website>http://www.who.int</website>
    <sponsorType>Research organisation</sponsorType>
    <contactDetails>
      <address>20, Avenue Appia</address>
      <city>Geneva -27</city>
      <country>Switzerland</country>
      <zip>CH 1211</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.3575.4</gridId>
    <rorId>https://ror.org/01f80g185</rorId>
  </sponsor>
  <funder id="Funder12977-0">
    <name>United Nations Children's Fund (UNICEF)/United Nations Development Programme (UNDP)/World Bank/World Health Organization (WHO) - Special Programme for Research and Training in Tropical Diseases (TDR)</name>
    <fundRef/>
  </funder>
  <funder id="Funder12977-1">
    <name>European Commission (Belgium)</name>
    <fundRef>http://dx.doi.org/10.13039/501100000780</fundRef>
  </funder>
  <funder id="Funder12977-2">
    <name>WHO Global Malaria Programme</name>
    <fundRef/>
  </funder>
  <funder id="Funder12977-3">
    <name>US Agency for International Development (USAID) (USA)</name>
    <fundRef/>
  </funder>
  <funder id="Funder12977-4">
    <name>Irish Aid (Ireland)</name>
    <fundRef/>
  </funder>
  <funder id="Funder12977-5">
    <name>Karolinska Institutet (Sweden)</name>
    <fundRef>http://dx.doi.org/10.13039/501100004047</fundRef>
  </funder>
  <funder id="Funder12977-6">
    <name>Sall Family Foundation (USA)</name>
    <fundRef>http://dx.doi.org/10.13039/100007098</fundRef>
  </funder>
  <funder id="Funder12977-7">
    <name>University of Oxford Clinical Trial Service Unit (UK)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-11-09T00:00:00.000Z" version="26">
    <isrctn dateAssigned="2005-04-05T00:00:00.000Z">46147225</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Phase III, double-blind, randomised, placebo-controlled trial to evaluate efficacy against radiological pneumonia and invasive pneumococcal disease in Gambian infants</title>
      <scientificTitle/>
      <acronym>PVT</acronym>
      <studyHypothesis>To assess the efficacy of a nine-valent pneumococcal conjugate vaccine in children.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>First episode of radiological pneumonia</primaryOutcome>
      <secondaryOutcome>1. Clinical or severe clinical pneumonia
2. Invasive pneumococcal disease
3. All-cause admissions</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Not provided at time of registration</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN46147225</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>RPC096</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Phase III, double-blind, randomised, placebo-controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Not Specified</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2000-08-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2004-01-01T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Gambia</country>
	<country>Switzerland</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="c6ef39be-1461-4359-98eb-1a847a24eb26">
	  <name>20, Avenue Appia</name>
	  <address/>
	  <city>Geneva-27</city>
	  <state/>
	  <country>Switzerland</country>
	  <zip>CH 1211</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Infants aged at least 6 weeks and less than one year
2. Resident in study area
3. Written informed consent obtained from mother</inclusion>
      <ageRange>Child</ageRange>
      <lowerAgeLimit unit="Weeks" value="6.0"/>
      <upperAgeLimit unit="Years" value="1.0"/>
      <gender>Both</gender>
      <targetEnrolment>17500</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>Approx. 17500</totalTarget>
      <exclusion>1. Aged less than 6 weeks or more than 1 year
2. Not resident in study area
3. Planning to move out of study area within 4 months
4. Previous receipt of Diphtheria, Pertussis, Tetanus (DPT)-Haemophilus influenzae type b (Hib) vaccine
5. Uncertain prior vaccination record
6. Serious chronic illness
7. Inclusion in previous vaccine trial
8. Failure of family to give consent</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2000-08-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2004-01-01T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Pneumococcus/vaccines</description>
	<diseaseClass1>Infections and Infestations</diseaseClass1>
	<diseaseClass2>Vaccination</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Treatment group:
Nine-valent pneumococcal/polysaccharide protein conjugate vaccine which contains 2 µg of type 1, 4, 5, 9V, 14, 19F, 23F polysaccharides, 4 µg of type 6B polysaccharide and 2 µg of type 18 oligosaccharide linked to the diphtheria toxoid protein CRM197, reconstituted with DPT-Hib (Tetramune™) from the same manufacturer

Placebo group:
Lyophilised placebo cake reconstituted with Tetramune™</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Phase III</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2005 Results article in https://pubmed.ncbi.nlm.nih.gov/15794968 Results</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="dbfa319c-6053-4e08-90e4-135c801573e3" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2005-03-01T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="https://pubmed.ncbi.nlm.nih.gov/15794968"/>
	<description>Results</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder12796-0</funderId>
      <funderId>Funder12796-1</funderId>
      <funderId>Funder12796-2</funderId>
      <funderId>Funder12796-3</funderId>
      <funderId>Funder12796-4</funderId>
      <contactId>Contact50264_12796</contactId>
      <sponsorId>Sponsor48635</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact50264_12796">
    <title>Dr</title>
    <forename>Felicity</forename>
    <surname>Cutts</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>20, Avenue Appia</address>
      <city>Geneva-27</city>
      <country>Switzerland</country>
      <zip>CH 1211</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">cuttsf@who.int</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor48635">
    <organisation>National Institute of Allergy and Infectious Diseases - Division of Microbiology and Infectious Diseases (USA)</organisation>
    <website/>
    <sponsorType>Government</sponsorType>
    <contactDetails>
      <address>6610 Rockledge Drive, Rm 6037</address>
      <city>Bethesda</city>
      <country>United States of America</country>
      <zip>20892</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+1 3014022126</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">ehorigan@niaid.nih.gov</email>
    </contactDetails>
    <privacy>Public</privacy>
    <gridId>grid.419681.3</gridId>
    <rorId>https://ror.org/043z4tv69</rorId>
  </sponsor>
  <funder id="Funder12796-0">
    <name>National Institutes of Health (NIH) (USA)</name>
    <fundRef>http://dx.doi.org/10.13039/100000002</fundRef>
  </funder>
  <funder id="Funder12796-1">
    <name>World Health Organization (WHO)/Department of Immunisation, Vaccines and Biologicals (IVB) (Switzerland)</name>
    <fundRef/>
  </funder>
  <funder id="Funder12796-2">
    <name>Bill and Melinda Gates Foundation (USA)</name>
    <fundRef>http://dx.doi.org/10.13039/100000865</fundRef>
  </funder>
  <funder id="Funder12796-3">
    <name>United States Agency for International Development (USAID) (USA)</name>
    <fundRef>http://dx.doi.org/10.13039/100000200</fundRef>
  </funder>
  <funder id="Funder12796-4">
    <name>Medical Research Council (UK)</name>
    <fundRef>http://dx.doi.org/10.13039/501100000265</fundRef>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-10-04T00:00:00.000Z" version="20">
    <isrctn dateAssigned="2005-04-04T00:00:00.000Z">57684245</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>A randomised comparison of out patient psychodynamic versus cognitive behavioural group psychotherapy in patients with somatoform pain</title>
      <scientificTitle/>
      <acronym>MASOPA</acronym>
      <studyHypothesis>Somatoform disorder with pain as a leading complaint (International Statistical Classification of Diseases and Related Health Problems - tenth revision [ICD10]: F45).

The study was designed to compare efficacy of psychodynamic and cognitive behavioural group psychotherapy in patients with somatoform pain. Therefore, a total of 150 patients are randomised to one of either therapies. Both therapies are manualized and supervisioned by video.  Patients living more than one hour driving distance to the university hospital who cannot take part in out patient therapy serve as controls by receiving care as usual.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Pain intensity and pain disability.  Due to the chronic condition, a one year follow-up will service as the primary outcome.</primaryOutcome>
      <secondaryOutcome>Pain intensity and pain disability.</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Not provided at time of registration</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN57684245</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>1</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2000-01-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2005-11-30T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Germany</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="373c3d3e-75f5-4381-890f-c62d50ea997d">
	  <name>Untere zahlbacher 8</name>
	  <address/>
	  <city>Mainz</city>
	  <state/>
	  <country>Germany</country>
	  <zip>D-55131</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>Patients were included if they had persistent pain (&gt;6 months) without an adequate physical explanation after a broad multidisciplinary check and if they could understand German.

Patients were referred by their general practitioners or specialists in or outside the university hospital. A total of 150 patients will be randomised to one of either therapies, patients living more than one hour driving distance to the university hospital cannot take part in out patient therapy and will serve as controls by receiving treatment as usual (n = 70). Due to the chronic condition, a one year follow-up will serve as primary outcome. A two year follow-up is intended.</inclusion>
      <ageRange>Adult</ageRange>
      <gender>Not Specified</gender>
      <targetEnrolment>150</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>150</totalTarget>
      <exclusion>Age &lt;18 or &gt;65, psychosis, severe substance dependency, missing understanding of German language, and a request to retire because of disease.</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2000-01-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2005-11-30T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Somatoform pain</description>
	<diseaseClass1>Mental and Behavioural Disorders</diseaseClass1>
	<diseaseClass2>Somatoform pain</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Patients receive out patient psychotherapy for 6 months. They were randomised into psychodynamic versus cognitive behavioural therapy. Therapy was manualized. Sessions took place twice a week and once a week respectively. The total amount of therapy was 3600 minutes in psychodynamic and 2750-3000 minutes cognitive behavioural therapy. Groups consist of 8-10 patients starting therapy together, they were closed for further participants.</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
        
      </outputs>
    <parties>
      <funderId>Funder12881-0</funderId>
      <contactId>Contact50387_12881</contactId>
      <sponsorId>Sponsor48756</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact50387_12881">
    <title>Dr</title>
    <forename>Ulrich T</forename>
    <surname>Egle</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Untere zahlbacher 8</address>
      <city>Mainz</city>
      <country>Germany</country>
      <zip>D-55131</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+49 (0)6131 177381</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">egle@psychosomatik.klinik.uni-mainz.de</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor48756">
    <organisation>German Research Foundation (Deutsche Forschungsgemeinschaft)</organisation>
    <website/>
    <sponsorType>Research organisation</sponsorType>
    <contactDetails>
      <address>Kennedyallee 40</address>
      <city>Bonn</city>
      <country>Germany</country>
      <zip>D53175</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+49 (0)228 8851</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">postmaster@dfg.de</email>
    </contactDetails>
    <privacy>Public</privacy>
    <gridId>grid.424150.6</gridId>
    <rorId>https://ror.org/018mejw64</rorId>
  </sponsor>
  <funder id="Funder12881-0">
    <name>German Research Foundation (Deutsche Forschungsgemeinschaft)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-10-17T00:00:00.000Z" version="22">
    <isrctn dateAssigned="2005-02-10T00:00:00.000Z">73387335</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Zinc supplementation during acute childhood diarrhoea: a cluster randomised trial in rural Pakistan</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>The hypothesis being tested is that distribution of zinc through existing government and private health care system will reduce incidence of childhood diarrhoea, and antibiotic use by at least 30%. 

The objectives of this trial are:
1. To evaluate if the administration of zinc supplement for 14 days to children with acute diarrhoea will lead to:
1.1. Reduction in use of Oral Rehydration Sachets (ORS) in the community, and 
1.2. Reduction in use of antibiotics and anti-diarrhoeal medications at the community level
2. To document the acceptance of the treatment as well as the adherence to the treatment instructions
3. Reduction in the severity of diarrhoea and improved recovery rates
4. Reduction in rates of hospitalisation and need for intravenous rehydration
5. Reduced child mortality due to diarrhoea</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>1. ORS use rate
2. Antibiotic use rate
3. Overall drug use rate for diarrhoea
4. Incidence/prevalence of diarrhoea
5. Duration of diarrhoea/episodes in days
6. Duration of  use of ORS, antibiotics and zinc
7. Prevalence /incidence of vomiting
8. Hospitalisation rate for diarrhoea
9. Hospitalisation rate for all causes
10. Total expenditure per household and per episode of diarrhoea</primaryOutcome>
      <secondaryOutcome>No secondary outcome measures</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Ethics approval received from the World Health Organization (WHO) Ethical Review Committee on the 26th January 2006.</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN73387335</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>WHO/HNI04006</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2005-01-26T00:00:00.000Z</overallStartDate>
      <overallEndDate>2007-01-26T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Pakistan</country>
	<country>Switzerland</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="33d76bcb-f97c-448c-ba2d-8a9f8e22eeb8">
	  <name>World Health Organization</name>
	  <address/>
	  <city>Geneva-27</city>
	  <state/>
	  <country>Switzerland</country>
	  <zip>CH 1211</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Children with diarrhoea from 6 to 59 months and 2 to 6 months presenting to any health care facility including both public and private
2. Informed consent</inclusion>
      <ageRange>Child</ageRange>
      <lowerAgeLimit unit="Months" value="2.0"/>
      <upperAgeLimit unit="Months" value="59.0"/>
      <gender>Both</gender>
      <targetEnrolment>5000</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>5000 children (2500 per group)</totalTarget>
      <exclusion>1. Chronic and recurrent diarrhoea
2. Children less then 2 months or above 5 years</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2005-01-26T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2007-01-26T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Childhood diarrhoea</description>
	<diseaseClass1>Infections and Infestations</diseaseClass1>
	<diseaseClass2>Non-chronic diarrhoea</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Administration of 10 to 20 mg elemental zinc daily through oral rehydration versus the existing program of oral rehydration alone in management of acute diarrhoea for 14 days. No placebo is being used in the control clusters.</description>
	<interventionType>Supplement</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>Zinc supplementation</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
        
      </outputs>
    <parties>
      <funderId>Funder12885-0</funderId>
      <contactId>Contact50391_12885</contactId>
      <sponsorId>Sponsor48760</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact50391_12885">
    <title>Dr</title>
    <forename>Olivier</forename>
    <surname>Fontaine</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>World Health Organization
20, Avenue Appia</address>
      <city>Geneva-27</city>
      <country>Switzerland</country>
      <zip>CH 1211</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+41 22 791 2894</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">fontaineo@who.int</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor48760">
    <organisation>The Department of Child and Adolescent Health (CAH)/World Health Organization (WHO) (Switzerland) </organisation>
    <website>http://www.who.int</website>
    <sponsorType>Research organisation</sponsorType>
    <contactDetails>
      <address>20, Avenue Appia</address>
      <city>Geneva-27</city>
      <country>Switzerland</country>
      <zip>CH 1211</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.3575.4</gridId>
    <rorId>https://ror.org/01f80g185</rorId>
  </sponsor>
  <funder id="Funder12885-0">
    <name>The Department of Child and Adolescent Health (CAH)/World Health Organization (WHO) (Switzerland)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-10-18T00:00:00.000Z" version="21">
    <isrctn dateAssigned="2005-02-04T00:00:00.000Z">72335887</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>A Randomized Trial Comparing Same Day Discharge and a Single Bolus of Abciximab to Overnight Hospitalization and Bolus + Perfusion Abciximab After Uncomplicated Trans-Radial Coronary Artery Stenting</title>
      <scientificTitle/>
      <acronym>EArly discharge after trans-radial Stenting of coronarY arteries: The EASY study</acronym>
      <studyHypothesis>1. Discharge on the same day after uncomplicated trans-radial coronary artery stenting is safe and effective. 
2. Hospitalized patients can be safely returned to the referring center the same day following trans-radial coronary artery stenting. 
3. Abciximab given as a single bolus with optimal trans-radial coronary artery stenting is as safe and effective as bolus + 12 hrs perfusion and does not hamper early discharge. 
4. Same-day discharge is cost-effective and increases patient satisfaction.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>The primary end-point of the study is the composite of death, myocardial infarction, repeat hospitalization, urgent revascularization, severe thrombocytopenia, access site complications and major bleedings at 30 days following stent implantation.</primaryOutcome>
      <secondaryOutcome>The secondary end-point is the composite of death, myocardial infarction, repeat target vessel revascularization at 30 days, 6 months and 1 year following stent implantation. Other secondary end-points include the total hospital stay (days) between the index procedure and the first 30 days follow-up, the number of unsolicited medical visits in relation with the percutaneous procedure, index of patient satisfaction and direct and indirect costs.</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Not provided at time of registration</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN72335887</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber>NCT00169819</clinicalTrialsGovNumber>
      <protocolSerialNumber>H4S-CA-0050</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Single-centre</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2003-10-15T00:00:00.000Z</overallStartDate>
      <overallEndDate>2005-04-29T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Canada</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="bbb7ded2-8284-4cd1-a6b6-63bae0b2abeb">
	  <name>2725 Chemin Ste Foy</name>
	  <address/>
	  <city>Quebec</city>
	  <state/>
	  <country>Canada</country>
	  <zip>G1V 4G5</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>Approximately 1000 patients undergoing 'adhoc' percutaneous coronary intervention (PCI) will be randomized.

Inclusion Criteria:
1. Patients with documented ischemic coronary artery disease and scheduled for possible coronary artery stenting are eligible. 
2. Patient must be &gt;18 years of age. 
3. Patient and treating interventional cardiologist agree for randomization. 
4. Patient will be informed of the randomization process and will sign an informed consent. 
5. Diagnostic and therapeutic intervention performed through trans-radial/ulnar artery approach.</inclusion>
      <ageRange>Adult</ageRange>
      <lowerAgeLimit unit="Years" value="18.0"/>
      <gender>Both</gender>
      <targetEnrolment>1000</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>1000</totalTarget>
      <exclusion>CLINICAL:
1. Patients with recent (&lt;72 hrs) Q-wave (ST elevation) acute myocardial infarction
2. History of LV ejection fraction ≤30%
3. Unstable clinical condition 
4. Any complication compromising ambulation 
5. Concurrent participation in other investigational study requiring prolonged hospitalization 
6. Required prolonged hospitalization 
7. In&#150;cath lab transient vessel closure 
8. Resuscitation per PCI 
9. Hemodynamic collapse during PCI 
10. Severe entry site complication upon investigator decision 
11. Social isolation 
12. Serious cognitive disorders 
13. Femoral sheath (artery) 
14. Persisting chest pain 
15. No ASA prior PCI 
16. Allergy to ASA or thienopyridines precluding treatment for 30 days 
17. Any significant blood dyscrasia 
18. PCI without stent implantation (except for bifurcation lesion or re-dilatation for in-stent restenosis) 
19. International Normalised Ratio (INR) &gt;2.0 
20. Contraindication to Reopro administration 

ANGIOGRAPHIC:
1. Residual dissection of grade ≥B of NHBLI classification
2. Compromised or sub-occluded branch with diameter ≥ 1 mm 
3. Timi &lt;3 post-stenting 
4. Thrombus post-PCI</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2003-10-15T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2005-04-29T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Angina</description>
	<diseaseClass1>Circulatory System</diseaseClass1>
	<diseaseClass2>Angina</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Patients with stable or unstable angina referred for catheterization and possible percutaneous intervention are eligible.

After diagnostic trans-radial catheterization, patients receive a bolus of Abciximab and undergo dilatation and stent implantation. At the end of the uncomplicated procedure, patients are randomized between group 1: No perfusion of Abciximab and discharge 4-6 hours after PCI and group 2: Standard 12 hours Abciximab perfusion and overnight hospitalization. In case of complications, patients are included in a registry and receive standard 12 hours Abciximab perfusion. Electrocardiogram (ECG) and biology tests (creatine kinase [CK] CK-myocardial band [CK-MB], troponins) are performed before, 4-6 hours after and the next day after PCI. Clinical follow-up is performed at 24 hours, 30 days, 6 months and 1 year after PCI.</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>Abciximab</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2006 Results article in https://pubmed.ncbi.nlm.nih.gov/17145988 Results</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>true</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="8fccedc4-86f9-4240-999d-aa15032df1b0" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2006-12-12T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="https://pubmed.ncbi.nlm.nih.gov/17145988"/>
	<description>Results</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder12839-0</funderId>
      <contactId>Contact50319_12839</contactId>
      <sponsorId>Sponsor48690</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact50319_12839">
    <title>Dr</title>
    <forename>Olivier</forename>
    <surname>Bertrand</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>2725 Chemin Ste Foy</address>
      <city>Quebec</city>
      <country>Canada</country>
      <zip>G1V 4G5</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+1 418 656 8711 ext 3136</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">olivier.bertrand@crhl.ulaval.ca</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor48690">
    <organisation>Laval Hospital Research Center (Canada)</organisation>
    <website/>
    <sponsorType>Hospital/treatment centre</sponsorType>
    <contactDetails>
      <address>2725 Chemin Ste Foy</address>
      <city>Quebec</city>
      <country>Canada</country>
      <zip>G1V 4G5</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+1 418 656 8711</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">olivier.bertrand@crhl.ulaval.ca</email>
    </contactDetails>
    <privacy>Public</privacy>
  </sponsor>
  <funder id="Funder12839-0">
    <name>This Study is an Investigator Initiated Trial, which is supported by unrestricted grants from Eli-Lilly and Bristol-Myers-Squibb (Canada)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-10-26T00:00:00.000Z" version="21">
    <isrctn dateAssigned="2004-11-24T00:00:00.000Z">97670178</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Prevention of vitamin A deficiency by supplementation alongside routine vaccinations: a randomised controlled trial in Ghana infants</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>The primary objectives of the proposed trial are to:
1. Measure the effect of 400,000 IU of vitamin A given in two divided doses of 200,000 IU to mothers, and 3 doses of 50,000 IU of vitamin A given to their infants concurrently with Diphtheria, Pertussis and Tetanus (DPT)/Polio immunisations, on vitamin A status of the infants at 26 weeks of age
2. Compare the effect of such a regimen to that of the previously recommended regimen of 200,000 IU of vitamin A given to mothers and 3 doses of 25,000 IU of vitamin A given to their infants concurrently with DPT/Polio immunisations
3. Measure the side effects of 50,000 IU of vitamin A administered with DPT/Polio immunisations

The outcomes to be monitored for the above objectives include serum retinol levels, modified Retinol Dose Response (mRDR) tests, incidence of side effects such as bulging of the anterior fontanel and vomiting, and incidence of severe morbidity.

The secondary objectives are to:
4. Measure the effect of the maternal dose on breast milk retinol levels up to 9 months post partum
5. Examine if any impacts on infant vitamin A status are sustained beyond 6 months of age up to 9 months of age

Outcomes to be monitored for the secondary objectives include breast milk retinol concentrations and mRDR testing of infants at 9 months of age.

Related to the main objectives, the following hypotheses will be tested:
1. Giving 400,000 IU of vitamin A to mothers within 6 weeks of delivery, plus 50,000 IU given to their infants with their DPT/Polio immunisations, will improve infants' vitamin A status as measured by mean serum retinol, or by proportions below 20 ug/dl, or proportions of abnormal mRDR at 6 months of age. The proportion of infants with serum retinol concentration below 20 ug/dl will be reduced by 66% from 43%, which was achieved by the 25,000 IU-dosing regimen. Similarly, the proportion of infants with mRDR ratio greater than or equal to 0.06 will be reduced by 66% from 44%, which was achieved by 25,000 IU-dosing regimen.
2. Giving 50,000 IU of vitamin to infants with their DPT/Polio immunisations will produce no clinically significant side effects

The following additional hypotheses will be tested for the secondary objectives:
3. Giving 400,000 IU of vitamin to mothers in the post partum period will result in a greater improvement in breast milk retinol levels than that achieved with 200,000 IU, and that this improvement will be sustained up to 9 months
4. The improvement to infant vitamin A status at 6 months of age, due to the newly proposed supplementation regime, will be sustained beyond 6 months up to 9 months of age</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>1. Serum retinol levels, assessed by carrying out mRDR testing of infants at 6 weeks, 6 months and 9 months
2. Modified Retinol Dose Response (mRDR) tests
3. Incidence of side effects such as bulging of the anterior fontanel and vomiting
4. Incidence of severe morbidity</primaryOutcome>
      <secondaryOutcome>1. Breast milk retinol concentrations, assessed at 6 weeks, 6 months and 9 months for an assessment of the impact of the different supplementation regimes
2. mRDR testing of infants at 9 months of age</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Ethics approval received from:
1. Ethical Review Committee of the Ministry of Health (Ghana) on the 24th September 2001
2. London School of Hygiene and Tropical Medicine Ethics Committee on the 29th April 2002</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN97670178</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Prevention</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2004-01-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2006-01-01T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Ghana</country>
	<country>Switzerland</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="f41a5075-0fec-48a5-90b2-377d54cb44b7">
	  <name>World Health Organization</name>
	  <address/>
	  <city>Geneva-27</city>
	  <state/>
	  <country>Switzerland</country>
	  <zip>CH-1211</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Mothers normally resident in the study area
2. Informed consent obtained from the mother</inclusion>
      <ageRange>Not Specified</ageRange>
      <gender>Both</gender>
      <targetEnrolment>1400</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>1,400 mother-infant pairs.</totalTarget>
      <exclusion>1. Mothers unable to give informed consent
2. Mothers considered to be at high risk of adverse outcome in puerperal period
3. Multiple deliveries
4. Severe adverse reaction to vitamin A supplementation</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2004-01-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2006-01-01T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Vitamin A Deficiency</description>
	<diseaseClass1>Nutritional, Metabolic, Endocrine</diseaseClass1>
	<diseaseClass2>Nutritional deficiency</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>1st Group: 
1. Mothers 200,000 IU Vitamin A shortly after delivery
2. Infants: 25,000 IU Vitamin A with each Diphtheria, Pertussis, Tetanus (DPT) vaccine 1, 2 and 3

2nd Group: 
1. Mothers 200,000 IU Vitamin A at infant's Bacillus Calmette-Guerin (BCG) vaccine and another 200,000 IU Vitamin A at infant's 1st DPT
2. Infants: 50,000 IU Vitamin A with each DPT 1, 2 and 3</description>
	<interventionType>Supplement</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>Vitamin A supplementation</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
        
      </outputs>
    <parties>
      <funderId>Funder12807-0</funderId>
      <contactId>Contact50278_12807</contactId>
      <sponsorId>Sponsor48649</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact50278_12807">
    <title>Dr</title>
    <forename>Tracey</forename>
    <surname>Goodman</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>World Health Organization
20, Avenue Appia </address>
      <city>Geneva-27</city>
      <country>Switzerland</country>
      <zip>CH-1211</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">goodmant@who.int</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor48649">
    <organisation>World Health Organization (WHO)/Department of Immunisation, Vaccines and Biologicals (IVB) (Switzerland) </organisation>
    <website>http://www.who.int</website>
    <sponsorType>Research organisation</sponsorType>
    <contactDetails>
      <address>20, Avenue Appia</address>
      <city>Geneva-27</city>
      <country>Switzerland</country>
      <zip>CH-1211</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.3575.4</gridId>
    <rorId>https://ror.org/01f80g185</rorId>
  </sponsor>
  <funder id="Funder12807-0">
    <name>World Health Organization (WHO)/Department of Immunisation, Vaccines and Biologicals (IVB) (Switzerland)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-11-13T00:00:00.000Z" version="23">
    <isrctn dateAssigned="2004-09-22T00:00:00.000Z">99307171</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Comparing Warfarin to Aspirin after tissue valve replacement with Epic prosthesis in the aortic position: multicenter randomised trial</title>
      <scientificTitle/>
      <acronym>WoA Epic</acronym>
      <studyHypothesis>Patients with prosthetic heart valves have a higher risk of developing valve thrombosis and arterial thromboembolism. However, antithrombotic therapy in the early postoperative period after Biological Aortic Valve Replacement (BAVR) is still controversial. Many regimens have been described. Thus, the aim of this study will be to compare the validity of two different regimens of therapy in the early postoperative period after BAVR with St Jude Epic prosthesis, and to evaluate the benefits, particularly in terms of survival and cerebral protection from thromboembolism and major bleeding.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Not provided at time of registration</primaryOutcome>
      <secondaryOutcome>Not provided at time of registration</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Not provided at time of registration</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN99307171</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2001-01-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2002-12-01T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Italy</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="74fee8c1-5a74-486b-bc43-75315adc2071">
	  <name>Via Gramsci 13</name>
	  <address/>
	  <city>Parma</city>
	  <state/>
	  <country>Italy</country>
	  <zip>43100</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>This is a prospective randomised multicenter trial using patients who will be consecutively admitted to Cardiac Surgery Units. All patients undergoing Biological Aortic Valve Replacement (BAVR) with a St Jude Epic prosthesis and in sinus rhythm before the operation will be considered to participate to the study. The patients, after the operation, will be randomised to each group immediately before starting the specific aspirin (Acetylsalicylic Acid [ASA]) or warfarin therapy.</inclusion>
      <ageRange>Not Specified</ageRange>
      <gender>Not Specified</gender>
      <targetEnrolment>0</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>Not provided at time of registration</totalTarget>
      <exclusion>The patients with the following characteristics will be excluded: 
1. History of cerebral ischaemia
2. Coagulopathy
3. Carotid atherosclerotic disease (stenosis greater than 50%, soft and ulcerated plaque)
4. Peripheral vascular disease
5. Concomitant mitral valve disease
6. Double valve replacement
7. Previous chronic anticoagulation therapy
8. Allergies to ASA or warfarin
9. Comparison of atrial fibrillation (AF) at any time during the study except for transient episode during the hospitalisation
10. Promptly cardioverted</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2001-01-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2002-12-01T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Biological Aortic Valve Replacement</description>
	<diseaseClass1>Circulatory System</diseaseClass1>
	<diseaseClass2>Heart valve replacement</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Patients will receive a specific regimen of therapy according to the result of randomisation. The administration of Low Molecular Weight Heparin (LMWH) will start on the first postoperative day, whereas warfarin and ASA on day 2. In patients receiving warfarin the use of LMWH will be continued until warfarin reached therapeutic levels as shown by a Prothrombin Time (PT) according to the International Normalised Ratio (INR; range 2.0 to 3.0). Anticoagulation with warfarin will be maintained for 3 postoperative months, then will be discontinued and substituted with ASA. Those with concomitant coronary artery bypass grafting will not receive any double therapy warfarin plus ASA.</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>Warfarin and aspirin (Acetylsalicylic Acid [ASA])</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2004 Abstract results in https://pubmed.ncbi.nlm.nih.gov/15289387 PubMed Abstract:
2004 Other publications in http://circ.ahajournals.org/cgi/content/full/110/5/496 Full text:</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="12e74191-c806-4388-b388-7c27918a0dd8" outputType="abstract" artefactType="ExternalLink" dateCreated="2004-08-03T00:00:00.000Z" dateUploaded="" peerReviewed="false" patientFacing="false" createdBy="Data migration">
	<externalLink url="https://pubmed.ncbi.nlm.nih.gov/15289387"/>
	<description>PubMed Abstract:</description>
	<productionNotes/>
      </output>
      <output id="294b82ae-95e3-40a4-86de-b64772c4d5ee" outputType="otherpublications" artefactType="ExternalLink" dateCreated="2004-08-03T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="http://circ.ahajournals.org/cgi/content/full/110/5/496"/>
	<description>Full text:</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder12360-0</funderId>
      <funderId>Funder12360-1</funderId>
      <contactId>Contact44833_12360</contactId>
      <sponsorId>Sponsor42579</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact44833_12360">
    <title>Dr</title>
    <forename>Andrea</forename>
    <surname>Colli</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Via Gramsci 13</address>
      <city>Parma</city>
      <country>Italy</country>
      <zip>43100</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+39 349 5928935</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">colli.andrea@libero.it</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor42579">
    <organisation>University of Parma (Italy)</organisation>
    <website>http://www.unipr.it/</website>
    <sponsorType>University/education</sponsorType>
    <contactDetails>
      <address>Cardiac Surgery Unit
Via Gramsci 13</address>
      <city>Parma</city>
      <country>Italy</country>
      <zip>43100</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+39 349 5928935</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">colli.andrea@libero.it</email>
    </contactDetails>
    <privacy>Public</privacy>
    <gridId>grid.10383.39</gridId>
    <rorId>https://ror.org/02k7wn190</rorId>
  </sponsor>
  <funder id="Funder12360-0">
    <name>Company of Saint Paul (Compagnia di S Paolo) (Italy)</name>
    <fundRef/>
  </funder>
  <funder id="Funder12360-1">
    <name>Ministry for Universities and of Scientific and Technological Research (Ministero dell&#146;Università e della Ricerca Scientifica e Tecnologica [MURST]) (Italy)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-10-26T00:00:00.000Z" version="21">
    <isrctn dateAssigned="2004-09-22T00:00:00.000Z">83465214</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Prevention of vitamin A deficiency by supplementation alongside routine vaccinations: a randomised controlled trial in Tanzanian infants</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>The primary objectives of the trial are to:
1. Measure the effect of 400,000 IU of vitamin A given in two divided doses of 200,000 to mothers, and 3 doses of 50,000 IU of vitamin A given to their infants concurrently with Diphtheria, Pertussis and Tetanus (DPT)/Polio immunisations, on vitamin A status of the infants at 26 weeks of age
2. Compare the effect of such a regimen to that of the previously recommended regimen of 200,000 IU of vitamin A given to mothers and 3 doses of 25,000 IU of vitamin A given to their infants concurrently with DPT/Polio immunisations
3. Measure the short-term side effects of each of the two doses of 200,000 IU given to mothers, and of the 50,000 IU of vitamin A administered with each of the three DPT/Polio immunisations

The secondary objectives are to:
1. Measure the relative effect of the two different maternal dosing regimens on the breast milk retinol concentration up to at 6 and 9 months post partum
2. Measure the effect of the maternal doses of vitamin A on the relative incidence of short-term side effects in the mother over the 48-hour period after the first and second 200,000 IU maternal doses of vitamin A
3. Measure the effect of the maternal doses of vitamin A on the breast milk retinoic acid concentration 3 hours after the first and second 200,000 IU maternal doses of vitamin A
4. Examine if any relative impacts on vitamin A status are sustained at 9 months of age

Related to the main objectives, the following hypotheses will be tested:
HYPOTHESIS 1: Giving 400,000 IU of vitamin A to mothers within 6 weeks of delivery, plus 50,000 IU given to their infants with their DPT/Polio immunisations, will improve infants' vitamin A status to a significantly greater degree than giving 200,000 IU of vitamin A within 6 weeks of delivery, plus 25,000 IU given to their infants with each of their three DPT/Polio immunisations. This will be measured by mean serum retinol concentration, or by proportions below 20ug/dl, or proportions with abnormal modified Retinol Dose Response (mRDR) at 6 months of age. The proportion of infants with serum retinol concentration below 20ug/dl at 6 months of age will be approximately 37% in the comparison group infants and 27% or less in the group of infants allocated to receive the higher dose regimen.
HYPOTHESIS 2: Giving 50,000 IU of vitamin A to infants with their DPT/Polio immunisations will produce no significant increase in the incidence of short-term side effects, relative to 25,000IU.

The outcomes to be monitored for the above objectives include serum retinol concentrations, mRDR tests, and incidence of side effects such as bulging of anterior fontanelle and vomiting, and incidence of severe morbidity.

HYPOTHESIS 3: Giving 400,000 IU of vitamin A to mothers in the post partum period will result in a greater improvement in breast milk retinol concentrations at 6 months post partum than that achieved with 200,000IU, and that this improvement will be sustained up to 9 months.
HYPOTHESIS 4: Giving a second 200,000 IU dose of vitamin A to mothers in the post partum period will result in no significant increase in the incidence of short-term side effects, relative to no second dose.
HYPOTHESIS 5: Giving a second 200,000IU dose of vitamin A to mothers in the post partum period will result in no significant increase in the prevalence of potentially toxic breast milk retinoic acid concentrations 3 hours after the second maternal dose, relative to no second dose.
HYPOTHESIS 6: At 9 months of age, the vitamin A status of infants who were allocated to receive the higher dose regimen will be significantly better than the status of infants who were allocated to receive the lower dose regimen.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>1. Prevalence of Vitamin A Deficiency (VAD) (any: less than 20 mg/dL and severe: less than 10 mg/dL) at  6 months of age
2. Incidence of each of the following: 
2.1. Bulging fontanelle
2.2. Temperature greater than 37.5°C
2.3. Vomiting
2.4. Diarrhoea 
2.5. Inability to suck/feed during the two days following each vitamin A supplementation</primaryOutcome>
      <secondaryOutcome>1. Mean serum retinol concentration at 6 months of age 
2. Prevalence of VAD (any and severe) at 9 months of age 
3. Mean retinol concentration at 9 months of age</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Ethics approval received from the Research Ethics Committees (REC) of: 
1. National Institute for Medical Research, Ministry of Health (Tanzania) on the 1st October 2001
2. Second year of trial approved by the London School of Hygiene and Tropical Medicine on the 5th August 2003
3. World Health Organization (WHO) Secretariat Committee on Research Involving Human Subjects (SCRIHS) - conditional approval on 11th April 2003, amendments approved on 8th October 2003</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN83465214</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>WHO/RPC005</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Prevention</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2001-12-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2003-09-01T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Switzerland</country>
	<country>Tanzania</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="51d988c1-993f-41ff-acc6-2780e7f7e3f7">
	  <name>World Health Organization</name>
	  <address/>
	  <city>Geneva-27</city>
	  <state/>
	  <country>Switzerland</country>
	  <zip>CH-1211</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Mothers normally resident in the study area
2. Informed consent obtained from the mother</inclusion>
      <ageRange>Child</ageRange>
      <gender>Both</gender>
      <targetEnrolment>770</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>770 infants</totalTarget>
      <exclusion>1. Mothers unable to give informed consent
2. Mothers considered to be at high risk of adverse outcome in puerperal period
3. Multiple deliveries
4. Severe adverse reaction to vitamin A supplementation</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2001-12-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2003-09-01T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Vitamin A deficiency</description>
	<diseaseClass1>Nutritional, Metabolic, Endocrine</diseaseClass1>
	<diseaseClass2>Vitamin A deficiency</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>1st Group: 
1. Mothers 200,000 IU Vitamin A shortly after delivery
2. Infants: 25,000 IU Vitamin A with each Diphtheria, Pertussis, Tetanus (DPT) vaccine 1, 2 and 3

2nd Group: 
1. Mothers 200,000 IU Vitamin A at infant's Bacillus Calmette-Guerin (BCG) vaccine and another 200,000 IU Vitamin A at infant's 1st DPT
2. Infants: 50,000 IU Vitamin A with each DPT 1, 2 and 3

Time Frame: 
Recruitment should start in December 2001 and is expected to last for approximately 9 months. Hence the data required to address the primary endpoint will be available 15 months after the start of recruitment. Data required to address the secondary endpoints will be available 21 months after the start of recruitment. Assuming that the WHO-appointed micronutrient laboratory will be able to report the results of vitamin A-related analyses within six weeks of the completion of specimen collection, all laboratory and statistical analyses will be completed within 4 months of finishing field activities.</description>
	<interventionType>Supplement</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>Vitamin A supplementation</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
        
      </outputs>
    <parties>
      <funderId>Funder11309-0</funderId>
      <contactId>Contact41760_11309</contactId>
      <sponsorId>Sponsor39505</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact41760_11309">
    <title>Dr</title>
    <forename>Tracey</forename>
    <surname>Goodman</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>World Health Organization
20 Avenue Appia</address>
      <city>Geneva-27</city>
      <country>Switzerland</country>
      <zip>CH-1211</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">goodmant@who.int</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor39505">
    <organisation>World Health Organization (WHO)/Department of Immunisation, Vaccines and Biologicals (IVB) (Switzerland) </organisation>
    <website>http://www.who.int</website>
    <sponsorType>Research organisation</sponsorType>
    <contactDetails>
      <address>20, Avenue Appia</address>
      <city>Geneva-27</city>
      <country>Switzerland</country>
      <zip>CH-1211</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.3575.4</gridId>
    <rorId>https://ror.org/01f80g185</rorId>
  </sponsor>
  <funder id="Funder11309-0">
    <name>World Health Organization (WHO)/Department of Immunisation, Vaccines and Biologicals (IVB) (Switzerland)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-10-11T00:00:00.000Z" version="25">
    <isrctn dateAssigned="2004-07-28T00:00:00.000Z">12666644</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Efficacy of Metered Dose Inhaler (MDI) with attached Bottle spacer for bronchodilator therapy in infants and young children with acute lower airways obstruction (South Africa)</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>To compare the response to bronchodilator administered via a Metered Dose Inhaler (MDI) with bottle spacer compared to a MDI with conventional spacer in young children presenting to a health care facility with acute lower airways obstruction.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>The need for hospitalisation: this outcome has been chosen as this is clinically important and can be reliably measured. Differences between the two treatment groups for this primary outcome as a result of bias should be minimised by use of random allocation of treatment group with adequate allocation concealment and adequate blinding of the investigators deciding on hospitalisation.</primaryOutcome>
      <secondaryOutcome>1. Change in clinical score, measured as the difference between the clinical score at presentation to the clinical score recorded after the final bronchodilator treatment prior to discharge or hospitalisation
2. Change in oximetry, measured as the difference between oximetry recorded at presentation the room air to that recorded after the final bronchodilator treatment prior to discharge or hospitalisation
3. Number of bronchodilator treatments required prior to discharge (if not hospitalised). A bronchodilator treatment will be regarded as 5 puffs of salbutamol or a nebulisation
4. Need for systemic corticosteroids. Systemic steroids will be indicated for children with recurrent wheeze who require hospitalisation or who have required two or more bronchodilator treatments</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Ethics approval received from:
1. University of Cape Town Research and Ethics Committee, University of Cape Town 
2. World Health Organization (WHO) Ethical Review Committee</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN12666644</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>WHO/CAH ID 02002</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2003-04-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2005-11-01T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>South Africa</country>
	<country>Switzerland</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="2a1efb57-83ab-4d11-b498-396a1ed14b8b">
	  <name>World Health Organization</name>
	  <address/>
	  <city>Geneva -27</city>
	  <state/>
	  <country>Switzerland</country>
	  <zip>CH 1211</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Age 3 months to 5 years
2. Able to use MDI - spacer as assessed by the researcher administering inhaled treatment
3. Acute episode of lower airway obstruction (wheezing or hyperinflation)
4. Informed consent of parent/guardian</inclusion>
      <ageRange>Child</ageRange>
      <lowerAgeLimit unit="Months" value="3.0"/>
      <upperAgeLimit unit="Years" value="5.0"/>
      <gender>Both</gender>
      <targetEnrolment>396</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>396 children</totalTarget>
      <exclusion>1. Use of bronchodilator within the preceeding 4 hours
2. Known underlying cardiac or chronic pulmonary disease (other than asthma)
3. Presence of stridor or daily treatment with oral corticosteroids for more than 2 days prior</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2003-04-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2005-11-01T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Acute lower airways obstruction</description>
	<diseaseClass1>Respiratory</diseaseClass1>
	<diseaseClass2>Acute lower airways obstruction</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>This is an equivalence study.  Equivalence will be regarded as not more than an absolute 10% increase in hospitalisation with the bottle spacer. Assuming that hospitalisation with the conventional spacer will occur in 20% of children and that the spacers are equally effective, 198 children will be required in each group (total sample of 396 children) to demonstrate that hospitalisation with the bottle spacer is not more than 10% higher, with 80% power and a one-tailed a of 0.0505 i.e. given the above assumptions, the upper 90% confidence limit for a difference favouring the conventional spacer will be less than 10%.

Three different delivery systems will be compared:
1. Conventional spacer with MDI - a small volume (150 ml) valved spacer with an attached mask for children less than 3 years, and a mouthpiece for those 3 - 5 years
2. Modified 500 ml plastic bottle with MDI with attached mask for children less than 3 years
3. Jet nebuliser with attached mask or mouthpiece depending upon child's age</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2007 Results article in https://pubmed.ncbi.nlm.nih.gov/16905564 Results</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="1a72bd35-b4d6-41c3-838d-934befe108f1" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2007-02-01T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="https://pubmed.ncbi.nlm.nih.gov/16905564"/>
	<description>Results</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder11300-0</funderId>
      <contactId>Contact41751_11300</contactId>
      <sponsorId>Sponsor39496</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact41751_11300">
    <title>Dr</title>
    <forename>Shamim</forename>
    <surname>Qazi</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>World Health Organization
20, Avenue Appia</address>
      <city>Geneva -27</city>
      <country>Switzerland</country>
      <zip>CH 1211</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">qazis@who.int</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor39496">
    <organisation>The Department of Child and Adolescent Health (CAH)/World Health Organization (WHO) (Switzerland) </organisation>
    <website/>
    <sponsorType>Research organisation</sponsorType>
    <contactDetails>
      <address>20, Avenue Appia</address>
      <city>Geneva -27</city>
      <country>Switzerland</country>
      <zip>CH 1211</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.3575.4</gridId>
    <rorId>https://ror.org/01f80g185</rorId>
  </sponsor>
  <funder id="Funder11300-0">
    <name>The Department of Child and Adolescent Health (CAH)/World Health Organization (WHO) (Switzerland)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-10-11T00:00:00.000Z" version="25">
    <isrctn dateAssigned="2004-07-28T00:00:00.000Z">32365107</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Assessment and management of children aged 1 - 59 months presenting with wheeze and fast breathing: multicenter study in Pakistan and Thailand</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>Using current World Health Organization (WHO) guidelines, children with wheezing are being over-prescribed antibiotics and bronchodilators are under utilised. To improve the WHO case management guidelines, more data is needed about the clinical outcome in children with wheezing/pneumonia overlap.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Proportions of children aged 1 - 59 months with auscultatory wheeze and fast breathing or lower chest indrawing:
1. Respond to up to three cycles of inhaled salbutamol: response defined as no fast breathing or lower chest indrawing present
2. Fail therapy at day 3 or days 5 - 7 of the initial successful bronchodilator therapy with inhaled salbutamol? Therapy failure defined as:
2.1. Relapse: develop fast breathing or chest indrawing afresh, that does not respond to three cycles of inhaled salbutamol
2.2. Development of any danger sign (except wheezing and fever in young infant)
2.3. Death 
2.4. Severe adverse reaction to salbutamol</primaryOutcome>
      <secondaryOutcome>In children aged 1 - 59 months with auscultatory wheeze and fast breathing or lower chest indrawing:
1. Proportion with audible wheeze at initial assessment
2. Proportion of responders to up to three cycles of inhaled salbutamol associated with:
2.1. Age 
2.2. Respiratory Syncytial Virus (RSV) isolation
2.3. Season
2.4. Number of previous wheezing episodes
2.5. Audible versus auscultatory wheeze
2.6. Family history of asthma
3. Proportion of relapses in children who showed initial improvement associated with:
3.1. Age 
3.2. RSV isolation
3.3. Season
3.4. Number of previous wheezing episodes
3.5. Audible versus auscultatory wheeze
3.6. Family history of asthma
4. Received any antibiotic for this or any concurrent illness before follow-up
5. Loss to follow-up
6. Withdrawal of consent</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Ethics approval received fron:
1. Institutional Review Board (IRB) of Pakistan Institute of Medical Sciences, Islamabad, Pakistan
2. IRB of Queen Sirikit National Institute of Child Health, Bangkok, Thailand
3. World Health Organization (WHO) Ethical Review Committee</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN32365107</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>WHO/CAH ID 99025</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2001-05-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2002-04-01T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Pakistan</country>
	<country>Switzerland</country>
	<country>Thailand</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="d8fedca6-9b39-4dab-a4b7-6cf6ed6ec2cd">
	  <name>World Health Organization</name>
	  <address/>
	  <city>Geneva-27</city>
	  <state/>
	  <country>Switzerland</country>
	  <zip>CH 1211</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Age 1 to 59 months
2. Audible/auscultatory wheeze
3. Respiratory rate above age specific cut off point or lower chest indrawing
4. Classified as no pneumonia with wheeze</inclusion>
      <ageRange>Child</ageRange>
      <lowerAgeLimit unit="Months" value="1.0"/>
      <upperAgeLimit unit="Months" value="59.0"/>
      <gender>Both</gender>
      <targetEnrolment>1622</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>1622</totalTarget>
      <exclusion>1. Presence of danger sign:
1.1. Up to two months: stopped feeding well, drowsy, convulsions, stridor in a calm child, fever
1.2. 2 - 59 months: convulsions, clinically severe malnutrition, unable to drink
2. Antibiotics during last 48 hours</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2001-05-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2002-04-01T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Wheeze and fast breathing</description>
	<diseaseClass1>Respiratory</diseaseClass1>
	<diseaseClass2>Respiratory problems</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>1. Inhaled Salbutamol and reassessment after up to three cycles of bronchodilator therapy repeated at 15 minute interval if necessary
2. Metered Dose Inhaler (MDI) with spacer device</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2004 Results article in http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=retrieve&amp;db=pubmed&amp;list_uids=15499063 Results</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="3ce338e9-07fd-4fec-ae50-250cdba2bdf4" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2004-11-01T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=retrieve&amp;db=pubmed&amp;list_uids=15499063"/>
	<description>Results</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder11301-0</funderId>
      <contactId>Contact41752_11301</contactId>
      <sponsorId>Sponsor39497</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact41752_11301">
    <title>Dr</title>
    <forename>Shamim</forename>
    <surname>Qazi</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>World Health Organization
20 Avenue Appia</address>
      <city>Geneva-27</city>
      <country>Switzerland</country>
      <zip>CH 1211</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">qazis@who.int</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor39497">
    <organisation>The Department of Child and Adolescent Health (CAH)/World Health Organization (WHO) (Switzerland) </organisation>
    <website>http://www.who.int/child-adolescent-health/</website>
    <sponsorType>Research organisation</sponsorType>
    <contactDetails>
      <address>20, Avenue Appia</address>
      <city>Geneva -27</city>
      <country>Switzerland</country>
      <zip>CH 1211</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.3575.4</gridId>
    <rorId>https://ror.org/01f80g185</rorId>
  </sponsor>
  <funder id="Funder11301-0">
    <name>The Department of Child and Adolescent Health (CAH)/World Health Organization (WHO) (Switzerland)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-11-07T00:00:00.000Z" version="21">
    <isrctn dateAssigned="2004-01-23T00:00:00.000Z">87471242</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>A randomised controlled trial investigating the clinical and cost-effectiveness of a patient self-management programme (SMP) for basic footcare in the elderly</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>To design and implement a new patient self-management programme for elderly patients seeking podiatry for basic foot problems. Access to NHS chiropody is often gained on "entitlement" rather than clinical need and in the elderly routine follow up is becoming a costly problem. The Department of Health has called on the profession to tackle this issue within the constraints of current funding levels. We have identified successful use of patient self-management programmes (SMP) for chronic low-grade conditions in other clinical fields and our key objective in this study is to develop a relevant programme for basic footcare in the elderly. We aim to test this, in terms of its clinical and cost-effectiveness, against conventional care in a (as yet unfunded) randomised controlled trial. The SMP will contain elements of information, giving training and education and telephone helpline support involving patients, relatives, carers, voluntary sector workers and podiatry services. We are currently validating a foot health disability measure as the primary outcome measure alongside measures of foot morbidity, patient satisfaction, quality of life and foot health knowledge.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>EuroQol, foot disability index - to be validated, foot morbidity Index, foot health knowledge questionnaire - based on SMP, patient satisfaction questionnaire.</primaryOutcome>
      <secondaryOutcome>Not provided at time of registration</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Not provided at time of registration</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN87471242</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>rctc94 441772</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>1999-01-02T00:00:00.000Z</overallStartDate>
      <overallEndDate>2001-01-04T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>England</country>
	<country>United Kingdom</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="d87d5759-bdf1-46fb-a340-d38451978972">
	  <name>University of Leeds</name>
	  <address/>
	  <city>Leeds</city>
	  <state/>
	  <country>United Kingdom</country>
	  <zip>LS2 9NZ</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>Feasibility study - sample of 50 subjects, mostly new referrals to the NHS podiatry service in Calderdale.</inclusion>
      <ageRange>Not Specified</ageRange>
      <gender>Not Specified</gender>
      <targetEnrolment>153</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>153</totalTarget>
      <exclusion>Diabetes mellitis, circulatory disorders.</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>1999-01-02T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2001-01-04T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Basic foot care</description>
	<diseaseClass1>Musculoskeletal Diseases</diseaseClass1>
	<diseaseClass2>Basic foot care</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Patient self-management programme versus standard care.</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2003 Results article in http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=14615000</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="2858bb54-74ef-4317-bf85-fc5760d0ff1a" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2003-11-01T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=14615000"/>
	<description/>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder6102-0</funderId>
      <contactId>Contact7452_6102</contactId>
      <sponsorId>Sponsor5355</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact7452_6102">
    <title>Dr</title>
    <forename>Philip</forename>
    <surname>Helliwell</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>University of Leeds
Rheumatology &amp; Rehabilitation Research Unit
36 Clarendon Road</address>
      <city>Leeds</city>
      <country>United Kingdom</country>
      <zip>LS2 9NZ</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+44 (0)113 233 4952</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">p.helliwell@leeds.ac.uk</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor5355">
    <organisation>NHS R&amp;D Regional Programme Register - Department of Health (UK)</organisation>
    <website>http://www.doh.gov.uk</website>
    <sponsorType>Government</sponsorType>
    <contactDetails>
      <address>The Department of Health
Richmond House
79 Whitehall</address>
      <city>London</city>
      <state/>
      <country>United Kingdom</country>
      <zip>SW1A 2NL</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+44 (0)20 7307 2622</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">dhmail@doh.gsi.org.uk</email>
    </contactDetails>
    <privacy>Public</privacy>
  </sponsor>
  <funder id="Funder6102-0">
    <name>NHS Executive Northern and Yorkshire (UK)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-10-01T00:00:00.000Z" version="23">
    <isrctn dateAssigned="2003-11-17T00:00:00.000Z">32121581</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Baclofen for maintenance treatment of opioid dependence: A randomised double-blind placebo-controlled clinical trial</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>Not provided at time of registration</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Not provided at time of registration</primaryOutcome>
      <secondaryOutcome>Not provided at time of registration</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Not provided at time of registration</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN32121581</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>G36</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2001-11-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2002-11-01T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Iran</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="4eca6003-9cea-4752-ad47-7bf306405841">
	  <name>Roozbeh Psychiatric Hospital</name>
	  <address/>
	  <city>Tehran</city>
	  <state/>
	  <country>Iran</country>
	  <zip>13337</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>Subjects were eligible for the study if they:
1. Met DSM-IV criteria for opioid dependence
2. Were detoxified at our addiction clinic
3. Were between 18 and 60 years of age
4. Gave written informed consent for participation in the study

Opioid dependence (according to Diagnostic and Statistical Manual of Mental Disorders, fourth edition [DSM-IV] criteria).</inclusion>
      <ageRange>Not Specified</ageRange>
      <gender>Not Specified</gender>
      <targetEnrolment>40</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>40</totalTarget>
      <exclusion>Not provided at time of registration</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2001-11-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2002-11-01T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Opioid dependence</description>
	<diseaseClass1>Mental and Behavioural Disorders</diseaseClass1>
	<diseaseClass2>Drug addiction</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>A total of 40 opioid-dependent patients were detoxified and randomly assigned to receive baclofen (20 mg three times a day [t.i.d.]) or placebo (in identical-appearing tablets t.i.d.) in a 12-week, double blind, parallel-group trial.</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>Baclofen</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2003 Results article in https://pubmed.ncbi.nlm.nih.gov/14624703 Results</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="40ae47f0-e3dc-4a59-b045-d6aac2d2afb4" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2003-11-18T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="https://pubmed.ncbi.nlm.nih.gov/14624703"/>
	<description>Results</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder5724-0</funderId>
      <contactId>Contact7156_5724</contactId>
      <sponsorId>Sponsor5319</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact7156_5724">
    <title>Dr</title>
    <forename>Seyed Mohammad</forename>
    <surname>Assadi</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Roozbeh Psychiatric Hospital
South Kargar Avenue</address>
      <city>Tehran</city>
      <country>Iran</country>
      <zip>13337</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+98 (0)21 542222</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">assadism@sina.tums.ac.ir</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor5319">
    <organisation>Roozbeh Addiction Department (Iran) </organisation>
    <website/>
    <sponsorType>Hospital/treatment centre</sponsorType>
    <contactDetails>
      <address>Roozbeh Psychiatric Hospital
South Kargar Avenue</address>
      <city>Tehran</city>
      <country>Iran</country>
      <zip>13337</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+98 (0)21 542222</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">a3057@sina.tums.ac.ir</email>
    </contactDetails>
    <privacy>Public</privacy>
    <gridId>grid.416042.5</gridId>
    <rorId>https://ror.org/019mzt973</rorId>
  </sponsor>
  <funder id="Funder5724-0">
    <name>Roozbeh Addiction Department (Iran) (ref: G36)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-10-19T00:00:00.000Z" version="22">
    <isrctn dateAssigned="2003-09-08T00:00:00.000Z">05874865</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Intensive Scheduled Management strategy for improving blood pressure control in patients in primary care</title>
      <scientificTitle/>
      <acronym>ISM</acronym>
      <studyHypothesis>Comparing intensive scheduled management of hypertension (aggressive achievement of target blood pressure over 16 weeks) with usual management of hypertension.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Blood pressure control on 24-hour Ambulatory Blood Pressure Monitoring (ABPM), measured at 16 weeks and one year.</primaryOutcome>
      <secondaryOutcome>1. Patient quality of life
2. Physician compliance with the intensive protocol
3. Patient compliance with medication
4. Adverse effects</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Not provided at time of registration</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN05874865</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>NA 4884</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Quality of life</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2002-07-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2006-11-01T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Canada</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="90b40474-608f-4f15-b517-eb443318d6bb">
	  <name>Centre for Studies in Primary Care</name>
	  <address/>
	  <city>Kingston, Ontario</city>
	  <state/>
	  <country>Canada</country>
	  <zip>K7L 5E9</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Adults (age 18 and older) who are patients of family physicians 
2. Must be diagnosed with essential hypertension but not have yet achieved target levels</inclusion>
      <ageRange>Not Specified</ageRange>
      <gender>Not Specified</gender>
      <targetEnrolment>0</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>Not provided at time of registration</totalTarget>
      <exclusion>1. A diagnosis of secondary hypertension
2. Pregnancy
3. Hypertension management primarily by a consultant
4. Inability to provide informed consent</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2002-07-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2006-11-01T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Hypertension</description>
	<diseaseClass1>Circulatory System</diseaseClass1>
	<diseaseClass2>Hypertension</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>This study is designed to test the premise that guidelines, to be effective in primary care, need to be operationalised for the practitioner. To this end we have devised a protocol where medications are initiated at the recommended starting dose and increased by one recommended increment before adding the next drug. The goal is to increase the medications over the 16-week period such that, if necessary to reach the target blood pressure level, a patient is on a medium dose of three different antihypertensive agents.</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2003 Protocol article in https://pubmed.ncbi.nlm.nih.gov/14690550 Protocol</publicationDetails>
      <publicationStage>Protocol</publicationStage>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="ce62c718-c1f8-4360-b25a-29ddb79b8550" outputType="protocolarticle" artefactType="ExternalLink" dateCreated="2003-12-22T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="https://pubmed.ncbi.nlm.nih.gov/14690550"/>
	<description>Protocol</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder5155-0</funderId>
      <contactId>Contact5584_5155</contactId>
      <sponsorId>Sponsor5270</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact5584_5155">
    <title>Dr</title>
    <forename>Marshall</forename>
    <surname>Godwin</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Centre for Studies in Primary Care
220 Bagot Street</address>
      <city>Kingston, Ontario</city>
      <country>Canada</country>
      <zip>K7L 5E9</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+1 613-549-4480</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">godwinm@post.queensu.ca</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor5270">
    <organisation>The Heart and Stroke Foundation of Ontario (Canada) </organisation>
    <website/>
    <sponsorType>Charity</sponsorType>
    <contactDetails>
      <address>1920 Yonge Street
4th Floor</address>
      <city>Toronto, Ontario</city>
      <country>Canada</country>
      <zip>M4S 3E2</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+1 416 489 7100</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">mail@hsf.on.ca</email>
    </contactDetails>
    <privacy>Public</privacy>
    <gridId>grid.423576.1</gridId>
    <rorId>https://ror.org/00qbpyp73</rorId>
  </sponsor>
  <funder id="Funder5155-0">
    <name>The Heart and Stroke Foundation of Ontario (Canada)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-10-10T00:00:00.000Z" version="25">
    <isrctn dateAssigned="2003-01-06T00:00:00.000Z">37786144</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Effect of pamidronate on bone loss and implant stability after total hip arthroplasty</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>Not provided at time of registration</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Not provided at time of registration</primaryOutcome>
      <secondaryOutcome>Not provided at time of registration</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Not provided at time of registration</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN37786144</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>W0597</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2002-01-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2004-01-01T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>England</country>
	<country>United Kingdom</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="ff1d1e39-f982-46f6-9532-2b461342359f">
	  <name>Bone Metabolism Group</name>
	  <address/>
	  <city>Sheffield</city>
	  <state/>
	  <country>United Kingdom</country>
	  <zip>S5 7AU</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>Men and women undergoing primary total hip arthroplasty for osteoarthritis of the hip.</inclusion>
      <ageRange>Not Specified</ageRange>
      <gender>Both</gender>
      <targetEnrolment>0</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>Not provided at time of registration</totalTarget>
      <exclusion>Not provided at time of registration</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2002-01-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2004-01-01T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Periprosthetic bone loss after total hip replacement</description>
	<diseaseClass1>Musculoskeletal Diseases</diseaseClass1>
	<diseaseClass2>Periprosthetic bone loss</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Pamidronate sodium as a single 90 mg infusion versus saline infusion given on the 5th day postoperatively after total hip arthroplasty</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>Pamidronate</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2005 Results article in https://pubmed.ncbi.nlm.nih.gov/15607868/ Results</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="335d0431-261c-47db-bcc9-3105e39d2a62" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2005-01-01T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="https://pubmed.ncbi.nlm.nih.gov/15607868/"/>
	<description>Results</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder1509-0</funderId>
      <contactId>Contact5233_1509</contactId>
      <sponsorId>Sponsor5003</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact5233_1509">
    <title>Mr</title>
    <forename>Jeremy</forename>
    <surname>Wilkinson</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Bone Metabolism Group
University of Sheffield
Division of Clinical Sciences
Northern General Hospital
Herries Road</address>
      <city>Sheffield</city>
      <country>United Kingdom</country>
      <zip>S5 7AU</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+44 (0)114 271 4705</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">wilkomark@aol.com</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor5003">
    <organisation>Arthritis Research Campaign (ARC) (UK)</organisation>
    <website>http://www.arc.org.uk</website>
    <sponsorType>Charity</sponsorType>
    <contactDetails>
      <address>Copeman House
St Mary's Court
St Mary's Gate
Chesterfield</address>
      <city>Derbyshire</city>
      <country>United Kingdom</country>
      <zip>S41 7TD</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">-</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">info@arc.org.uk</email>
    </contactDetails>
    <privacy>Public</privacy>
    <gridId>grid.507369.e</gridId>
    <rorId>https://ror.org/02jkpm469</rorId>
  </sponsor>
  <funder id="Funder1509-0">
    <name>Arthritis Research Campaign (UK)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-10-09T00:00:00.000Z" version="22">
    <isrctn dateAssigned="2002-12-18T00:00:00.000Z">73264439</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Feasibility study to evaluate the clinical and cost effectiveness of foot orthoses in the management of plantar heel pain</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>Not provided at time of registration</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Not provided at time of registration</primaryOutcome>
      <secondaryOutcome>Not provided at time of registration</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Not provided at time of registration</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN73264439</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>RRC300/SG</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2001-01-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2002-01-01T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>England</country>
	<country>United Kingdom</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="05eee5aa-5238-4005-9075-4ea0cea65c9e">
	  <name>University of Teesside</name>
	  <address/>
	  <city>Middlesbrough</city>
	  <state/>
	  <country>United Kingdom</country>
	  <zip>TS1 3BA</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>48 patients clinically diagnosed with plantar heel pain. The inclusion criteria included the following:
1. Unilateral plantar heel pain of at least 2-months duration
2. A history of night-time or early morning pain, which decreases after walking, and/or increases after exercise or prolonged periods of standing
3. Heel pain severe enough to either cause a reduction in physical activity, a visit to a health professional, or the use of medication
4. Good general health</inclusion>
      <ageRange>Not Specified</ageRange>
      <gender>Both</gender>
      <targetEnrolment>48</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>48</totalTarget>
      <exclusion>Not provided at time of registration</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2001-01-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2002-01-01T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Plantar heel pain</description>
	<diseaseClass1>Musculoskeletal Diseases</diseaseClass1>
	<diseaseClass2>Plantar heel pain</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Two types of foot orthoses (based on costs and function) were measured at baseline, 4 and 8 weeks using general (EQ5D), specific (Foot Health Status Questionnaire) outcome measures together with an economic questionnaire</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2004 Results article in https://pubmed.ncbi.nlm.nih.gov/15153583/ Results</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="9d75ad9f-6133-4387-aa90-7209cc737e1e" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2004-05-01T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="https://pubmed.ncbi.nlm.nih.gov/15153583/"/>
	<description>Results</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder1502-0</funderId>
      <contactId>Contact5122_1502</contactId>
      <sponsorId>Sponsor5081</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact5122_1502">
    <title>Dr</title>
    <forename>Keith</forename>
    <surname>Rome</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>University of Teesside
School of Health and Social Care</address>
      <city>Middlesbrough</city>
      <country>United Kingdom</country>
      <zip>TS1 3BA</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+44 (0)1642 384977</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">K.Rome@tees.ac.uk</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor5081">
    <organisation>North Tyneside AHA Trust Research Unit (UK)</organisation>
    <website/>
    <sponsorType>Hospital/treatment centre</sponsorType>
    <contactDetails>
      <address>North Tyneside General Hospital
Research Support Unit
Rake Lane</address>
      <city>North Shields</city>
      <state>England</state>
      <country>United Kingdom</country>
      <zip>NE29 8NH</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
  </sponsor>
  <funder id="Funder1502-0">
    <name>Department of Health (UK) - Directorate of Health &amp; Social Care</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-10-09T00:00:00.000Z" version="24">
    <isrctn dateAssigned="2002-11-06T00:00:00.000Z">78545137</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Determining if ingestion of silybum marianum (milk thistle) influences the metabolisation of indinavir in healthy subjects: a randomised controlled phase I study</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>Not provided at time of registration</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Not provided at time of registration</primaryOutcome>
      <secondaryOutcome>Not provided at time of registration</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Not provided at time of registration</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN78545137</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2003-01-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2005-12-31T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Canada</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="5fec9d35-6140-43f0-a1e3-88da1c82e491">
	  <name>Director of Research, Canadian College of Naturopathic Medicine</name>
	  <address/>
	  <city>North York, Ontario</city>
	  <state/>
	  <country>Canada</country>
	  <zip>M2K 1E2</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Documented Enzyme-Linked Immunosorbent Assay (ELISA) and Western Blot results negative for Human Immunodeficiency Virus (HIV)
2. Aged 18 - 35 years
3. Sex male, race Caucasian, and normal findings of laboratory and physical examinations</inclusion>
      <ageRange>Adult</ageRange>
      <lowerAgeLimit unit="Years" value="18.0"/>
      <gender>Male</gender>
      <targetEnrolment>24</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>24</totalTarget>
      <exclusion>Not provided at time of registration</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2003-01-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2005-12-31T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Drug interactions</description>
	<diseaseClass1 xmlns:isrctn="http://www.67bricks.com/isrctn">Other</diseaseClass1>
	<diseaseClass2/>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Milk thistle (silybum marianum) and indinavir. 

Twenty-four healthy male participants: All individuals will receive a HIV test and Liver Function Tests (LFTs - aspartate aminotransferase [AST], alanine aminotransferase [ALT], gamma-glutamyl transferase [GGT]) to exclude HIV and liver disease, and also a Complete Blood Count (CBC).

Subjects are requested to discontinue all medications, alcohol, caffeine, nicotine and other known CYP 3A4 inducers and inhibitors. Informed consent will be obtained from all participants.</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Phase I</phase>
	<drugNames>Milk thistle, indinavir</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2005 Results article in https://pubmed.ncbi.nlm.nih.gov/15666173 Results</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="a96757a3-18ef-42b4-81c2-dbced905bded" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2005-03-01T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="https://pubmed.ncbi.nlm.nih.gov/15666173"/>
	<description>Results</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder1474-0</funderId>
      <contactId>Contact5230_1474</contactId>
      <sponsorId>Sponsor5103</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact5230_1474">
    <title>Mr</title>
    <forename>Edward</forename>
    <surname>Mills</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Director of Research, Canadian College of Naturopathic Medicine
1255 Sheppard Ave East</address>
      <city>North York, Ontario</city>
      <country>Canada</country>
      <zip>M2K 1E2</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+1 416 498 1255 ext 324</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">emills@ccnm.edu</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor5103">
    <organisation>Ontario HIV Treatment Network</organisation>
    <website/>
    <sponsorType>Not defined</sponsorType>
    <contactDetails>
      <address>1300 Yonge Street
Suite 308</address>
      <city>Toronto, Ontario</city>
      <country>Canada</country>
      <zip>M4T 1X3</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+1 416 642 6486&lt;BR/&gt;Toll Free: +1 877 743 6486</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">info@ohtn.on.ca</email>
    </contactDetails>
    <privacy>Public</privacy>
    <gridId>grid.423128.e</gridId>
    <rorId>https://ror.org/03hgdjp72</rorId>
  </sponsor>
  <funder id="Funder1474-0">
    <name>Ontario HIV Treatment Network (Canada)</name>
    <fundRef>http://dx.doi.org/10.13039/501100000085</fundRef>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-10-09T00:00:00.000Z" version="24">
    <isrctn dateAssigned="2002-10-15T00:00:00.000Z">09811591</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Cluster randomised controlled trial of an educational intervention to optimise antibiotic prescribing for acute cough</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>This study aims to establish a valid estimate of the effect of perceived patient demand on General Practitioners (GPs) antibiotic prescribing, specifically for patients consulting with acute cough as one of the most prominent complaints, and to contribute to the necessary understanding of this complex prescription decision.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>The antibiotic prescribing rate by GPs for adult patients with acute cough.</primaryOutcome>
      <secondaryOutcome>1. Type of antibiotics prescribed, if any
2. Change in antibiotic prescribing affecting symptom resolution</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>This study was approved by the medical ethics committee of the University of Antwerp (A99-088).</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN09811591</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>GP practice</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2000-01-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2002-01-01T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Belgium</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="d94116c2-51a1-4555-887e-099aac7f2bfa">
	  <name>Centre for General Practice</name>
	  <address/>
	  <city>Antwerp</city>
	  <state/>
	  <country>Belgium</country>
	  <zip>B-2610</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>Flemish GPs randomised participants into an intervention and a control group including:
1. Immunocompetent patients
2. Aged 18 - 65 years old
3. With a new or worsening cough present for less than 30 days as (one of the) most prominent complaint(s) and as the reason for a first encounter at the GPs practice</inclusion>
      <ageRange>Adult</ageRange>
      <lowerAgeLimit unit="Years" value="18.0"/>
      <gender>Both</gender>
      <targetEnrolment>85</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>85 Flemish GPs</totalTarget>
      <exclusion>Not provided at time of registration</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2000-01-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2002-01-01T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Acute cough</description>
	<diseaseClass1>Respiratory</diseaseClass1>
	<diseaseClass2>Cough</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Only the GPs in the intervention group received our guideline for the management of acute cough, followed by an educational outreach visit to discuss the implementation of the guideline and a postal reminder with the key message of the guideline.</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2006 Results article in https://pubmed.ncbi.nlm.nih.gov/16536958 Results</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="74253a6d-e27b-46b9-bd39-5cbe27c4dace" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2006-03-01T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="https://pubmed.ncbi.nlm.nih.gov/16536958"/>
	<description>Results</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder1469-0</funderId>
      <funderId>Funder1469-1</funderId>
      <contactId>Contact5244_1469</contactId>
      <sponsorId>Sponsor5030</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact5244_1469">
    <title>Mr</title>
    <forename>Samuel</forename>
    <surname>Coenen</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Centre for General Practice
University of Antwerp
Universiteitsplein 1</address>
      <city>Antwerp</city>
      <country>Belgium</country>
      <zip>B-2610</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+32 (0)3 820 25 25</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">samuel.coenen@ua.ac.be</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor5030">
    <organisation>University of Antwerp (Belgium)</organisation>
    <website>http://www.ua.ac.be/</website>
    <sponsorType>University/education</sponsorType>
    <contactDetails>
      <address>Centre for General Practice
Universiteitsplein 1</address>
      <city>Antwerp</city>
      <country>Belgium</country>
      <zip>B-2610</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.5284.b</gridId>
    <rorId>https://ror.org/008x57b05</rorId>
  </sponsor>
  <funder id="Funder1469-0">
    <name>Fund for Scientific Research, Flanders (Belgium) - Samuel Coenen was research assistant</name>
    <fundRef/>
  </funder>
  <funder id="Funder1469-1">
    <name>The Scientific Society of Flemish General Practitioners (Belgium) - funded the development of the guideline for the management of acute cough</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-10-05T00:00:00.000Z" version="24">
    <isrctn dateAssigned="2002-10-10T00:00:00.000Z">27981153</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>The clinical management of chemotherapy-induced nausea and vomiting with adjuvant Progressive Muscle Relaxation Training (PMRT) and imagery techniques in breast cancer patients</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>Not provided at time of registration</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Not provided at time of registration</primaryOutcome>
      <secondaryOutcome>Not provided at time of registration</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Not provided at time of registration</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN27981153</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>811006</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>1999-01-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2001-01-01T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Hong Kong</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="fa9b3430-b6ab-4b6c-bc1d-7a42c0e8216a">
	  <name>Nethersole School of Nursing</name>
	  <address/>
	  <city>-</city>
	  <state/>
	  <country>Hong Kong</country>
	  <zip>-</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Patients diagnosed with breast cancer and have no exposure to cytotoxic chemotherapeutic agent prior to the study (chemotherapy-naive)
2. Females between the age of 18 - 70 years
3. Clinical indication to receive adriamycin with cyclophosphamide (AC) as adjuvant or salvage chemotherapy for treatment of breast cancer
4. Able to read and write Chinese
5. Agree to sign the informed consent</inclusion>
      <ageRange>Adult</ageRange>
      <lowerAgeLimit unit="Years" value="18.0"/>
      <gender>Female</gender>
      <targetEnrolment>0</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>Not provided at time of registration</totalTarget>
      <exclusion>Not provided at time of registration</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>1999-01-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2001-01-01T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Breast cancer</description>
	<diseaseClass1>Cancer</diseaseClass1>
	<diseaseClass2>Breast cancer</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>PMRT 1 hour prior to chemotherapy administration and daily thereafter for another 5 days (total of 6 PMRT sessions). Each session lasts for 25 minutes followed by 5 minutes of imagery techniques.</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2002 Results article in https://pubmed.ncbi.nlm.nih.gov/11904789 Results</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="e3e13440-f1d3-4e85-9e61-dd53a45b9d20" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2002-04-01T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="https://pubmed.ncbi.nlm.nih.gov/11904789"/>
	<description>Results</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder1442-0</funderId>
      <contactId>Contact5020_1442</contactId>
      <sponsorId>Sponsor5063</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact5020_1442">
    <title>Dr</title>
    <forename>A</forename>
    <surname>Molassiotis</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Nethersole School of Nursing
Chinese University of Hong Kong</address>
      <city>-</city>
      <country>Hong Kong</country>
      <zip>-</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
  </contact>
  <sponsor id="Sponsor5063">
    <organisation>Hong Kong Health Services Research Fund (China)</organisation>
    <website>http://www.fhb.gov.hk/grants/english/funds/funds_hhsrf/funds_hhsrf_abt/funds_hhsrf_abt.html</website>
    <sponsorType>Government</sponsorType>
    <contactDetails>
      <address>Health Welfare and Food Bureau
Government Secretariat, HKSAR
20th floor Murray Building
Garden Road</address>
      <city>-</city>
      <country>Hong Kong</country>
      <zip>-</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+852 (0)2973 8288</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">hsrf@hwfb.gov.hk</email>
    </contactDetails>
    <privacy>Public</privacy>
    <gridId>grid.453538.c</gridId>
    <rorId>https://ror.org/03qh32912</rorId>
  </sponsor>
  <funder id="Funder1442-0">
    <name>Hong Kong Health Services Research Fund (Hong Kong)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-10-03T00:00:00.000Z" version="24">
    <isrctn dateAssigned="2002-10-03T00:00:00.000Z">23374750</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>A randomised placebo-controlled trial of a traditional chinese herbal formula in the treatment of primary dysmenorrhoea</title>
      <scientificTitle/>
      <acronym>FADD (Four-Agents-Decoction for Dysmenorrhoea)</acronym>
      <studyHypothesis>Added as of 23/04/07:
Four-Agents-Decoction (Si Wu Tang) is effective in treating primary dysmenorrhoea.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Added as of 23/04/07:
Pain intensity evaluated by an online unmarked Visual Analogue Scale (VAS) of one to ten cm matched 1000 scales in our database for the first five days of each menstrual cycle.</primaryOutcome>
      <secondaryOutcome>Added as of 23/04/07:
Uterine artery pulsatility index measured by study gynecologists.</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Added as of 23/04/07:
Approval received from the Human Ethics Committee, National Health Research Institutes; EC9103001(02/20/2002); EC9106001(11/11/2002); EC0930306 (04/27/2004).</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN23374750</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2003-01-02T00:00:00.000Z</overallStartDate>
      <overallEndDate>2004-07-16T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Taiwan</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="8375f72e-eb58-4f28-b317-bfc1b4d9aaa7">
	  <name>Division of Clinical Research</name>
	  <address/>
	  <city>Zhunan, Miaoli County</city>
	  <state/>
	  <country>Taiwan</country>
	  <zip>35053</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>College women aged 18 years and older suffering from menstrual pain with no pathological findings.

Added as of 23/04/07:
1. College women aged 18 years and older suffering from menstrual pain with no pathological findings
2. Cycles lasting 21 to 35 days with the actual menses periods lasting three to seven days, and having at least four consecutive painful periods in the past six months with the pain starting one day before or on the day of onset of bleeding</inclusion>
      <ageRange>Adult</ageRange>
      <lowerAgeLimit unit="Years" value="18.0"/>
      <gender>Female</gender>
      <targetEnrolment>78</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>78 (added as of 23/04/2007)</totalTarget>
      <exclusion>Added as of 23/04/07:
1. Taking oral contraceptive pills
2. Unwilling to refrain from sexual activity during the study
3. Having had severe gastrointestinal, gynaecological or autoimmune diseases, or gynaecological surgery, including pregnancy</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2003-01-02T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2004-07-16T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Primary dysmenorrhea</description>
	<diseaseClass1>Urological and Genital Diseases</diseaseClass1>
	<diseaseClass2>Noninflammatory disorders of female genital tract</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Two groups: four-agents decoction and placebo, both are in capsule form.

Added as of 23/04/07:
Two groups: Four-Agents-Dcoction (Si Wu Tang) and placebo, both are in capsule form. 

Intervention:
This Four-Agents-Decoction (Si Wu Tang) will be custom-made with raw materials prepared according to the original pharmacopoeia and concoctioned by water extraction in 1:13 ratio from single batched roots of the four plants in equal proportions: 
1. Prepared Radix Rehmanniae praeparata
2. Radix Angelicae sinensis
3. Radix Paeoniae alba, and 
4. Rhizoma Ligustici chuanxiong

Each capsule contains approximately 500 mg of granules from concentrated decoction, and this is sealed and secured with a band at the interface by a capsule supply company to ensure concealment of the aroma from the materials.  

Control:
The identical looking placebo capsules are filled with a powder mixture of cornstarch and caramel.  Regimens of five capsules are packaged in aluminum packets for easier handling and to prevent Four-Agents-Decoction (Si Wu Tang) from moisture exposure. 

Clinic visit number and case number are to be marked on each packet in both text and bar code.  The dosage is 15 capsules daily for five days from the onset of bleeding or pain determined after taking considerations: 
1. Habitual usages provided from the three surveys
2. Literature reports
3. A comparison of the concentrations of two indices, paeoniflorin and ferulic acid, in a one-day dose of a commercially available powder with the decoction made from raw materials
4. Information from the study&#146;s traditional Chinese medicine physicians, and 
5. Input from the study&#146;s leading gynaecologist.  

Ibuprofen tablet (400 mg), four times daily for three days, is provided for unbearable menstrual pain after holding it off.  The participants will record the pain intensity they experience right before taking ibuprofen, the intake of all drugs, the use of other remedies, the amount of collected menstrual blood for evaluating menorrhagia if any, and the number of days missing work or school on an online diary.  The intervention duration will be three menstrual cycles.</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>Four-Agents-Decoction (Si Wu Tang)</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2007 Results article in http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17710126 Results</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="9161f646-cbbe-4c39-9a98-6ec6de1b0b0f" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2007-08-15T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17710126"/>
	<description>Results</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder1437-0</funderId>
      <funderId>Funder1437-1</funderId>
      <funderId>Funder1437-2</funderId>
      <contactId>Contact5143_1437</contactId>
      <sponsorId>Sponsor5057</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact5143_1437">
    <title>Dr</title>
    <forename>Lan Lan Liang</forename>
    <surname>Yeh</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Division of Clinical Research
National Health Research Institutes
35 Keyan Road</address>
      <city>Zhunan, Miaoli County</city>
      <country>Taiwan</country>
      <zip>35053</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+886 37 246166</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">lanlanliang2@yahoo.com</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor5057">
    <organisation>National Health Research Institutes (Taiwan)</organisation>
    <website>http://www.nhri.org.tw</website>
    <sponsorType>Government</sponsorType>
    <contactDetails>
      <address>35 Keyan Road</address>
      <city>Zhunan, Miaoli County</city>
      <country>Taiwan</country>
      <zip>35053</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.59784.37</gridId>
    <rorId>https://ror.org/02r6fpx29</rorId>
  </sponsor>
  <funder id="Funder1437-0">
    <name>Intramural funding, National Health Research Institutes (Taiwan)</name>
    <fundRef/>
  </funder>
  <funder id="Funder1437-1">
    <name>Added as of 23/04/07:</name>
    <fundRef/>
  </funder>
  <funder id="Funder1437-2">
    <name>A supplemental grant from the Department of Health and The Office of National Science and Technology Program for Biotechnology and Pharmaceuticals (Taiwan)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-10-04T00:00:00.000Z" version="24">
    <isrctn dateAssigned="2002-08-02T00:00:00.000Z">55477154</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Dementia: Diagnosis and management in primary care - a primary care based education/research project</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>The project aims to investigate the effectiveness of different educational interventions in enabling primary care practitioners to respond to the needs of older people with dementia and their families. There are three study hypotheses:
1. Practitioners in practices which receive an educational intervention will demonstrate an increase in knowledge about recommended practice regarding the diagnosis and management of dementia compared to those who receive no such education
2. Medical records of people with a diagnosis of dementia in practices which receive an educational intervention will have a greater increase in concordance with North of England Evidence Based Guidelines on The Primary Care Management of Dementia compared to those who receive no such intervention
3. Families attending practices which receive an educational intervention will fare better on a range of outcomes including knowledge of dementia, knowledge and use of support services, satisfaction and stress</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Not provided at time of registration</primaryOutcome>
      <secondaryOutcome>Not provided at time of registration</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Not provided at time of registration</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN55477154</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>QRD/98/01/Dykes</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>GP practice</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Quality of life</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>1999-07-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2003-03-31T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>United Kingdom</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="629cd561-2df9-44a7-80c2-5fca28c2a6bd">
	  <name>Professor in Dementia Studies</name>
	  <address/>
	  <city>Bradford</city>
	  <state/>
	  <country>United Kingdom</country>
	  <zip>BD5 OBB</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>Being a general practice</inclusion>
      <ageRange>Not Specified</ageRange>
      <gender>Not Specified</gender>
      <targetEnrolment>0</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>Not provided at time of registration</totalTarget>
      <exclusion>Not provided at time of registration</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>1999-07-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2003-03-31T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Alzheimer's disease</description>
	<diseaseClass1>Nervous System Diseases</diseaseClass1>
	<diseaseClass2>Alzheimer's disease</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Four groups: 
1. Computer assisted learning
2. Decision support software
3. Small group practice learning
4. No intervention</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2006 Results article in https://pubmed.ncbi.nlm.nih.gov/16565124 Results</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="d4222d99-f726-4040-a9fa-d5aa37bcff74" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2006-03-25T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="https://pubmed.ncbi.nlm.nih.gov/16565124"/>
	<description>Results</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder1408-0</funderId>
      <contactId>Contact5385_1408</contactId>
      <sponsorId>Sponsor5001</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact5385_1408">
    <title>Professor</title>
    <forename>Murna</forename>
    <surname>Downs</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Professor in Dementia Studies
Head of Bradford Dementia Group
School for Health Studies
Unity Building
University of Bradford</address>
      <city>Bradford</city>
      <country>United Kingdom</country>
      <zip>BD5 OBB</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+44 (0)1274 233991</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">M.Downs@Bradford.ac.uk</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor5001">
    <organisation>Alzheimer's Society (UK)</organisation>
    <website/>
    <sponsorType>Charity</sponsorType>
    <contactDetails>
      <address>Gordon House
10 Greencoat Place</address>
      <city>London</city>
      <country>United Kingdom</country>
      <zip>SW1P 1PH</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+44 (0)207 306 0606</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">enquiries@alzheimers.org.uk</email>
    </contactDetails>
    <privacy>Public</privacy>
    <gridId>grid.432249.a</gridId>
    <rorId>https://ror.org/0472gwq90</rorId>
  </sponsor>
  <funder id="Funder1408-0">
    <name>Alzheimer's Society (UK) - through the Dykes Bequest</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-10-04T00:00:00.000Z" version="25">
    <isrctn dateAssigned="2002-07-19T00:00:00.000Z">85530591</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Functional evaluation of surgery and exercise in the treatment of prolapsed intervertebral disc</title>
      <scientificTitle/>
      <acronym>Not Applicable</acronym>
      <studyHypothesis>Not provided at time of registration</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Not provided at time of registration</primaryOutcome>
      <secondaryOutcome>Not provided at time of registration</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Not provided at time of registration</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN85530591</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>D0571</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>1997-01-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>1999-01-01T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>England</country>
	<country>United Kingdom</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="41824c51-835b-4e7c-951c-eaebd3ec9f0e">
	  <name>Anatomy Department</name>
	  <address/>
	  <city>Bristol</city>
	  <state/>
	  <country>United Kingdom</country>
	  <zip>BS2 8EJ</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Age between 18 and 65 years
2. Radiological evidence of disc protrusion in a position that correlates with the patient's signs and symptoms
3. Selection for decompression surgery</inclusion>
      <ageRange>Adult</ageRange>
      <lowerAgeLimit unit="Years" value="18.0"/>
      <gender>Both</gender>
      <targetEnrolment>0</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>Not provided at time of registration</totalTarget>
      <exclusion>Not provided at time of registration</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>1997-01-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>1999-01-01T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Prolapsed intervertebral disc</description>
	<diseaseClass1>Musculoskeletal Diseases</diseaseClass1>
	<diseaseClass2>Intervertebral disc disorders</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Patients randomised to the Exercise Group receive a 4 week postoperative exercise programme that begins 4 weeks after surgery. They attend the Physiotherapy Department at a local hospital for two 1-hour exercise classes per week over a period of 4 weeks. The classes involve some aerobic exercise but concentrate on exercises for strengthening and mobilising the trunk muscles such as back extension and flexion exercises. Classes are led by a physiotherapist but patients progress at their own pace. Attendance is recorded by the physiotherapist, and compliance with the exercise programme is monitored by means of weekly diary sheets kept by the patient and handed in at the end of the programme.

Control group received care as usual.</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2000 Results article in https://pubmed.ncbi.nlm.nih.gov/10851101 Results</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="6c8b2838-67e9-4774-9415-0c096308c441" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2000-06-15T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="https://pubmed.ncbi.nlm.nih.gov/10851101"/>
	<description>Results</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder1424-0</funderId>
      <contactId>Contact5221_1424</contactId>
      <sponsorId>Sponsor5003</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact5221_1424">
    <title>Dr</title>
    <forename>Trish</forename>
    <surname>Dolan</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Anatomy Department
University of Bristol
Southwell Street</address>
      <city>Bristol</city>
      <country>United Kingdom</country>
      <zip>BS2 8EJ</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+44 (0)117 928 8363</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">trish.dolan@bris.ac.uk</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor5003">
    <organisation>Arthritis Research Campaign (ARC) (UK)</organisation>
    <website>http://www.arc.org.uk</website>
    <sponsorType>Charity</sponsorType>
    <contactDetails>
      <address>Copeman House
St Mary's Court
St Mary's Gate
Chesterfield</address>
      <city>Derbyshire</city>
      <country>United Kingdom</country>
      <zip>S41 7TD</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">-</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">info@arc.org.uk</email>
    </contactDetails>
    <privacy>Public</privacy>
    <gridId>grid.507369.e</gridId>
    <rorId>https://ror.org/02jkpm469</rorId>
  </sponsor>
  <funder id="Funder1424-0">
    <name>Arthritis Research Campaign (UK)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-10-04T00:00:00.000Z" version="24">
    <isrctn dateAssigned="2002-07-18T00:00:00.000Z">98945627</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Control of Rheumatoid Arthritis (RA) by oral tolerance</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>Not provided at time of registration</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Not provided at time of registration</primaryOutcome>
      <secondaryOutcome>Not provided at time of registration</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Not provided at time of registration</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN98945627</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>S0523</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>1998-01-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2000-01-01T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>England</country>
	<country>United Kingdom</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="2590b32c-62e5-4c9f-aa04-e2fa64ab78c3">
	  <name>Academic Department of Rheumatology</name>
	  <address/>
	  <city>London</city>
	  <state/>
	  <country>United Kingdom</country>
	  <zip>SE22 8PT</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. RA patients aged over 18 and fulfilling the 1987 American College of Rheumatology (ACR) criteria for the diagnosis of RA were entered into the study after giving their written informed consent
2. Patients must have had the disease at least two years and have failed at least one Slow Acting Anti-Rheumatic Drug (SAARD)
3. All the patients had to have active arthritis defined by the presence of three out of four clinical criteria: three or more swollen joints, six or more tender joints, early morning stiffness over 45 minutes and Erythrocyte Sedimentation Rate (ESR) over 28 mm/h. Oral steroid treatment was permitted if the dose was more than 10 mg/day</inclusion>
      <ageRange>Not Specified</ageRange>
      <gender>Not Specified</gender>
      <targetEnrolment>0</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>Not provided at time of registration</totalTarget>
      <exclusion>Not provided at time of registration</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>1998-01-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2000-01-01T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Rheumatoid arthritis</description>
	<diseaseClass1>Musculoskeletal Diseases</diseaseClass1>
	<diseaseClass2>Rheumatoid arthritis</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Patients were randomly assigned to receive either 0.05 mg, 0.5 mg or 5 mg daily of bovine type II collagen (CII) or placebo for six months</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>Bovine type II collagen</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2001 Results article in https://pubmed.ncbi.nlm.nih.gov/11592359 Results</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="c1b881cb-17a2-44a6-bcae-d4c422cecf1b" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2001-09-01T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="https://pubmed.ncbi.nlm.nih.gov/11592359"/>
	<description>Results</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder1404-0</funderId>
      <contactId>Contact5056_1404</contactId>
      <sponsorId>Sponsor5003</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact5056_1404">
    <title>Dr</title>
    <forename>Ernest</forename>
    <surname>Choy</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Academic Department of Rheumatology
GKT School of Medicines
King's College Hospital (Dulwich)
East Dulwich Grove</address>
      <city>London</city>
      <country>United Kingdom</country>
      <zip>SE22 8PT</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+44 (0)20 7346 6446</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor5003">
    <organisation>Arthritis Research Campaign (ARC) (UK)</organisation>
    <website>http://www.arc.org.uk</website>
    <sponsorType>Charity</sponsorType>
    <contactDetails>
      <address>Copeman House
St Mary's Court
St Mary's Gate
Chesterfield</address>
      <city>Derbyshire</city>
      <country>United Kingdom</country>
      <zip>S41 7TD</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">-</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">info@arc.org.uk</email>
    </contactDetails>
    <privacy>Public</privacy>
    <gridId>grid.507369.e</gridId>
    <rorId>https://ror.org/02jkpm469</rorId>
  </sponsor>
  <funder id="Funder1404-0">
    <name>Arthritis Research Campaign (UK)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-10-04T00:00:00.000Z" version="24">
    <isrctn dateAssigned="2002-07-18T00:00:00.000Z">88303017</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>An evaluation of the use of computer assisted learning in the teaching of musculoskeletal examination skills</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>In order to optimise the treatment of people with arthritis and related conditions it is important that all doctors have the necessary skills to examine and assess joints. In the past teaching of these skills has not been a priority in medical schools and there is a need for it to be improved, despite financial and staffing restrictions. Rheumatology nurse specialists are increasingly involved in the assessment and treatment of patients and there is a similar need for effective but efficient training in this group. The aim of our study is to test whether a multimedia computer package is of value in helping medical students, GP trainees and nurse specialists in learning to assess the shoulder and knee joints. Our findings will also be a guide to whether it is worth developing similar computer based packages in the future.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Not provided at time of registration</primaryOutcome>
      <secondaryOutcome>Not provided at time of registration</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Not provided at time of registration</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN88303017</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>H0628</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Other</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Quality of life</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2001-09-30T00:00:00.000Z</overallStartDate>
      <overallEndDate>2005-06-29T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>England</country>
	<country>United Kingdom</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="c8afc273-50f0-4dcb-916d-4d1b97cf79e9">
	  <name>Staffordshire Rheumatology Centre</name>
	  <address/>
	  <city>Stoke-on-Trent</city>
	  <state/>
	  <country>United Kingdom</country>
	  <zip>ST6 7AG</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>Undergraduate medical students.</inclusion>
      <ageRange>Not Specified</ageRange>
      <gender>Not Specified</gender>
      <targetEnrolment>0</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>Not provided at time of registration</totalTarget>
      <exclusion>Not provided at time of registration</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2001-09-30T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2005-06-29T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Arthritis</description>
	<diseaseClass1>Musculoskeletal Diseases</diseaseClass1>
	<diseaseClass2>Arthritis</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>CDROM versus video (undergraduate medical students).</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2005 Results article in https://pubmed.ncbi.nlm.nih.gov/16208642 Results</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="b5f54603-94a3-48b7-8af2-66753cb1f4c5" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2005-10-15T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="https://pubmed.ncbi.nlm.nih.gov/16208642"/>
	<description>Results</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder1421-0</funderId>
      <contactId>Contact5028_1421</contactId>
      <sponsorId>Sponsor5003</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact5028_1421">
    <title>Dr</title>
    <forename>Andrew</forename>
    <surname>Hassell</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Staffordshire Rheumatology Centre
Haywood Hospital
High Lane
Burslem</address>
      <city>Stoke-on-Trent</city>
      <country>United Kingdom</country>
      <zip>ST6 7AG</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+44 (0)1782 556308</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">andyhassell@doctors.org.uk</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor5003">
    <organisation>Arthritis Research Campaign (ARC) (UK)</organisation>
    <website>http://www.arc.org.uk</website>
    <sponsorType>Charity</sponsorType>
    <contactDetails>
      <address>Copeman House
St Mary's Court
St Mary's Gate
Chesterfield</address>
      <city>Derbyshire</city>
      <country>United Kingdom</country>
      <zip>S41 7TD</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">-</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">info@arc.org.uk</email>
    </contactDetails>
    <privacy>Public</privacy>
    <gridId>grid.507369.e</gridId>
    <rorId>https://ror.org/02jkpm469</rorId>
  </sponsor>
  <funder id="Funder1421-0">
    <name>Arthritis Research Campaign (UK)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-10-04T00:00:00.000Z" version="25">
    <isrctn dateAssigned="2002-07-16T00:00:00.000Z">41782781</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Evaluation of the Oxfordshire Physiotherapy Service for patients with low back pain: a multicentre randomised controlled trial</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>To measure the effectiveness of routine physiotherapy compared with an assessment session and advice from a physiotherapist for patients with low back pain.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Scores on the Oswestry disability index at 12 months: 0% (no disability) to 100% (totally disabled or bed ridden).</primaryOutcome>
      <secondaryOutcome>1. Scores on the Oswestry disability index at two and six months
2. Scores on the Roland and Morris disability questionnaire at 2, 6, and 12 months
3. General health was measured with the 36-item Short Form health survey (SF-36) at 2, 6, and 12 months (higher scores indicate better health)
4. Patient perceived benefit of treatment was measured on a scale from 0 (no benefit) to 10 (maximum benefit) and on a dichotomous scale (perceived benefit or no perceived benefit)</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Not provided at time of registration</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN41782781</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>F0519</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Quality of life</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>1997-10-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2001-01-01T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Scotland</country>
	<country>United Kingdom</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="b9da1466-5fc2-4acd-bf57-704249aa8ead">
	  <name>Faculty of Health Sciences</name>
	  <address/>
	  <city>Edinburgh</city>
	  <state/>
	  <country>United Kingdom</country>
	  <zip>EH6 8HF</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Aged 18+ years 
2. Subacute (more than 6 weeks less than 3 months) or chronic (more than 3 months) mechanical low back pain 
3. With or without leg pain or neurological signs</inclusion>
      <ageRange>Adult</ageRange>
      <lowerAgeLimit unit="Years" value="18.0"/>
      <gender>Both</gender>
      <targetEnrolment>286</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>286</totalTarget>
      <exclusion>1. Patients with serious conditions including:
1.1. Systemic rheumatological disease
1.2. Gynaecological problems
1.3. Ankylosing spondylitis
1.4. Tumours
1.5. Infection
2. Past spinal operations
3. Treatment for physical problems in the past month
4. Referred for intensive functional restoration programmes</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>1997-10-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2001-01-01T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Low back pain</description>
	<diseaseClass1>Musculoskeletal Diseases</diseaseClass1>
	<diseaseClass2>Low back pain</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Group 1: Advice group - 
This group will have a single contact with a physiotherapist who will offer self management advice as specified in the advice booklet (see below). Specific exercises will not be advised.

Group 2: Routine physiotherapy treatment - 
The physiotherapists will decide on the content of treatment according to their assessment. Treatment will be restricted to a combination of the following techniques depending on the physiotherapists' clinical judgment: 
1. Mobilisation techniques including manipulation
2. Soft tissue techniques
3. Individual exercise programmes 
4. Heat or cold treatment. 

No electrotherapy or traction will be used. Trial participants will receive a maximum of six treatment sessions. Information will be recorded on the type of physiotherapy intervention and the level of training and clinical experience of the physiotherapist.

Advice booklet: 
Patients in group 1 and group 2 will be given a standardised advice booklet that has been produced by a group of experts in the field of low back pain. The advice in the booklet will be explained by the physiotherapist in a session lasting up to 1 hour. It will encourage activity and discourage bed rest.</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2004 Results article in https://pubmed.ncbi.nlm.nih.gov/15377573 Results</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="f61dda43-45b7-40f0-9716-5f423fce0583" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2004-09-25T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="https://pubmed.ncbi.nlm.nih.gov/15377573"/>
	<description>Results</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder1420-0</funderId>
      <contactId>Contact5084_1420</contactId>
      <sponsorId>Sponsor5003</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact5084_1420">
    <title>Dr</title>
    <forename>Helen</forename>
    <surname>Frost</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Faculty of Health Sciences
Physiotherapy Department
Queen Margaret University College 
Duke Street 
Leith</address>
      <city>Edinburgh</city>
      <country>United Kingdom</country>
      <zip>EH6 8HF</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+44 (0)131 317 3654</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">hfrost@qmuc.ac.uk</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor5003">
    <organisation>Arthritis Research Campaign (ARC) (UK)</organisation>
    <website>http://www.arc.org.uk</website>
    <sponsorType>Charity</sponsorType>
    <contactDetails>
      <address>Copeman House
St Mary's Court
St Mary's Gate
Chesterfield</address>
      <city>Derbyshire</city>
      <country>United Kingdom</country>
      <zip>S41 7TD</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">-</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">info@arc.org.uk</email>
    </contactDetails>
    <privacy>Public</privacy>
    <gridId>grid.507369.e</gridId>
    <rorId>https://ror.org/02jkpm469</rorId>
  </sponsor>
  <funder id="Funder1420-0">
    <name>Arthritis Research Campaign (UK)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-10-03T00:00:00.000Z" version="24">
    <isrctn dateAssigned="2002-07-15T00:00:00.000Z">25152388</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>A double-blind placebo-controlled trial of intra-articular triamcinolone with and without physiotherapy in adhesive capsulitis</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>To assess the effectiveness of intra-articular triamcinolone injection and physiotherapy singly or combined in the treatment of adhesive capsulitis of the shoulder.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Not provided at time of registration</primaryOutcome>
      <secondaryOutcome>Not provided at time of registration</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Not provided at time of registration</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN25152388</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>M0567</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>1998-10-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2002-04-01T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Northern Ireland</country>
	<country>United Kingdom</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="107b23d4-bf02-4015-b16e-a23d0e735eed">
	  <name>Rheumatology Department</name>
	  <address/>
	  <city>Dundonald</city>
	  <state/>
	  <country>United Kingdom</country>
	  <zip>BT16 1RH</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>Painful shoulder for more than 4 weeks and less than 6 months with greater than 25% limitation of active and passive range of movement in external rotation and abduction as compared with the contralateral shoulder.</inclusion>
      <ageRange>Not Specified</ageRange>
      <gender>Not Specified</gender>
      <targetEnrolment>0</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>Not provided at time of registration</totalTarget>
      <exclusion>Not provided at time of registration</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>1998-10-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2002-04-01T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Adhesive capsulitis of the shoulder</description>
	<diseaseClass1>Musculoskeletal Diseases</diseaseClass1>
	<diseaseClass2>Adhesive capsulitis of shoulder</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>1. Intra-articular triamcinolone and physiotherapy
2. Intra-articular triamcinolone without physiotherapy
3. Intra-articular placebo and physiotherapy
4. Intra-articular placebo without physiotherapy</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>Triamcinolone</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2005 Results article in https://pubmed.ncbi.nlm.nih.gov/15657070 Results</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="3ff5420c-2926-46a7-8671-4c8435085c1f" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2005-04-01T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="https://pubmed.ncbi.nlm.nih.gov/15657070"/>
	<description>Results</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder1378-0</funderId>
      <contactId>Contact5105_1378</contactId>
      <sponsorId>Sponsor5003</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact5105_1378">
    <title>Dr</title>
    <forename>Ian</forename>
    <surname>Ryans</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Rheumatology Department 
Ulster Hospital</address>
      <city>Dundonald</city>
      <country>United Kingdom</country>
      <zip>BT16 1RH</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+44 (0)2890 484511</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor5003">
    <organisation>Arthritis Research Campaign (ARC) (UK)</organisation>
    <website>http://www.arc.org.uk</website>
    <sponsorType>Charity</sponsorType>
    <contactDetails>
      <address>Copeman House
St Mary's Court
St Mary's Gate
Chesterfield</address>
      <city>Derbyshire</city>
      <country>United Kingdom</country>
      <zip>S41 7TD</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">-</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">info@arc.org.uk</email>
    </contactDetails>
    <privacy>Public</privacy>
    <gridId>grid.507369.e</gridId>
    <rorId>https://ror.org/02jkpm469</rorId>
  </sponsor>
  <funder id="Funder1378-0">
    <name>Arthritis Research Campaign (UK)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-10-04T00:00:00.000Z" version="24">
    <isrctn dateAssigned="2002-07-15T00:00:00.000Z">71084664</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Applicability of an educational-behavioural joint protection programme in practice</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>Not provided at time of registration</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Not provided at time of registration</primaryOutcome>
      <secondaryOutcome>Not provided at time of registration</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Not provided at time of registration</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN71084664</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>H0606</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Quality of life</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>1998-01-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2000-01-01T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>England</country>
	<country>United Kingdom</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="f5826e0d-0f8e-427e-9162-6ac8a98d6b61">
	  <name>Rheumatology</name>
	  <address/>
	  <city>Derby</city>
	  <state/>
	  <country>United Kingdom</country>
	  <zip>DE1 2QY</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Diagnosed with Rheumatoid Arthritis (RA) by a Consultant Rheumatologist
2. Wrist and or metacarpophalangeal joint disease currently or recently (within previous 6 months) affecting hand function
3. Currently experiencing hand pain on activity</inclusion>
      <ageRange>Not Specified</ageRange>
      <gender>Not Specified</gender>
      <targetEnrolment>0</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>Not provided at time of registration</totalTarget>
      <exclusion>Not provided at time of registration</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>1998-01-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2000-01-01T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Rheumatoid arthritis (RA)</description>
	<diseaseClass1>Musculoskeletal Diseases</diseaseClass1>
	<diseaseClass2>Rheumatoid arthritis</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>1. Joint protection educational-behavioural programme: four x 2 hour weekly meetings. Specific training on joint protection (approx 5 h practical). Supported by information pack and patient workbook, goal setting, home programme
2. Waiting list control (no intervention)</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2001 Results article in https://pubmed.ncbi.nlm.nih.gov/11561117 Results</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="71f6f91a-5652-479e-a06e-db185a3fff90" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2001-09-01T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="https://pubmed.ncbi.nlm.nih.gov/11561117"/>
	<description>Results</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder1396-0</funderId>
      <contactId>Contact5026_1396</contactId>
      <sponsorId>Sponsor5003</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact5026_1396">
    <title>Dr</title>
    <forename>Alison</forename>
    <surname>Hammond</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Rheumatology
Derbyshire Royal Infirmary
London Road</address>
      <city>Derby</city>
      <country>United Kingdom</country>
      <zip>DE1 2QY</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+44 (0)1332 347141</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">alison.hammond@sdah-tr.trent.nhs.uk</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor5003">
    <organisation>Arthritis Research Campaign (ARC) (UK)</organisation>
    <website>http://www.arc.org.uk</website>
    <sponsorType>Charity</sponsorType>
    <contactDetails>
      <address>Copeman House
St Mary's Court
St Mary's Gate
Chesterfield</address>
      <city>Derbyshire</city>
      <country>United Kingdom</country>
      <zip>S41 7TD</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">-</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">info@arc.org.uk</email>
    </contactDetails>
    <privacy>Public</privacy>
    <gridId>grid.507369.e</gridId>
    <rorId>https://ror.org/02jkpm469</rorId>
  </sponsor>
  <funder id="Funder1396-0">
    <name>Arthritis Research Campaign (UK)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-10-02T00:00:00.000Z" version="24">
    <isrctn dateAssigned="2002-07-15T00:00:00.000Z">92332799</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>The effectiveness of magnetic bracelets as used in the consumer market for pain in osteoarthritis</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>To determine the effectiveness of commercially available magnetic bracelets for pain control in osteoarthritis of the hip and knee.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Not provided at time of registration</primaryOutcome>
      <secondaryOutcome>Not provided at time of registration</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Not provided at time of registration</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN92332799</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>E0542</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2001-12-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2003-12-01T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>England</country>
	<country>United Kingdom</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="1181916e-096a-43c1-86e4-154fe1c3fedc">
	  <name>Department of Complementary Medicine</name>
	  <address/>
	  <city>Exeter</city>
	  <state/>
	  <country>United Kingdom</country>
	  <zip>EX2 4NT</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>Men and women aged 45 to 80 years at entry into the trial with osteoarthritis of the hip and or knee either radiologically proven or diagnosed by a consultant rheumatologist or consultant orthopaedic surgeon.</inclusion>
      <ageRange>Adult</ageRange>
      <gender>Both</gender>
      <targetEnrolment>194</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>194</totalTarget>
      <exclusion>Not provided at time of registration</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2001-12-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2003-12-01T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Osteoarthritis</description>
	<diseaseClass1>Musculoskeletal Diseases</diseaseClass1>
	<diseaseClass2>Osteoarthritis</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>1. Will receive bracelets with active magnets
2. Will receive the placebo bracelet, with less active magnets
3. Will receive a control bracelet, with no magnets</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2004 Results article in https://pubmed.ncbi.nlm.nih.gov/15604181 Results</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="9db394ba-5cc9-49fd-8cd0-4bb65393006e" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2004-12-18T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="https://pubmed.ncbi.nlm.nih.gov/15604181"/>
	<description>Results</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder1397-0</funderId>
      <contactId>Contact5315_1397</contactId>
      <sponsorId>Sponsor5003</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact5315_1397">
    <title>Professor</title>
    <forename>E</forename>
    <surname>Ernst</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Department of Complementary Medicine
University of Exeter
25 Victoria Park Road</address>
      <city>Exeter</city>
      <country>United Kingdom</country>
      <zip>EX2 4NT</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+44 (0)1392 424989</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">e.ernst@exeter.ac.uk</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor5003">
    <organisation>Arthritis Research Campaign (ARC) (UK)</organisation>
    <website>http://www.arc.org.uk</website>
    <sponsorType>Charity</sponsorType>
    <contactDetails>
      <address>Copeman House
St Mary's Court
St Mary's Gate
Chesterfield</address>
      <city>Derbyshire</city>
      <country>United Kingdom</country>
      <zip>S41 7TD</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">-</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">info@arc.org.uk</email>
    </contactDetails>
    <privacy>Public</privacy>
    <gridId>grid.507369.e</gridId>
    <rorId>https://ror.org/02jkpm469</rorId>
  </sponsor>
  <funder id="Funder1397-0">
    <name>Arthritis Research Campaign (UK)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-10-03T00:00:00.000Z" version="25">
    <isrctn dateAssigned="2002-07-15T00:00:00.000Z">91217042</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>A prospective randomised placebo controlled trial of treatment for fibrosing alveolitis in scleroderma</title>
      <scientificTitle/>
      <acronym>FAST study</acronym>
      <studyHypothesis>Does routine treatment with cyclophosphamide, azathioprine and prednisolone improve outcomes in fibrosing alveolitis associated with scleroderma?</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>1. Change in percent predicted Forced Vital Capacity (FVC)
2. Change in single-breath diffusing capacity for carbon monoxide (DLCO)</primaryOutcome>
      <secondaryOutcome>1. Changes in appearance on high-resolution computed tomography
2. Change in dyspnoea scores</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Not provided at time of registration</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN91217042</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>D0554</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>1998-10-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2003-10-31T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>England</country>
	<country>United Kingdom</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="b4f97861-6455-435a-b76e-cfc608569846">
	  <name>Royal Brompton Hospital</name>
	  <address/>
	  <city>London</city>
	  <state/>
	  <country>United Kingdom</country>
	  <zip>SW3 6MP</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Aged 18 - 75 years
2. American College of Rheumatology (ACR) criteria for scleroderma
3. Evidence for fibrosing alveolitis - High Resolution Computed Tomography (HRCT) or surgical biopsy</inclusion>
      <ageRange>Adult</ageRange>
      <lowerAgeLimit unit="Years" value="18.0"/>
      <gender>Both</gender>
      <targetEnrolment>45</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>45</totalTarget>
      <exclusion>Not provided at time of registration</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>1998-10-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2003-10-31T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Fibrosing alveolitis in scleroderma</description>
	<diseaseClass1>Musculoskeletal Diseases</diseaseClass1>
	<diseaseClass2>Systemic sclerosis</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Intravenous cyclophosphamide plus prednisolone for 6 months followed by azathioprine for 2.5 years or placebo for all drugs</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>Cyclophosphamide, azathioprine and prednisolone</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2006 Results article in https://pubmed.ncbi.nlm.nih.gov/17133610 Results</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="fcb434c9-d5fe-4580-b409-3389d8a921de" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2006-12-01T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="https://pubmed.ncbi.nlm.nih.gov/17133610"/>
	<description>Results</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder1398-0</funderId>
      <contactId>Contact5378_1398</contactId>
      <sponsorId>Sponsor5003</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact5378_1398">
    <title>Professor</title>
    <forename>RM</forename>
    <surname>duBois</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Royal Brompton Hospital
Sydney Street</address>
      <city>London</city>
      <country>United Kingdom</country>
      <zip>SW3 6MP</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+44 (0)20 7351 8327</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">r.dubois@rbh.nthames.nhs.uk</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor5003">
    <organisation>Arthritis Research Campaign (ARC) (UK)</organisation>
    <website>http://www.arc.org.uk</website>
    <sponsorType>Charity</sponsorType>
    <contactDetails>
      <address>Copeman House
St Mary's Court
St Mary's Gate
Chesterfield</address>
      <city>Derbyshire</city>
      <country>United Kingdom</country>
      <zip>S41 7TD</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">-</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">info@arc.org.uk</email>
    </contactDetails>
    <privacy>Public</privacy>
    <gridId>grid.507369.e</gridId>
    <rorId>https://ror.org/02jkpm469</rorId>
  </sponsor>
  <funder id="Funder1398-0">
    <name>Arthritis Research Campaign (UK)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-10-03T00:00:00.000Z" version="24">
    <isrctn dateAssigned="2002-07-15T00:00:00.000Z">14554919</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Induction of true remission in early poor prognosis (erosive) rheumatoid arthritis (RA) - a randomised study of methotrexate and intra-articular corticosteroids or placebo</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>Not provided at time of registration</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Not provided at time of registration</primaryOutcome>
      <secondaryOutcome>Not provided at time of registration</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Not provided at time of registration</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN14554919</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>E0516</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Not Specified</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>1995-06-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>1997-03-01T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>England</country>
	<country>United Kingdom</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="95c89564-f534-4a66-b7fb-a14b34eeb038">
	  <name>Rheumatology and Rehabilitation Research Unit</name>
	  <address/>
	  <city>Leeds</city>
	  <state/>
	  <country>United Kingdom</country>
	  <zip>LS2 9NZ</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. All patients to meet the American College of Rheumatology criteria for RA
2. Poor prognosis disease according to criteria based on the presence of factors known to be predictive of poor long-term outcome
3. Adequate contraception a prerequisite</inclusion>
      <ageRange>Not Specified</ageRange>
      <gender>Not Specified</gender>
      <targetEnrolment>82</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>82</totalTarget>
      <exclusion>Not provided at time of registration</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>1995-06-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>1997-03-01T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Early rheumatoid arthritis</description>
	<diseaseClass1>Musculoskeletal Diseases</diseaseClass1>
	<diseaseClass2>Rheumatoid arthritis</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>1. Receive combination therapy (n = 40)
2. Receive sulfasalazine (SSZ) alone (n = 42)</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2000 Results article in https://pubmed.ncbi.nlm.nih.gov/10943871 Results</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="4f2d9cfa-da2c-4f00-ab2a-333100f03726" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2000-08-01T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="https://pubmed.ncbi.nlm.nih.gov/10943871"/>
	<description>Results</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder1399-0</funderId>
      <contactId>Contact5388_1399</contactId>
      <sponsorId>Sponsor5003</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact5388_1399">
    <title>Professor</title>
    <forename>Paul</forename>
    <surname>Emery</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Rheumatology and Rehabilitation Research Unit
University of Leeds
36 Clarendon Road</address>
      <city>Leeds</city>
      <country>United Kingdom</country>
      <zip>LS2 9NZ</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+44 (0)113 233 4940</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">p.emery@leeds.ac.uk</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor5003">
    <organisation>Arthritis Research Campaign (ARC) (UK)</organisation>
    <website>http://www.arc.org.uk</website>
    <sponsorType>Charity</sponsorType>
    <contactDetails>
      <address>Copeman House
St Mary's Court
St Mary's Gate
Chesterfield</address>
      <city>Derbyshire</city>
      <country>United Kingdom</country>
      <zip>S41 7TD</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">-</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">info@arc.org.uk</email>
    </contactDetails>
    <privacy>Public</privacy>
    <gridId>grid.507369.e</gridId>
    <rorId>https://ror.org/02jkpm469</rorId>
  </sponsor>
  <funder id="Funder1399-0">
    <name>Arthritis Research Campaign (UK)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-10-02T00:00:00.000Z" version="24">
    <isrctn dateAssigned="2002-07-12T00:00:00.000Z">12245727</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Four year follow-up of a randomised controlled trial of joint protection for people with rheumatoid arthritis (RA)</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>To evaluate the long-term effects of joint protection on health status of people with early rheumatoid arthritis (RA).</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Not provided at time of registration</primaryOutcome>
      <secondaryOutcome>Not provided at time of registration</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Not provided at time of registration</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN12245727</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>H0592</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>1999-11-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2000-08-30T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>England</country>
	<country>United Kingdom</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="cd66fad5-2d77-479a-b632-56fcaa905f4b">
	  <name>Rheumatology</name>
	  <address/>
	  <city>Derby</city>
	  <state/>
	  <country>United Kingdom</country>
	  <zip>DE1 2QY</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Adult patients with diagnosis of rheumatoid arthritis
2. Wrist and or metacarpophalangeal joint disease currently or recently (within previous 6 months) affecting hand function
3. Currently experiencing hand pain on activity
4. Up to 5 years disease duration</inclusion>
      <ageRange>Not Specified</ageRange>
      <gender>Not Specified</gender>
      <targetEnrolment>0</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>Not provided at time of registration</totalTarget>
      <exclusion>Not provided at time of registration</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>1999-11-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2000-08-30T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Rheumatoid arthritis</description>
	<diseaseClass1>Musculoskeletal Diseases</diseaseClass1>
	<diseaseClass2>Rheumatoid arthritis</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Participants randomly allocated to:
1. Standard Arthritis Education Programme (AEP): 4 x 2 hour weekly programme of education and practical advice delivered by rheumatology team. Education based on standard practice, e.g., information about RA, drugs, exercise, joint protection, relaxation, pain management, benefits, diet.
2. Joint protection educational-behavioural programme: 4 x 2 hour weekly meetings. Specific training on joint protection (approx 5 hour practical). Supported by information pack and patient workbook, goal setting, home programme.</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2004 Results article in https://pubmed.ncbi.nlm.nih.gov/15293486 Results</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="833f2be0-96ae-4c3f-b86a-d16a870e46b5" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2004-08-01T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="https://pubmed.ncbi.nlm.nih.gov/15293486"/>
	<description>Results</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder1395-0</funderId>
      <contactId>Contact5026_1395</contactId>
      <sponsorId>Sponsor5003</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact5026_1395">
    <title>Dr</title>
    <forename>Alison</forename>
    <surname>Hammond</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Rheumatology
Derbyshire Royal Infirmary
London Road</address>
      <city>Derby</city>
      <country>United Kingdom</country>
      <zip>DE1 2QY</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+44 (0)1332 347141</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">alison.hammond@sdah-tr.trent.nhs.uk</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor5003">
    <organisation>Arthritis Research Campaign (ARC) (UK)</organisation>
    <website>http://www.arc.org.uk</website>
    <sponsorType>Charity</sponsorType>
    <contactDetails>
      <address>Copeman House
St Mary's Court
St Mary's Gate
Chesterfield</address>
      <city>Derbyshire</city>
      <country>United Kingdom</country>
      <zip>S41 7TD</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">-</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">info@arc.org.uk</email>
    </contactDetails>
    <privacy>Public</privacy>
    <gridId>grid.507369.e</gridId>
    <rorId>https://ror.org/02jkpm469</rorId>
  </sponsor>
  <funder id="Funder1395-0">
    <name>Arthritis Research Campaign (UK)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-10-02T00:00:00.000Z" version="24">
    <isrctn dateAssigned="2002-07-10T00:00:00.000Z">65477168</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>A randomised controlled study of combination therapy in rheumatoid arthritis (RA) patients with a suboptimal response to sulphasalazine</title>
      <scientificTitle/>
      <acronym>MASCOT</acronym>
      <studyHypothesis>Not provided at time of registration</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Not provided at time of registration</primaryOutcome>
      <secondaryOutcome>Not provided at time of registration</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Not provided at time of registration</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN65477168</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>C0640</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2002-07-31T00:00:00.000Z</overallStartDate>
      <overallEndDate>2005-04-29T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Scotland</country>
	<country>United Kingdom</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="5d495472-292e-42ae-b593-b012956f2d3e">
	  <name>Centre for Rheumatic Diseases</name>
	  <address/>
	  <city>Glasgow</city>
	  <state/>
	  <country>United Kingdom</country>
	  <zip>G4 0SF</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Male or female
2. Age 18 - 75 years
3. Onset of disease after age 16  
4. Disease duration less than 5 years
5. Active inflammatory arthritis which is defined as six or more swollen joints plus two of the following:
5.1. Morning stiffness more than 45 minutes
5.2. Nine or more tender joints 
5.3. Erythrocyte Sedimentation Rate (ESR) more than 28 mm/h</inclusion>
      <ageRange>Not Specified</ageRange>
      <gender>Not Specified</gender>
      <targetEnrolment>0</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>Not provided at time of registration</totalTarget>
      <exclusion>Not provided at time of registration</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2002-07-31T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2005-04-29T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Rheumatoid arthritis</description>
	<diseaseClass1>Musculoskeletal Diseases</diseaseClass1>
	<diseaseClass2>Rheumatoid arthritis</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Sulphasalazine will be used as a disease modifying agent for 6 months, target dose 40 mg/kg (to maximum tolerated dose or 4 g daily as maximum permitted dose).  At 6 months those with a suboptimal response defined below will be randomly allocated to:
1. Sulphasalazine and methotrexate placebo
2. Sulphasalazine and active methotrexate
3. Active methotrexate and sulphasalazine placebo

The maximum permitted dose of methotrexate will be 30 mg/week or methotrexate placebo. The maximum permitted dose of sulphasalazine will be 4 g/daily and no intra-articular or intramuscular steroid permitted within 1 month of the 6 month and 18 month assessments. All patients will receive weekly folic acid 5 mg daily between 6 and 18 months whether allocated to group 1, 2 or 3.</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>Sulphasalazine, methotrexate, folic acid</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2007 Results article in https://pubmed.ncbi.nlm.nih.gov/16926184 Results</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="c61ebb69-31bc-4001-a3f7-dd9329072cac" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2007-02-01T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="https://pubmed.ncbi.nlm.nih.gov/16926184"/>
	<description>Results</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder1392-0</funderId>
      <contactId>Contact5082_1392</contactId>
      <sponsorId>Sponsor5003</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact5082_1392">
    <title>Dr</title>
    <forename>H</forename>
    <surname>Capell</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Centre for Rheumatic Diseases
Glasgow Royal Infirmary
Castle Street</address>
      <city>Glasgow</city>
      <country>United Kingdom</country>
      <zip>G4 0SF</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+44 (0)141 211 4965</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">hilary.capell@northglasgow.scot.nhs.uk</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor5003">
    <organisation>Arthritis Research Campaign (ARC) (UK)</organisation>
    <website>http://www.arc.org.uk</website>
    <sponsorType>Charity</sponsorType>
    <contactDetails>
      <address>Copeman House
St Mary's Court
St Mary's Gate
Chesterfield</address>
      <city>Derbyshire</city>
      <country>United Kingdom</country>
      <zip>S41 7TD</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">-</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">info@arc.org.uk</email>
    </contactDetails>
    <privacy>Public</privacy>
    <gridId>grid.507369.e</gridId>
    <rorId>https://ror.org/02jkpm469</rorId>
  </sponsor>
  <funder id="Funder1392-0">
    <name>Arthritis Research Campaign (UK)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-10-02T00:00:00.000Z" version="25">
    <isrctn dateAssigned="2002-07-10T00:00:00.000Z">79105828</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Can monthly low dose intramuscular (IM) steroids prevent erosive damage in established rheumatoid arthritis? A randomised placebo controlled trial</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>To evaluate the benefits of 120 mg intramuscular (IM) depomedrone versus placebo in patients with established Rheumatoid Arthritis (RA) whose disease was inadequately controlled by existing Disease Modifying Anti-Rheumatic Drugs (DMARDs).</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>1. Disease activity assessed every 6 months using:
1.1. Numbers of swollen and tender joints (out of 28)
1.2. Articular pain (100 mm Visual Analogue Scale [VAS])
1.3. Patient&#146;s and physician&#146;s global assessments (100 mm VAS)
1.4. ESR
1.5. C-Reactive Protein (CRP)
1.6. Health Assessment Questionnaire (HAQ) scores
1.7. 28 joint count Disease Activity Scores (DAS28)
2. Radiological damage in the hands and feet assessed every 12 months using a modification of Larsen&#146;s method
3. Adverse effects assessed every 6 months, including specific information on fractures, hypertension, hyperglycaemia, weight gain, and infections. Bone density was assessed in the lumbar spine and hip by Dual energy X ray Absorptiometry (DXA) at 0 and 24 months</primaryOutcome>
      <secondaryOutcome>No secondary outcome measures</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Research ethics committees at each collaborating centre approved the trial. All patients enrolled gave informed consent.</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN79105828</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>C0560</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>1997-11-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2003-04-01T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>England</country>
	<country>United Kingdom</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="32bdc15b-c326-4a55-9dd7-416c8ea750f1">
	  <name>Academic Department of Rheumatology</name>
	  <address/>
	  <city>London</city>
	  <state/>
	  <country>United Kingdom</country>
	  <zip>SE22 8PT</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Age equal to or more than 18 years
2. Diagnosis of rheumatoid arthritis according to the 1987 American College of Rheumatology criteria
3. Disease duration equal to or more than 2 years
4. One or more erosions on plain X-rays of the hands, wrists and feet
5. Continuous treatment with a Slow-Acting Anti-Rheumatic Drug (SAARD) for at least 3 months (parenteral gold, penicillamine, sulphasalazine, methotrexate, azathioprine and cyclosporin)
6. Continuing active disease with over 6 swollen joints and an Erythrocyte Sedimentation Rate (ESR) over 30 mm/h</inclusion>
      <ageRange>Adult</ageRange>
      <lowerAgeLimit unit="Years" value="18.0"/>
      <gender>Both</gender>
      <targetEnrolment>91</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>91</totalTarget>
      <exclusion>1. End stage joint destruction (Larsen score greater than 100)
2. Previous or current oral steroid treatment
3. Contraindications to parenteral steroids (for example, recent gastric ulcer perforation or bleed)
4. Serious comorbidity (for example, end stage renal or liver disease)
5. Patients not taking DMARDs, taking experimental drugs, taking DMARDs that have no effect on x-ray progression (for example, antimalarial drugs), or taking DMARDs which may interact poorly with IM depot steroids</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>1997-11-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2003-04-01T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Rheumatoid arthritis</description>
	<diseaseClass1>Musculoskeletal Diseases</diseaseClass1>
	<diseaseClass2>Rheumatoid arthritis</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Patients will be randomised to receive either:
1. Monthly IM injections of 120 mg depomedrone
2. Sterile normal saline as placebo</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>Depomedrone</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2005 Results article in https://pubmed.ncbi.nlm.nih.gov/15760929 Results</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="35a9b444-f256-4fd3-8199-709ab24f8f9b" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2005-09-01T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="https://pubmed.ncbi.nlm.nih.gov/15760929"/>
	<description>Results</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder1373-0</funderId>
      <contactId>Contact5056_1373</contactId>
      <sponsorId>Sponsor5003</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact5056_1373">
    <title>Dr</title>
    <forename>Ernest</forename>
    <surname>Choy</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Academic Department of Rheumatology
GKT School of Medicines
King's College Hospital (Dulwich)
East Dulwich Grove</address>
      <city>London</city>
      <country>United Kingdom</country>
      <zip>SE22 8PT</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+44 (0)20 7346 6446</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor5003">
    <organisation>Arthritis Research Campaign (ARC) (UK)</organisation>
    <website>http://www.arc.org.uk</website>
    <sponsorType>Charity</sponsorType>
    <contactDetails>
      <address>Copeman House
St Mary's Court
St Mary's Gate
Chesterfield</address>
      <city>Derbyshire</city>
      <country>United Kingdom</country>
      <zip>S41 7TD</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">-</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">info@arc.org.uk</email>
    </contactDetails>
    <privacy>Public</privacy>
    <gridId>grid.507369.e</gridId>
    <rorId>https://ror.org/02jkpm469</rorId>
  </sponsor>
  <funder id="Funder1373-0">
    <name>Arthritis Research Campaign (UK)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-10-02T00:00:00.000Z" version="20">
    <isrctn dateAssigned="2002-06-14T00:00:00.000Z">03930168</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Efficacy of EPs 7630 in acute non-streptococcal tonsillopharyngitis</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>This study was a prospective, monocentre, randomised, open clinical pilot trial, comparing the efficacy of the herbal medicine EPs 7630 versus symptomatic therapy in patients with acute, non-streptococcal tonsillopharyngitis.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Not provided at time of registration</primaryOutcome>
      <secondaryOutcome>Not provided at time of registration</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Not provided at time of registration</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN03930168</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>UM002</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>1997-03-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>1997-04-30T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Germany</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="1bfe8cac-51b2-44be-b180-b0193dc1e322">
	  <name>Director Research Center HomInt</name>
	  <address/>
	  <city>Karlsruhe</city>
	  <state/>
	  <country>Germany</country>
	  <zip>76202</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>The study took place between March and April 1997. It is terminated. Patients, who met the following inclusion criteria, were suitable for the trial: 
1. Age 6-10 years
2. Acute exsudative tonsillopharyngitis
3. Duration of symptoms less than 48 h
4. No Group A Beta Hemolytic Streptococcus (GABHS)-infection
5. Tonsillopharyngitis Severity Score (TSS) 6 or more points, and 
6. Informed consent in writing by legal guardians who were able to understand the nature, meaning and consequences of the trial</inclusion>
      <ageRange>Not Specified</ageRange>
      <gender>Not Specified</gender>
      <targetEnrolment>60</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>60</totalTarget>
      <exclusion>Not provided at time of registration</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>1997-03-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>1997-04-30T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Acute, non-streptococcal tonsillopharyngitis</description>
	<diseaseClass1>Ear, Nose and Throat</diseaseClass1>
	<diseaseClass2>Acute, non-streptococcal tonsillopharyngitis</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>60 patients were randomised to receive either:
1. Herbal remedy EPs 7630, 20 drops thrice daily, or
2. Symptomatic therapy (gargling with fruit vinegar and lukewarm water, Priessnitz compresses).

The duration of individual treatment lasted over a maximum of 10 days.</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>EPs 7630</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      
    </outputs>
    <parties>
      <funderId>Funder1390-0</funderId>
      <contactId>Contact5151_1390</contactId>
      <sponsorId>Sponsor5067</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact5151_1390">
    <title>Dr</title>
    <forename>Marianne</forename>
    <surname>Heger</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Director Research Center HomInt
PO Box 41 02 40</address>
      <city>Karlsruhe</city>
      <country>Germany</country>
      <zip>76202</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
  </contact>
  <sponsor id="Sponsor5067">
    <organisation>ISO Arzneimittel GmbH &amp; Co KG (Germany)</organisation>
    <website>http://www.iso-arznei.de</website>
    <sponsorType>Industry</sponsorType>
    <contactDetails>
      <address>Bunsenstrasse 6-10</address>
      <city>Ettlingen</city>
      <state/>
      <country>Germany</country>
      <zip>76275</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.487229.2</gridId>
    <rorId>https://ror.org/045xrc244</rorId>
  </sponsor>
  <funder id="Funder1390-0">
    <name>ISO Arzneimittel GmbH &amp; Co KG</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-10-02T00:00:00.000Z" version="23">
    <isrctn dateAssigned="2002-04-29T00:00:00.000Z">29863938</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>A randomised controlled trial of intra-muscular Lorazepam versus intra-muscular Haloperidol and Promethazine in the management of psychotic agitations and aggression</title>
      <scientificTitle/>
      <acronym>TREC-INDIA (Tranquilizacao Rapida-Ensaio Clinico; translated from Portuguese - 'Rapid Tranquillisation-Clinical Trial')</acronym>
      <studyHypothesis>To compare interventions commonly used for controlling agitation or violence in people with serious psychiatric disorders.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>1. Tranquil or asleep by 4 hours
2. The time of onset of tranquillisation and/or sleep

Participants were considered to be tranquil when they were calm and not exhibiting agitated, aggressive or dangerous behaviour. Patients were considered to be asleep if, on inspection, they appeared to be sound asleep and were not aroused by ambient disturbances.</primaryOutcome>
      <secondaryOutcome>These assessments were conducted only on participants who were awake, as extrapyramidal symptoms are usually not apparent during sleep or, in the case of dystonia or akathisia, are likely to prevent sleep:
1. Clinical Global Impression &#150; Severity (CGI&#150;S) scale at entry
2. CGI&#150;Improvement (CGI&#150;I) scale with respect to aggression and violence
3. Simpson&#150;Angus extrapyramidal side-effects rating scale 
4. Barnes Akathisia Scale 
5. Any other clinically important adverse effects, especially dystonia

Other outcomes within the first 4 hours were:
6. The use of additional medication for control of agitated or aggressive behaviour
7. The use of physical restraints
8. The need for further medical attention and numbers absconding

Participants were also followed up 2 weeks later to check for adverse effects or adverse outcomes and compliance with oral medication.</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Not provided at time of registration</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN29863938</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2002-01-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2002-12-31T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>India</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="cac6a3a2-ee1f-4396-ad5b-161c3d71b5fa">
	  <name>Department of Psychiatry Unit II</name>
	  <address/>
	  <city>Bagayam Vellore</city>
	  <state/>
	  <country>India</country>
	  <zip>632 002</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>Patients need acute intramuscular sedation because of disturbed and dangerous behaviour as decided by the attending physician.</inclusion>
      <ageRange>Not Specified</ageRange>
      <gender>Not Specified</gender>
      <targetEnrolment>200</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>200</totalTarget>
      <exclusion>1. The clinician believes that one of the two treatments represents an additional risk for the patient
2. Feels that one of the two treatments is definitely indicated for a given patient</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2002-01-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2002-12-31T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Serious mental illnesses combined with overt aggression or agitation</description>
	<diseaseClass1>Mental and Behavioural Disorders</diseaseClass1>
	<diseaseClass2>Overt aggression or agitation</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>1. Haloperidol (up to 10 mg IM) with promethazine (up to 50 mg IM)
2. Lorazepam (4 mg IM)

Doses are not fixed and are at the discretion of the attending doctors.</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>Lorazepam, Haloperidol, Promethazine</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2004 Results article in https://pubmed.ncbi.nlm.nih.gov/15231557 Results</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="0f501d4f-9638-4891-af9e-31086c9afef8" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2004-07-01T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="https://pubmed.ncbi.nlm.nih.gov/15231557"/>
	<description>Results</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder1367-0</funderId>
      <funderId>Funder1367-1</funderId>
      <funderId>Funder1367-2</funderId>
      <contactId>Contact5187_1367</contactId>
      <sponsorId>Sponsor5040</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact5187_1367">
    <title>Dr</title>
    <forename>Prathap</forename>
    <surname>Tharyan</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Department of Psychiatry Unit II
Mental Health Center
Christian Medical College</address>
      <city>Bagayam Vellore</city>
      <country>India</country>
      <zip>632 002</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+91 (416) 262603 ext 4259</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">dralexander_in@yahoo.com</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor5040">
    <organisation>Christian Medical College and Hospital (India)</organisation>
    <website>http://www.cmch-vellore.edu/</website>
    <sponsorType>Hospital/treatment centre</sponsorType>
    <contactDetails>
      <address>Bagayam</address>
      <city>Vellore</city>
      <country>India</country>
      <zip>632002</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.11586.3b</gridId>
    <rorId>https://ror.org/00c7kvd80</rorId>
  </sponsor>
  <funder id="Funder1367-0">
    <name>Christian Medical College and Hospital (India) - Fluid Research Grant</name>
    <fundRef/>
  </funder>
  <funder id="Funder1367-1">
    <name>The Cochrane Schizophrenia Group (CSG) (UK) - supported with funding for sundries</name>
    <fundRef/>
  </funder>
  <funder id="Funder1367-2">
    <name>The doctors and nurses of Vellore freely gave support, enthusiasm and skill.</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-10-03T00:00:00.000Z" version="25">
    <isrctn dateAssigned="2001-11-18T00:00:00.000Z">89811481</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>UK Pacing And Cardiovascular Events study: benefits in quality of life and cognitive function</title>
      <scientificTitle/>
      <acronym>UKPACE</acronym>
      <studyHypothesis>Does dual chamber pacing improve the quality of life and cognitive function of elderly patients with complete heart block?</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Not provided at time of registration</primaryOutcome>
      <secondaryOutcome>Not provided at time of registration</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Not provided at time of registration</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN89811481</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>PG/96150</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>1997-01-30T00:00:00.000Z</overallStartDate>
      <overallEndDate>1999-01-30T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>England</country>
	<country>United Kingdom</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="cae09bf5-c2d9-4805-862a-50ab2f6913f6">
	  <name>Cardiovascular Investigation Unit</name>
	  <address/>
	  <city>Newcastle upon Tyne</city>
	  <state/>
	  <country>United Kingdom</country>
	  <zip>NE14 4AH</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>Patients over the age of 70 with atrioventricular block treated by implantation of pacemaker.</inclusion>
      <ageRange>Senior</ageRange>
      <gender>Both</gender>
      <targetEnrolment>0</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>Not provided at time of registration</totalTarget>
      <exclusion>Not provided at time of registration</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>1997-01-30T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>1999-01-30T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Sinus syndrome and atrioventricular nodal disease</description>
	<diseaseClass1>Circulatory System</diseaseClass1>
	<diseaseClass2>Sick sinus syndrome</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Mode of pacemaker at implantation, i.e., single chamber ventricular or physiological.</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>1997 Protocol article in https://pubmed.ncbi.nlm.nih.gov/9391280/ Protocol of entire UKPACE study
2004 Results article in https://pubmed.ncbi.nlm.nih.gov/15580719/ Results</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="4266927c-682b-4272-a859-d0a89bf9578c" outputType="protocolarticle" artefactType="ExternalLink" dateCreated="1997-09-01T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="https://pubmed.ncbi.nlm.nih.gov/9391280/"/>
	<description>Protocol of entire UKPACE study</description>
	<productionNotes/>
      </output>
      <output id="4793aa26-a580-4e64-9faa-a0166aa16aee" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2004-11-01T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="https://pubmed.ncbi.nlm.nih.gov/15580719/"/>
	<description>Results</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder1256-0</funderId>
      <contactId>Contact5394_1256</contactId>
      <sponsorId>Sponsor5027</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact5394_1256">
    <title>Professor</title>
    <forename>RA</forename>
    <surname>Kenny</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Cardiovascular Investigation Unit
Ward 15 Offices 
Royal Victoria Infirmary 
Queen Victoria Road</address>
      <city>Newcastle upon Tyne</city>
      <country>United Kingdom</country>
      <zip>NE14 4AH</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+44 (0)191 2225316</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">R.A.Kenny@ncl.ac.uk</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor5027">
    <organisation>British Heart Foundation (UK)</organisation>
    <website>http://www.bhf.org.uk/</website>
    <sponsorType>Charity</sponsorType>
    <contactDetails>
      <address>14 Fitzhardinge Street</address>
      <city>London</city>
      <state/>
      <country>United Kingdom</country>
      <zip>W1H 6DH</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+44 (0)20 7935 0185</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">research@bhf.org.uk</email>
    </contactDetails>
    <privacy>Public</privacy>
    <gridId>grid.452924.c</gridId>
    <rorId>https://ror.org/02wdwnk04</rorId>
  </sponsor>
  <funder id="Funder1256-0">
    <name>British Heart Foundation (UK) (ref: PG/96150)</name>
    <fundRef>http://dx.doi.org/10.13039/501100000274</fundRef>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-10-02T00:00:00.000Z" version="24">
    <isrctn dateAssigned="2001-10-31T00:00:00.000Z">21931925</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Test of the open artery hypothesis</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>Effect on ventricular modelling of angioplasty and stenting of the occluded infarct related artery (IRA) among patients with their first Q wave anterior myocardial infarction.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Not provided at time of registration</primaryOutcome>
      <secondaryOutcome>Not provided at time of registration</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Not provided at time of registration</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN21931925</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>PG/97051</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>1997-03-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>1999-06-01T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>England</country>
	<country>United Kingdom</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="1ebf817a-c17f-4a1f-aa21-687401e3cee1">
	  <name>Dept of Cardiology</name>
	  <address/>
	  <city>London</city>
	  <state/>
	  <country>United Kingdom</country>
	  <zip>SE1 7EH</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>Patients with Thrombolysis in Myocardial Infarction (TIMI) grade 0 or I.</inclusion>
      <ageRange>Not Specified</ageRange>
      <gender>Not Specified</gender>
      <targetEnrolment>0</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>Not provided at time of registration</totalTarget>
      <exclusion>Patients with TIMI grade II or III in the IRA or multi-vessel disease will be excluded.</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>1997-03-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>1999-06-01T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Cardiovascular disease</description>
	<diseaseClass1>Circulatory System</diseaseClass1>
	<diseaseClass2>Thrombolysis in myocardial infarction</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Angiography and angioplasty carried out within 28 days of the acute event. Patients to be randomised into intervention or non-intervention groups. 
Patients with TIMI grade II or III in the IRA or multi-vessel disease will be excluded. 
Remaining patients with TIMI grade 0 or I will be randomised to intervention plus optimal medical therapy or optimal medical therapy alone.</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2002 Results article in https://pubmed.ncbi.nlm.nih.gov/12225709/ Results</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="f3155d39-a20e-4f90-a6f2-4abef5594ccd" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2002-09-04T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="https://pubmed.ncbi.nlm.nih.gov/12225709/"/>
	<description>Results</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder1273-0</funderId>
      <contactId>Contact5156_1273</contactId>
      <sponsorId>Sponsor5027</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact5156_1273">
    <title>Dr</title>
    <forename>MS</forename>
    <surname>Marber</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Dept of Cardiology
The Rayne Institute
St Thomas' Hospital
Lambeth Palace Road</address>
      <city>London</city>
      <country>United Kingdom</country>
      <zip>SE1 7EH</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+44 (0)20 7836 5454</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">mike.marber@kcl.ac.uk</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor5027">
    <organisation>British Heart Foundation (UK)</organisation>
    <website>http://www.bhf.org.uk/</website>
    <sponsorType>Charity</sponsorType>
    <contactDetails>
      <address>14 Fitzhardinge Street</address>
      <city>London</city>
      <state/>
      <country>United Kingdom</country>
      <zip>W1H 6DH</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+44 (0)20 7935 0185</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">research@bhf.org.uk</email>
    </contactDetails>
    <privacy>Public</privacy>
    <gridId>grid.452924.c</gridId>
    <rorId>https://ror.org/02wdwnk04</rorId>
  </sponsor>
  <funder id="Funder1273-0">
    <name>British Heart Foundation (UK) (ref: PG/97051)</name>
    <fundRef>http://dx.doi.org/10.13039/501100000274</fundRef>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-10-04T00:00:00.000Z" version="21">
    <isrctn dateAssigned="2000-04-06T00:00:00.000Z">95257778</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>UKALL R2 - Acute Lymphoblastic Leukaemia trial</title>
      <scientificTitle/>
      <acronym>UKALL R2</acronym>
      <studyHypothesis>To compare continuing chemotherapy with unrelated donor BMT in relapsed childhood ALL following a common re-induction and consolidation regimen.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Survival, disease free survival</primaryOutcome>
      <secondaryOutcome>Not provided at time of registration</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Not provided at time of registration</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN95257778</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>G8223452</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Not Specified</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>1995-02-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2008-09-30T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>England</country>
	<country>United Kingdom</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="78b22238-f68e-432f-9f8b-119414ed949e">
	  <name>The Children's Hospital</name>
	  <address/>
	  <city>Birmingham</city>
	  <state/>
	  <country>United Kingdom</country>
	  <zip>B16 8ET</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>They are children under 15 years at original diagnosis and treated on UKALL trials or pilot studies with first relapse less than 4 years from the start of treatment of ALL at any site and no suitable related bone marrow treatment (BMT) donor is available</inclusion>
      <ageRange>Not Specified</ageRange>
      <gender>Not Specified</gender>
      <targetEnrolment>200</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>200 - Closed to recruitment - in long term follow-up</totalTarget>
      <exclusion>1. They are multiply relapsed patients 
2. They have a prior history of toxicity or organ damage such that completion of the protocol is felt unlikely at the outset 
3. They have had an isolated CNS or testicular relapse more than 6 months off treatment.</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>1995-02-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2008-09-30T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Acute Lymphoblastic Leukaemia</description>
	<diseaseClass1>Cancer</diseaseClass1>
	<diseaseClass2>Acute Lymphoblastic Leukaemia</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Continuing chemotherapy/unrelated donor BMT</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2005 Results article in http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15982346 Results</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="5e2f3595-e450-40e0-a053-f0df3597f36f" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2005-07-01T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15982346"/>
	<description>Results</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder1163-0</funderId>
      <contactId>Contact5167_1163</contactId>
      <sponsorId>Sponsor5055</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact5167_1163">
    <title>Dr</title>
    <forename>PJ</forename>
    <surname>Darbyshire</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>The Children's Hospital
Ladywood Middleway</address>
      <city>Birmingham</city>
      <country>United Kingdom</country>
      <zip>B16 8ET</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor5055">
    <organisation>Medical Research Council (MRC) (UK)</organisation>
    <website>http://www.mrc.ac.uk</website>
    <sponsorType>Research council</sponsorType>
    <contactDetails>
      <address>20 Park Crescent</address>
      <city>London</city>
      <state/>
      <country>United Kingdom</country>
      <zip>W1B 1AL</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+44 (0)20 7636 5422</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">clinical.trial@headoffice.mrc.ac.uk</email>
    </contactDetails>
    <privacy>Public</privacy>
  </sponsor>
  <funder id="Funder1163-0">
    <name>UK Medical Research Council</name>
    <fundRef/>
  </funder>
</fullTrial></allTrials>